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Abstract
The heptavalent pneumococcal polysaccharide-CRM197 conjugate vaccine (Pnc7) has been 
introduced to target the major disease causing pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F 
and 23F) in childhood where invasive pneumococcal disease remains a significant global cause of 
childhood mortality. The aim of this thesis was to address questions related to the pneumococcal 
capsular polysaccharide specific B cell response.
One week after a single dose of Pnc7 vaccine it was possible to detect spontaneously secreting 
IgG plasma cells in the peripheral blood of 12 month old toddlers and young adults. The plasma 
cells were identified as either CD20+CD27+sIg+CD38+ or CD20'CD27+sIglo/'CD38+.
Prior to immunisation memory B cells specific for pneumococcal capsular polysaccharides were 
present in 100% of young adults, but barely detectable in adults aged 47-65 years and were 
undetectable in toddlers. A single dose of Pnc7 induced elevated frequencies of IgG memory B 
cells in all age groups, but two doses were required in order to generate equivalent frequencies in 
adults and toddlers. The generation of IgG memory was dependent on age at time of  
immunisation and on the serotype polysaccharide.
Generation of IgG memory requires previous natural exposure or immunisation to prime the 
immune system. Such exposure generates IgM memory in young children and enhancing IgM 
memory may be important for protection. The IgM response can be replaced by generation of a 
high avidity IgG response, enhance protection of the very young and elderly through 
immunisation.
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Chapter 1: Introduction
1.1 Streptococcus pneumoiaVirulence and 
pathogenicity factors.
Streptococcus pneumoniae is a commensal organism, harmlessly residing among the natural flora 
of the nasopharyngeal (NP) mucosa (1, 2). The pneumococcus was first described in 1881 by 
George Miller Sternberg, who isolated the bacterium from an infected rabbit following prior 
inoculation with his own saliva (2, 3).
Figure 1.1 An Electronmicrograph of encapsulated (A and G), and non-capsulated (B and H) 
pneumococci.
Viewed following conventional fixation (A and B), and LRR fixation (G and H) prior to FESEM 
(Hammerschmidt et al, 2005 figure 3 (4)).
S. pneumoniae is a Gram positive bacterium that exists in a characteristic diploid form or as 
single cells or short, filamentous chains depending on the nutrition available during growth as 
shown in figure 1.1 (4, 5). The pneumococcus has three major structural outer layers, i) a 
cytoplasmic membrane, ii) a cell wall and iii) a polysaccharide capsule. Many of the components
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of the cell wall and capsule are essential for the virulence or invasiveness o f the pneumococcus 
and the major ones are shown in figures 1.2 and 1.3.
The role of virulence factors includes inhibition of opsonophagocytosis, complement activation 
and avoidance o f specific antibody formation. Pathogenicity results mainly from factors released 
by the pneumococcus following bacterial cell death and lysis, and the main outcome of these 
pathogenicity factors is localised inflammation (6, 7).
The pneumococcus is able to exist in both a non-encapsulated (transparent) form and an 
encapsulated (opaque) form due to phase variation of the polysaccharide capsule (4). The 
transparent form appears as in figure 1.2, where surface proteins and cell wall components that 
mediate adherence to host cells are exposed. In this form the pneumococcus is able to adhere 
directly to the nasopharyngeal mucosa (8). The opaque form, as seen in figure 1.3, expresses the 
serotype specific capsule that protects the bacterium from both innate and adaptive host immune 
responses.
1.1.1 Transparent pneumococci
The major antigenic determinants of the pneumococcus are exposed in the transparent phase 
(figure 1.2). The bacterial cell wall, which is in direct contact with the bacterial cell membrane, 
is composed mainly of a triple layer of peptidoglycan. Covalently attached to the peptidoglycan 
layer are surface proteins and cell wall polysaccharide (CwPS). In the opaque form the 
peptidoglycan layer also acts as an anchor for the serotype specific polysaccharide capsule o f the 
pneumococcus.
CwPS contains teichoic acid (TA), lipoteichoic acid (LTA) and phosphorylcholine (PCh)
residues that have roles in the direct activation of complement and also in pneumococcal 
adherence to the epithelial cells of the mucosa (9). The PCh residues promote the adherence of  
C-reactive protein (CRP) to the pneumococcus (10). CRP is a potent activator o f the classical 
complement pathway that generates C3b that binds to the surface of the pneumococcus leading to
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opsonisation. Along with natural antibody to the CwPS the C3b component of complement 
mediates the clearance of pneumococci from the blood and possibly mucosal surfaces by 
opsonophagocytic uptake by polymorphonuclear leukocytes (PMNs).
The PCh residues with the surface bound teichoic acid residues contribute to the adherence of 
pneumococci to host epithelial cells by binding the chemokine receptor platelet activating factor 
receptor (PAF-r) (9, 11) that is expressed on activated epithelial cells (12). There is evidence 
from mouse models that infection of the host with influenza virus increases the risk of 
colonisation and invasive disease caused by the pneumococcus (13). These studies have 
suggested a mechanism whereby the influenza virus neuraminidase exposes host epithelial cell 
surface structures and induces production of the inflammatory mediator interleukin (IL)-l which 
in turn up-regulates expression of PAF-r, to which the pneumococcus can adhere. This 
interaction is thought to be among the mechanisms of transit from the mucosa to the blood (12- 
14). In humans, antibody directed against PCh or teichoic acid residues o f the CwPS are 
generated in response to exposure to pneumococcus (15, 16). However, although some protective 
influence against invasive disease has been demonstrated in mouse models (15), the same has not 
been proven in humans (16).
As pathogenicity factors during bacteraemia, both peptidoglycan and CwPS have been shown to 
induce the inflammation seen in invasive pneumococcal disease (IPD) in mice (5, 12,17,18). 
Immunogenic surface proteins are also covalently anchored into the cell wall and membrane and 
the major ones include pneumococcal surface protein A (PspA), pneumococcal surface 
adhesin A (PsaA) and pneumococcal surface protein C (PspC, also known as choline 
binding protein A (CbpA) and SpsA) shown in figure 1.2 (19).
Of these proteins, PspA in particular is required for full virulence (20, 21) and it is expressed on 
all pneumococcal serotypes. PspA is attached to the pneumococcal cell wall by a choline binding 
domain and shows some variability between serotypes. Immunisation with PspA induces cross- 
protective antibody suggesting a number of common epitopes occur between the different
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serotypes (6, 7, 20-22). One reported function of PspA is interference with the alternative 
complement pathway. It blocks the deposition of the C3 break down product, inactivated C3b 
(iC3b) on the bacterial cell surface. This allows the pneumococcus to avoid phagocytosis by 
macrophages that express complement receptors (CR) 2, 3 and CR4 (23).
In humans Factor H binds host cell sialic acid residues and enhances cleavage o f C3 convertase 
(C3bBb). Complement Factor I then cleaves the remaining C3b, preventing it binding to host cell 
surfaces, thereby preventing opsonisation of host cells Bacterial cell surfaces do not possess the 
sialic acid residues required for the binding o f Factor H, and instead the serum protein, properdin, 
binds to C3bBb, stabilising it on the bacterial cell surface. This allows alternative complement 
pathway amplification of C3b and binding to the bacteria (24). Another pneumococcal surface 
protein, PspC, provides a mechanism that enables pneumococci to interfere with C3b 
opsonisation process described above. PspC binds Factor H at the bacterial cell surface, this 
leads to cleavage of the C3bBb complex, thus reducing the deposition o f C3b on the bacterial 
surface (19, 25-30).
PspC binding of Factor H also mediates adherence o f pneumococci to the mucosal surface by 
interacting with the secretory piece o f human secretory IgA (slgA) which then 
polyimmunoglobulin receptor (plgR) (19, 25). Deletion o f either PsaA or PspC created avirulent 
mutant strains with reduced ability to adhere to host cell surfaces (7).
Thus expression of PsaA, PspA and PspC by pneumococci counteracts spontaneous deposition of 
C3b and enhances adherence to the mucosa increasing the length of colonisation time and 
invasiveness.
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Figure 1.2 A schematic of the non-capsular (transparent) phase of the pneumococcus showing the 
major virulence and pathogenicity factors (22).
1.1.2 Opaque pneumococci
The major virulence determinant of opaque pneumococci is the polysaccharide capsule. It is the 
capsule that allows identification of pneumococcal isolates, by a test called the Quellung reaction. 
This process has lead to the identification of over 90 serotypes of encapsulated pneumococci (31). 
The capsule covers the entire surface of the organism, hiding the immunogenic cell wall and 
protein components, as shown in figure 1.3, with just PspA extending beyond the cover.
The capsule consists of highly repetitive polysaccharide subunits and in some cases may also 
contain proteins, glycolipids and PCh residues. In general the presence of the capsule means the 
pneumococcus is resistant to complement deposition and phagocytosis in the blood (1) but the 
presence of PCh residues within the capsule structure increase vulnerability to complement 
deposition mediated by CRP binding to the PCh residues (10). Therefore serotype virulence is 
determined in part by these differences in the capsule constituents (1). The capsule is produced 
during the exponential growth phase of the bacteria when conditions are favourable for survival. 
Encapsulated strains are ten times more virulent than the un-encapsulated strains in mice (32).
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The pneumococcus is able to change the serotype specificity of the expressed capsule altering its 
virulence depending on the underlying genetic strain (33). This was also seen in a mouse model 
where infection site, capsular type and genetic background all determined virulence of a serotype 
3 pneumococcal strain (34).
By regulating the amount of capsule expressed the pneumococcus is able to prolong its survival 
time in the nasopharynx because the capsule prevents agglutination of the bacteria by the mucous 
(2, 4, 35). A reduced level of capsule expression, timed with proximity to the epithelia o f the 
nasopharynx and lung promotes adherence mediated by the otherwise occluded surface proteins 
(4,35).
The capsular polysaccharides are immunogenic to varying degrees and specific serum antibody is 
generated following exposure of the host to specific capsular types (1). This serum antibody is 
crucial in protecting the host against invasive disease (36).
The protective role of the anti-capsular antibody in controlling colonisation is less clear but is 
aided by antibody directed against the surface proteins, and also CD4+ T-helper cells recruited at 
the time of infection (37, 38). Murine studies have revealed that the proteins hidden by the 
capsule are highly conserved and generate less serum antibody than proteins that remain visible to 
the immune system in encapsulated variants (39). For example the more variable proteins PspA 
and PspC are detectable by flow cytometry using encapsulated strains, while the more conserved 
proteins, PsaA and Ppm A (putative protease maturation protein A), are not (9, 39). However, 
data from another mouse study suggested that exposure to pneumococci generates serum antibody 
specific for conserved proteins and may correlate with protection, while not actually mediating 
the mechanism of protection (40).
Therefore the capsule not only allows the pneumococcus to survive in the blood stream by 
occluding highly conserved, immunogenic proteins from the immune system. It also serves to 
regulate the accessibility of the pneumococcal adhesins to the cell surfaces limiting exposure of
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these proteins to the immune system. Variation of the capsular type allows for escape from 
capsule specific antibody generated during exposure.
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Figure 1.3 A schematic of the encapsulated (opaque) phase variant of the pneumococcus showing the 
main structural and antigenic components (22).
1.2 The role of secretory components in the 
pathogenicity and virulence of the pneumococcus.
The pneumococcus secretes a number of enzymes that contribute towards i) bacterial cell 
adherence to and invasion of the host epithelial cell layer and ii) induction of the inflammatory 
responses associated with pneumococcal infection.
The pneumococcus must avoid clearance from mucosal cell surfaces in order to cause invasive 
disease. This is partly achieved by IgAl protease, which acts directly on secretory IgAl 
(slgAl), breaking down the slgAl structure, separating the Fc, Fab and IgA secretory component 
from each other (7). This prevents opsonisation of the pneumococcus and clearance from 
nasopharyngeal epithelial cell surfaces (41).
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Adherence of pneumococci to the surface of host epithelial cells is aided by neuraminidase, an 
enzyme that exists in two forms (NanA and NanB). This enzyme cleaves the sialic acid residues 
on host cell glycolipids (6, 7, 22). Attachment is also thought to be aided by some, as yet 
unidentified proteins produced by pneumococci that target host cell glycoconjugates containing, 
N-acetyl-D-glucosamine-|3(l-3)galactose, N-acetyl-D-galactosamine-p(l-3)galactose or 
glucosamine (22). Once the pneumococcus has attached to the epithelial cell surface it may 
remain for some time or only transiently. The persistence of colonisation may depend on the 
activity of other bacterial and host cell factors, e.g. teichoic acid residues, CbpA and SpsA. To 
cause invasive disease the pneumococcus must enter the blood stream. Translocation of the 
pneumococcus from the epithelial cell surface into the blood is aided by the enzyme 
hyaluronidase which acts on hyaluronic acid present in connective tissue allowing invasion of 
the bacterium.
The primary mechanism of clearance of pneumococci from the blood is opsonophagocytosis. 
Capsule specific antibody and the complement component C3b synergise to opsonise intact 
pneumococci which are targeted for phagocytosis by neutrophils, via FcyRIIa (CD32) and 
complement receptors (42). Hostetter (43) demonstrated that some capsules blocked C3b to C3d 
conversion and that this rendered the pneumococcus vulnerable to phagocytosis. Serotypes that 
enhanced the degradation of C3b to C3d were resistant to phagocytosis and therefore more 
virulent.
Blood borne pneumococci are also able to avoid opsonisation and phagocytic killing by blocking 
the binding of complement Factor H and also by C3-degrading protease (44). Secretion of  
neutrophil esterase inhibitor, allows the pneumococci to survive within the phagolysosome. 
Some of the symptoms of IPD are a result of pathogenicity factors that are released when the 
bacterial cell is lysed. These pathogenicity factors include the enzyme autolysin, which lyses the 
bacterial cell wall when environmental stress such as penicillin exposure, is encountered and 
leads to the release of cell wall breakdown products (teichoic acid and peptidoglycan) (22).
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Lysis of pneumococci releases pneumolysin, an enzyme conserved throughout all pneumococci, 
from within the bacterial cell and allowing it to lyse host epithelial cells. It has structural 
homology with CRP and has both lytic and complement activating properties (7). By interacting 
with Ig-Fc regions it is able to activate the classical complement cascade (45) by binding the PCh 
residues in CwPS. This leads to complement activation through direct interaction with Clq (a 
similar mechanism to CRP) (46). Release of pneumolysin from dead bacteria may divert the 
activated complement cascade away from healthy pneumococci by interacting with Clq  
molecules at some distance from intact pneumococci (47). The resulting classical complement 
cascade generates C3a and C5a (anaphylotoxins) that cause vascular permeabilisation, mast cell 
degranulation and polymorphonuclear cell (PMN) recruitment. Monocytes, attracted to the 
infection site by the anaphylotoxins, produce tumour necrosis factor-alpha (TNFa) and 
interleukin (IL)-1 (3 which mediate inflammatory processes. It also inhibits epithelial cell cilia 
beating and has detrimental effects on neutrophil activity, Ab synthesis and lymphocyte 
proliferation.
Another function of pneumolysin is the activation of host epithelial cells which release the 
chemokine, CCL5 which attracts CD4+ memory T cells to the infection site. The cytokines 
released by these T cells determine the outcome of disease with increased IL-10 and decreased 
IL-4 and IFNy inducing transition from carriage to IPD in mice (48).
1.3 Pneumococcal carriage, invasive disease and 
antibiotic resistance.
1.3.1 Nasopharyngeal carriage
The human host is exposed to pneumococci via transient carriage in the nasopharynx and upper 
respiratory tract. Carriage is defined as self-limiting colonisation by pneumococci in the absence 
of lower respiratory tract infection or IPD (49). The incidence of NP carriage increases with age
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(50) possibly from birth (51), so that by 2 years of age at least 95% of children have been exposed 
to one or more episodes of pneumococcal carriage (52). Colonisation rates peak by 3 years o f age 
when up to 50% of children may carry at least one isolate (53) but then decline to reach a stable 
level of around 8% of children by ten years of age. Pneumococci are then detectable in the 
nasopharynx at low rates, throughout life providing an important route for community 
transmission between infants (53) and from infants to adults (54, 55).
Generation of anti-capsular antibody in response to carriage is age and serotype dependent such 
that in children under 2 years of age carriage is detectable but no antibody is generated while in 
older children antibody is generated following carriage of immunogenic serotypes but not poor 
immunogenic serotypes such as 6B (56).
Despite the identification of 90 different serotypes o f pneumococcus based on the expressed 
capsule only a limited number are responsible for invasive disease. The serotypes isolated from 
the nasopharynx and those obtained from the blood in IPD cases are often similar. For example 
serotypes 6, 14, 19 and 23 are commonly carried and are also among those responsible for disease 
in children younger than 24 months of age (50, 57).
The duration of carriage of individual serotypes is related to the age of the host and is affected by 
the maturity of the immune system (53) and acquisition of carriage peaks during the winter (50). 
The carriage of pneumococci is thought to be a pre-requisite for the development IPD caused by 
the same serotype but disease does not occur following every incidence o f carriage, even with 
invasive serotypes (6, 36). In fact it has been reported that invasiveness of a particular serotype is 
inversely related to the frequency of its detection in the nasopharynx (figure 1.4a (58)) and 
possibly to the duration of carriage (figure 1.4b (59)).
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Figure 1.4 The relationships between incidence and duration of NP carriage versus IPD rates.
a) Shows the percentage of serotypes carried compared to the odds ratio (OR) for invasiveness (58). b) 
Duration of NP carriage versus the number of homologous serotype cases of IPD in the Oxford region (59). 
The serotypes circled in red are the serotypes investigated in this thesis.
Repeated exposure to pneumococci via the nasopharynx may help to maintain levels of naturally 
acquired antibody, since antibody levels wane in the absence of carriage o f a specific serotype 
(49, 60). Adults and children over the age of 2 years old generate antibody specific for the 
polysaccharide capsule and also to the surface proteins in response to NP carriage (56). However 
the precise role of serotype specific anti-capsular antibody in preventing colonisation is not as 
clear the role in protection from invasive disease (49). Immune responses that target the surface 
proteins may also play an important part in the age related decline o f carriage and disease rates (4, 
37). Antibodies targeting these proteins block adherence to epithelial cells, reducing the duration 
of carriage (39). Individuals with pre-existing anti-PspA antibodies have been shown to have 
reduced rates ofNP carriage (40) and it has also been suggested that CD4+ T cell help to mediate 
these anti-protein responses (37, 39).
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Prior upper respiratory infections such as influenza can increase the risk o f IPD from concurrently 
carried strains of pneumococcus (14), but by >2 years of age the risk of IPD declines rapidly, but 
the processes that contribute to this decline are not fully understood (61).
1.3.2 Pneumococcal disease
S. pneumoniae is responsible for more than 1 million infant deaths, world wide, per year. It 
remains the most common cause of invasive bacterial disease in all age groups (37, 62-65). IPD 
is most common at the extremes of age (<2yrs and >65yrs), where immunological status is either 
immature or in senescence. Disease occurs despite the universal exposure of individuals to 
pneumococci via NP carriage. The peak incidence o f pneumococcal disease has been shown to 
occur in the winter months, reaching a maximum rate during January in the USA (66) and the UK 
(figure 1.10).
The spectrum of infections caused by Streptococcus pneumoniae range from localised, mucosal 
infections, such as acute otitis media (AOM) to severe infections such as pneumonia and blood 
borne invasive diseases such as septicaemia and meningitis (67).
Data from the Health Protection Agency for 2004-2005 show that the incidence of both 
meningitis (Figure 1.6a) and all pneumococcal invasive disease (figure 1.6b) peaks during the 
first two years of life and again in older teenagers and adults, although the incidence of invasive 
disease is much higher in adults than infants.
Commensal and disease causing serotype occurrence is affected by age, community factors, 
socioeconomic status and geographical location (63, 64, 68). Scott et al (68) found that serotypes 
19 and 24 were more frequently carried while serotypes 1 and 5 were often the cause of disease.
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They also found that increasing age corresponded with dramatically reduced serotype 14 disease 
rates and a gradual decline in serotype 6 , 18, 19 and 23 disease (6 8 ).
Data for England and Wales 2004-5
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Figure 1.5 Pneumococcal invasive disease and meningitis cases in England and Wales during 2004-5. 
Data obtained from the HPA, reviewed 10-06-2006.
(http://www.hpa.org.uk/infections/topics_az/pneumococcal/agespecificmeningitiscases.htn and 
http://www.hpa.org.uk/infections/topics_az/pneumococcal/agespecificlabcasesIPD.htn).
Figure 1.6 shows the effect of geographical location on IPD causing serotype occurrence in the 
<5 years olds and >5 year olds. Although most disease is caused by serotypes 4, 6 , 9, 14, 18, 19 
and 23 a significant number of cases are caused by serotypes 1 and 5 in Europe, Africa and Asia 
but few in the USA and Canada (69).
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Anatomical location of disease also affects the serotype recovered. IPD is defined as the isolation 
of a pneumococcus from a normally sterile site, such as the cerebro-spinal fluid (CSF), middle ear 
fluid (MEF) or blood. Hausdorff et al (70) have reviewed the contribution of different serotypes 
to disease in these sites and the effects of age and geographical location. Serotype 14 
predominated in blood isolates from young children in the USA and Europe while serotype 1 was 
responsible for most IPD in Asia. In the CSF serotype 6 was most frequently isolated in the 
USA, Europe, Latin America and Oceania while serotype 2 was found in Asia and serotype 1 in 
Africa. Data for MEF isolates from the USA and Europe found serotype 19 caused most disease. 
In older children and adults IPD blood isolates frequently identified serotype 1 in Asia and 
Europe (70). Hausdorff et al (31) also reviewed AOM isolates and found serotypes 19F and 23F 
were the most common cause of AOM irrespective of geographical location (data from USA, 
Europe, Argentina and Israel).
Global location also affects the burden of pneumococcal disease with in a population. Parsons & 
Dockrell (63) reported the incidence of UK IPD to be 6.6/100,1000 (1995-1997), and a similar 
study determined it to be 37-48/100,000 in the <1 year olds and 21-36/100,000 in the >65year 
olds (64). USA rates for 1999 were 23/100,000. However, in developing countries IPD rates 
were much higher with case numbers of 139-224/100,000 in the <2year old age group and 
190/100,000 in the adults (71).
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Figure 1.6 Geographical distribution of IPD serotypes. The data represent serotyped isolates as a 
percentage of all IPD isolates from <5 year olds and >5 year olds at five geographical locations.
The data are presented in order of decreasing importance in the USA and Canada (blue) plotted with isolate 
frequency at other locations. Serotypes 1 and 5 are included as important IPD serotypes outside of North 
America (from table 2 (69)).
A recent UK study (72) found that serotype 14 was most frequently isolated from paediatric IPD 
cases followed by serotype- 1  but some isolates found were not covered by any o f the current 
vaccines. This was also seen in carriage study in Oxford were serotypes 14 and 1 were most 
commonly isolated from cases in all ages groups combined (figure 1.7). The HPA have shown an 
increase in the total number of isolates collected in England and Wales with a slight decline in 
serotype 14 IPD cases (20%-14%), and a rise in serotype 1 cases (4%-13%), for the years 
2000/01-2005/06
(ww w .hpa.or.uk/infections/topics a2/pneum ococcal/serotvpeD istribution2000-2006.htm ).
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Figure 1.7 Serotypes isolated from IPD cases in the <5 and >5 year olds in the Oxford region (1995- 
1999).
The data show the percentage of the total isolates, ordered in serotype prevalence in the <5 year old group 
(blue) with the serotype prevalence for all ages (red). Serotypes not seen in the <5yr olds are at the end of 
the chart (12F, 9N, 23A, 18A and 18B)(64). Serotypes included in Pnc7 are 4, 6B, 9V, 14, 18C, 19F and 
23F.
1.3.3 Antibiotic use and resistance
NP carriage of the pneumococcus combined with high rates of antimicrobial use in industrialised 
countries is thought to be a major contributing factor to the increase of antibiotic resistance in 
pneumococcal isolates.
The advent of antimicrobial therapies for infectious disease in the 1930s led to declining numbers 
of fatal IPD cases (18). Globally, overuse of antimicrobials has led to the generation of 
pneumococci carrying resistance genes to at least one of the commonly prescribed antibiotics
(73). The first described case of penicillin resistance was in 1945 and the first clinically resistant 
isolates in Australia in 1965, and South Africa in 1977. The serotypes affected appear to be 
mostly the serotypes associated with infection in children, such as serotypes-6 , 14, 19 and 23F
(74).
Pneumococci take up genetic elements, such as antibiotic resistance genes from other commensal 
bacteria, from the environment (75) and incorporate them by recombination events that generate 
mutations. An example is seen in the gene that encodes the penicillin binding protein (PBP). The
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PBP gene is a mosaic gene where recombination events have resulted in reduced affinity o f the 
resulting PBP for penicillin, conferring resistance on the pneumococcus (18, 75). The changes 
that occur at the DNA level remain within the clonal population even in the absence o f antibiotics
(75). Development of new drugs such as macrolides, was meant to overcome the increase in 
resistant pneumococci but replacement of penicillin with macrolides resulted in resistance to this 
class of antibiotics as well (73). In Canada there has been a 10% rise in resistant isolates since 
1997 with P-lactam and macrolide treatment failures reported (73, 75). It was increasing 
antimicrobial resistance that prompted development o f new pneumococcal vaccines with potential 
for broad protection. Pnc7 vaccine covers most o f the common resistant strains (serotypes-6, 9V, 
14, 19 and 23) (74, 76, 77) but there are non-vaccine serotypes with resistance to at least one 
antimicrobial drug, (serotypes-7 and 8), leading to concerns about serotype replacement with non­
vaccine types (76, 77).
1.3.4 The relationship between genetic background and the 
capsule based serotype of the pneumococcus.
Routine pneumococcal typing is based on the expression of the serotype specific, polysaccharide 
capsule. However, the pneumococcus is capable of exchanging genetic information via 
horizontal transfer o f DNA, including capsule related genes and those coding for antibiotic 
resistance (78-82). Therefore it became important to understand the genetic relationship between 
strains traditionally associated with IPD and newly arising strains (78-80, 82). Multilocus 
sequence typing (MLST) has recently been developed to track invasive pneumococcal isolates by 
looking at the genetic background of each strain (83). The MLST of an isolate can be related to 
the occurrence o f a particular clone in NP carriage or IPD (83). MLST is based on identifying the 
alleles of a set of house keeping genes {aroE, gdh, gki, recP, spi, xpt and ddl) conserved in all 
pneumococci. A particular set of alleles for each of the seven genes constitutes a sequence type
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(ST) (81, 83). Using the relatedness o f particular STs different pneumococcal strains have been 
grouped into clonal complexes (CC) with the parent ST (most common) providing the CC 
number, (e.g. ST199 belongs to CC199 which also includes closely related ST200, ST667, 
ST645, ST649 and ST1341) (78). Importantly the particular ST can be associated with multiple 
serotypes, for example ST199 is commonly isolated expressing serotype 1, 15B, 19A or 19F 
capsules (84) and ST667 with serotypes 14 and 19 capsules (80). The rate o f multiple capsule 
expression is not known but in one study of 2100 isolates only 11 STs were associated with 
multiple capsular types (78). The combination of ST and serotype may be related to invasiveness 
(80) and has been investigated in studies examining the relationship between ST and IPD, AOM 
or NP carriage (79, 80, 85, 86). A UK study (86) in the <5 year olds determined the ST for 645 
pneumococcal isolates. The result was 150 STs associated with 33 serotypes, o f which 66% were 
Pncl 1-13 related. Some sequence types occurred in both vaccine type (VT) and non-vaccine type 
(NVT) serotypes, in particular ST9 was most commonly found expressing a VT serotype 4 
capsule but also NVT serotype 8 and 19A capsules (86). Other studies found that IPD strains had 
less diverse STs than NP strains but particular IPD serotypes may be associated with more than 
one ST which may alter the invasiveness of the strain. For instance, ST9 was the most prevalent 
IPD ST in Oxfordshire (79) and was associated with a serotype 14 capsule (Odds Ratio of 8.3) 
while ST124 with serotype 14 capsule had an odds ratio of 6.4. Thus it was determined that in 
IPD the capsule had more influence on invasiveness than the ST while it appeared that a 
combination of ST and capsule aided in the ability of a strain to cause AOM (79, 80, 85).
This association of multiple capsule types with particular STs provides evidence of capsule 
switching so it was important to determine whether mass immunisation with Pnc7 would place a 
selective pressure on the occurrence of particular capsule-ST combinations (78, 82). No evidence 
of exchange o f genetic material between VT and NVT strains was found in the <5 year olds but 
STs occurred in both VT and NVT strains (78). Following the introduction of the Pnc7 vaccine 
in the USA there was a rise in serotype 19A IPD in the <5 year olds and prior to immunisation
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this was associated with CC199. Following immunisation the 19A capsule was also expressed by 
6 new STs (82). Of greater concern was the finding of CCs (CC13, CC37, CC81, CC156, 
CC172, CC199, CC236, CC268, CC1269 and CC1296), that were associated with antibiotic 
resistance and also with expression of multiple VT serotype capsules (78).
1.4 Pneumococcal vaccines
High rates of IPD treatment failure in the era of antimicrobial therapy due to increasing 
antimicrobial resistance has generated renewed interest in pneumococcal vaccine development. 
In 1983 a 23-valent, polysaccharide vaccine (23PsV) was licensed in the USA and then in Europe 
(87). Subsequently, following on from the success of the Haemophilus influenzae type B 
conjugate vaccines introduced in the USA and Europe in the early 1990s, a heptavalent 
pneumococcal conjugate vaccine (Pnc7) was introduced in the USA in 2000 and in the UK in the 
autumn of 2006.
Pneumococcal capsular serotypes included in these vaccines are shown in table 1.1. The 
relevance of these vaccine serotypes to disease in the UK is shown in figure 1.8. Most cases of 
pneumococcal infection reported during 2005-2006 were covered by the 23-valent polysaccharide 
vaccine and seven of the most common serotypes would also be covered by Pnc7 (figure 1.8). 
The extent o f coverage o f eleven and thirteen valent conjugate vaccines, currently in trials is also 
shown. Serotype 5, although not seen in England and Wales during this surveillance period has 
been among the top 11 or 12 serotypes in the <5 and >5 year old populations in Europe (figure
1.6) and is globally important as an invasive serotype.
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Table 1.1 Pneumococcal capsular polysaccharides contained in the new generation of pneumococcal 
vaccines.
The serotypes are colour coded to show overlap between the vaccines. The heptavalent vaccine serotypes 
are included in all of the vaccines. The extra serotypes for the 9-valent vaccine are shown in red, for the 
11-valent in blue and the 13-valent in green. Serotype 6A is underlined since it only appears in the 13- 
valent vaccine.
vaccine _______  serotypes covered______________________protein carrier
23-valent, polysaccharide 
vaccine (Pneumovax™ )
1, 2, 3, 4, 5, 6B, 7F, 8 , 9N, 9V, 10A, 
11 A, 12F, 14, 15B, 17F, 18C, 19A, 
19F, 20, 22F, 23F, 33F
N/A
Heptavalent -  conjugate 
vaccine (Prevenar™ )
4, 6B ,9V , 14, 18C, 19F, 23F CRM  1 97  
OM PC
Nonovalent 1 ,4 , 5, 6 B, 9V, 14, 18C, 19F, 23F CRM  ] 9 7
Eleven valent 1, 3, 4, 5, 6 B, 7F, 9V, 14, 18C, 19F, 
23F
c r m 197
Thirteen valent 1, 3, 4, 5, 6 A, 6 B, 7F, 9V, 14, 18C, 
19 A, 19F ,23F
?
Pneumococcocal serotype distribution for isolates referred for serotyping: 
Epidemiological years for England and Wales (July-June) 2005/6
Pneumococcal serotypes included in the licensed 23-valent polysaccharide vaccine ( E )  and 
7-valent polysaccharide-conjugate vaccine {M) introduced in September 2006 in UK schedules.
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Serotypes included in the 9-(*), 11 -(** ) and 13-valent (* * * )  conjugate vaccines 
( *  Serotype-5 is also included in the vaccines but is missing due to absence from UK disease isolates).
Figure 1.8 Coverage of IPD serotypes in the UK by current and new generation pneumococcal 
vaccines.
The data show the 24 most commonly isolated serotypes during 2005-2006, prior to the introduction of the 
Pnc7 vaccine into the infant immunisation schedule. Serotypes covered by the 23-valent polysaccharide 
vaccine (clear/blue hatched columns), the heptavalent (blue hatched columns only), 11-valent (red asterix) 
and 13-valent (green and red asterix) conjugate vaccines are indicated with the exception of serotype 5 
which was not isolated during this period.
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1.4.1 Pneumococcal polysaccharide vaccines
The capsular polysaccharides contained in this vaccine were based on those most responsible for 
invasive disease plus some cross-reacting serotypes (88). A number of serotypes such as 12F, 8, 
22F, 15A, 15B and 11A are responsible for invasive disease and are included in the 23PsV but 
not in the newer conjugated vaccines (table 1.1)(69). The potential coverage of the 23PsV was 
found to be within the region of 90% of all IPD isolates in industrialised nations (89).
However the efficacy of the vaccine has not been so impressive with only 60%-70% responders 
in healthy, young adults and even lower in the >65 year olds (30%-80% efficacy against IPD) 
depending on underlying conditions (89, 90). The antibody induced by 23-PsV in the >65 years 
olds decreased to negligible levels for all but the most immunogenic serotypes by ten years post 
immunisation (91).
Finally the polysaccharide vaccine was ineffective in infants under 2 years of age (92-97).
Thus the populations most at risk from IPD (figure 1.5b) were not effectively protected by the 
polysaccharide vaccine.
A number of studies have looked in more detail at the response to the 23-PsV vaccine, 
concentrating on the antibody isotype (98, 99), subclass(100-102), function (103-105) and 
antibody secreting cells (ASC) (106-114).
Many of these studies were performed to establish the effects of age and/or underlying 
physiological condition on the immune response to the 23-Ps vaccine.
It was observed that increasing age was detrimental to the function of the antibody generated 
when compared to healthy young adults (105, 115, 116). The proportion of IgG2 induced by 
plain polysaccharide vaccines also increased with age (100,101,117).
Administration of 23-Ps to individuals with underlying conditions such as infection with the 
human immunodeficiency virus (HIV)(118), asplenia (119, 120), nephritic syndrome, asthmatic
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bronchitis (121) and non-Hodgkins lymphoma (NHL) (122), resulted in altered immunogenicity 
of individual serotypes within the 23-Ps vaccine. The results from these studies generally showed 
reduced antibody longevity and function compared to age matched controls.
1.4.l .i  Thymus independent (TI) response
The polysaccharide capsules of the 90, pneumococcal serotypes are conventionally called T cell 
independent type-2 (TI-2) antigens. TI-2 antigens have multiple repeating epitopes (glycotopes 
in the case of polysaccharides), that are capable of stimulating B cells in the absence of cognate T 
cell help.
The TI-2 responsive B cell subsets include marginal zone B cells (MZB), IgM-memory B cells 
and B la and B ib cells and follicular (FO) B cells, all of which are discussed in later sections. 
These cells provide rapid innate and adaptive responses (123) to initial polysaccharide encounter 
and produce large amounts of IgM antibody some of which shows evidence o f somatic 
hypermutation in the absence of T cell help (124, 125). The antibody response is generally short­
lived and boosting fails to elicit increased antibody concentrations.
The TI-2 B cell responses occur in the extrafollicular regions o f the lymph node medullary cords 
or splenic bridging channels (126). They form foci o f proliferating antigen specific B cell clones 
that differentiate into short-lived, low avidity antibody secreting plasma cells (126-128). The 
lack of direct-antigen specific T cell help in these areas means that there are no appropriate co­
stimulatory signals to induce class-switching, somatic hypermutation o f immunoglobulin (Ig) 
variable (V)-genes, memory B cell or long-lived plasma cell formation (129, 130). This process 
occurs within the first 3-4 days following immunisation or infection.
Some studies have questioned the lack of a role for T cells in polysaccharide responses (131-134).
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For example, glycotopes are able to associate with the MHC-class-1 like molecule, CDlc. CDlc 
is expressed at high levels by MZB enabling them to present polysaccharide epitopes to y8-T cells 
that may elicit a helper response (124, 135).
Zwitterionic polysaccharides (with negative and positively charged moieties) are able to associate 
with MHC class II (135). Examples of such polysaccharides are the capsules from pneumococcal 
serotype 1 and 3 (136, 137). Ordinarily polysaccharides inhibit lysosomal processing and do not 
bind the cleft of MHC class II (138). However, pneumococci with zwitterionic polysaccharide 
capsules are taken up by APC and killed via the nitric oxide (NO) pathway (136). These 
polysaccharides are then processed prior to normally required endosomal-lysosomal fusion as a 
neutral rather than acidic pH is required (136). The processed polysaccharide is then able to 
localise in the binding cleft of MHC class II (HLA-DR) and be presented at the cell surface (136, 
137).
Pneumococcal polysaccharides have been shown to associate with dendritic cells (DC) and are 
taken up in endosomal compartments leading to altered cytokine production that may ultimately 
affect the outcome of the antibody response (139).
Finally, another marginal zone B cell surface receptor, SIGN-R1 (specific intracellular adhesion 
molecule-grabbing non-integrin-Rl), binds the capsular polysaccharide o f serotype-14 with high 
affinity, leading to uptake of the polysaccharide and activation of the MZB (140).
In children <2 years of age, the poor immunogenicity and longevity of the antibody response to 
23-Ps immunisation has been suggested to result from an immature splenic marginal zone and 
possibly an immature bone marrow stromal cell environment (141-143). The marginal zone of 
the spleen is probably the major physiological site for anti-polysaccharide responses generated 
against encapsulated, blood borne bacteria, (144) and is the site of germinal centre (GC) 
formation in older children and adults (145, 146).
39
The lack of efficacy of 23PsV in the elderly and children <2 years of age has led to the generation 
of pneumococcal glycoconjugate vaccines with the aim of enhancing the immune response to IPD 
causing serotypes.
1.4.2 Conjugate vaccines
Since children <2 years of age make poor TI-2 immune responses but effective T cell dependent 
(TD) responses to protein antigens, the immune response to polysaccharides has been 
successfully manipulated by joining the polysaccharide to a carrier protein to create 
glycoconjugate vaccines (147). Common carrier proteins are tetanus toxoid (tet), diphtheria 
toxoid (dip), mutant diphtheria toxoid-cross-reactive material (CRMi97) or outer membrane 
protein complex (OMPC) of Neisseria meningitidis (148, 149).
The original bacterial conjugate vaccine was introduced to protect infants and young children 
against invasive disease caused by Haemophilus influenzae Type B (HiB) (148, 150). The 
vaccine targets the capsular polysaccharide polyribosyl ribitol phosphate (PRP) and contains 
between 3-10 repeating units joined to a carrier protein to enhance its immunogenicity (148). 
Inclusion of this vaccine into the childhood immunisation programme led a to dramatic fall in 
disease rates and in carriage, that in turn led to herd immunity in the unvaccinated population 
(151). On the basis o f this success new pneumococcal conjugate vaccines (Pnc) were developed, 
containing 7-, 9-, 11 or 13 capsular polysaccharides, each individually conjugated to a carrier 
protein (Table l.i).
The Pnc7 has led to reduced rates of carriage and invasive disease in infants since its introduction 
into the USA immunisation schedules (152-157). Figure 1.9 shows how dramatically rates of 
IPD dropped following the Pnc7 introduction in the Northern California Kaiser Permanente
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population, for all children <5 years old (152, 158). Also of note is the slight increase in rates of 
non-vaccine and cross-reactive serotype IPD during the same vaccination period (152, 157). 
Pnc7-induced herd immunity has also reduced transmission of the bacteria from infants to other 
age groups resulting in a decline in disease rates in adults (159, 160). A study in the United 
States revealed a 93% reduction in invasive disease as well as reduced rates of pneumonia and 
otitis media (161).
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Figure 1.9 The effect of Pnc7 on rates of IPD in the <5 year olds in Northern California
(Black et al, figure 1 (152)). The chart shows the annual incidence of IPD for April 1996-March 2003. 
(2Q=2nd quarter- 1Q= 1st quarter).
In comparison to the original 23PsV, Pnc vaccines are highly immunogenic in infants and 
toddlers <2 years of age (studies 2, 4, 5, 6 , 7, 8  and 9 (152, 157, 162-166), Table 1.2). The Pnc 
vaccines are also immunogenic in older children and adults with underlying conditions such as 
recurrent infections (study 3 (167, 168)), or with HIV (169, 170), Table 1.2). Pnc7 vaccine 
successfully primes infants and toddlers to mount strong amnestic responses to subsequent 
booster immunisation with 23-Ps at 12-18 months (studies 2 and 7 (165, 166), Table 1.2), but 
only against Pnc7 serotypes and not unrelated serotypes that are included in 23-PsV booster doses
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(171). A similar effect has yet to be demonstrated in adults >50 years of age where immunisation 
with a Pnc5 vaccine failed to prime adults for stronger booster responses to 23-PsV (study 1(172), 
Table 1.2).
One major issue with the Pnc vaccine is that co-administration of other routine childhood 
immunisations appears to have a detrimental effect on the immune response to the polysaccharide 
antigens, particularly when Pnc containing tetanus toxoid as the carrier protein and diphtheria- 
tetanus-acellular Pertussis (DTaP) is given at the same time (studies 4 and 9 (157, 163), Table 
1.2 ).
Three UK studies showed that the benefit o f introducing the Pnc7 vaccine into the UK 
immunisation schedule would cut IPD rates by >60% (64, 72, 173). However, coverage of 
disease causing serotypes by the Pnc7 vaccine would be 79-84% in infants and <66% in adults 
>65years old (64, 72).
The current trends for pneumococcal disease for the UK and the coverage that might be obtained 
with the introduction of the heptavalent conjugate vaccine are shown in figure 1.10 (black line for 
the serotypes covered by the vaccine). It can also be seen from this data that an equivalent 
number of cases have occurred due to non heptavalent vaccine serotypes (red line), and it remains 
to be seen whether full vaccine coverage will have the same success in the UK as was seen in the 
USA.
The Pnc7 vaccine was introduced into the UK vaccine schedule in September 2006 (indicated by 
the green markers in figure 1.10). Two doses are to be given to infants at 2 and 4 months o f age 
with a 3rd dose at 12 months of age. A catch up campaign was also carried out using a single dose 
at 12 months of age. The original USA schedule was for 4 doses (2, 4, 6 and 12 months), but due 
to shortages only 31% of infants received the full primary schedule, 74% received 3 doses (152).
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Studies on number of doses have suggested that reduced dose schedules in infants and toddlers 
would suffice: i) a single dose at an optimal age of 5-7 months could protect against 15-62% IPD 
in the USA (174) and ii) a reduced, 2 dose schedule for priming was comparable to 3 dose 
priming in infants and a single dose in toddlers (175).
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Figure 1.10 Seasonal fluctuation in pneumococcal disease in the UK reported to the HPA between 
1999-29-03-2007.
( http://www.hpa.org.uk/infections/topics az/pneumococcal/I PD5WMA.htm)
Poor coverage of some serotypes in Western Europe and developing countries prompted 
development of nine- and eleven-valent conjugates (table 1 .i)( 176) and they improved serotype 
coverage dramatically (72).
Recent observations indicate the need for vaccines which provide broader protection. For 
example, there has been an increase in carriage of non-vaccine serotypes and also invasive 
disease caused by these serotypes since the introduction of the heptavalent vaccine (177). 
Increasing frequency of non-vaccine serotype carriage may be due to an expansion of 
asymptomatically carried pneumococcal serotypes, or be the result of genetic transformation via 
horizontal transfer of capsule genes, a process known as capsule switching which can be
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identified by MLST (81). Thus, benefits of immunisation with these multivalent vaccines maybe 
diluted by the emergence of new serotypes not previously seen as major causes of disease.
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I.4.2.i Thymus dependent (TD) response and the role of cytokines in Ig class 
switching
The carrier proteins of conjugated polysaccharide vaccines recruit CD4+ T cell help into the 
vaccine response. In the TD response CD4+ T helper (Th) cells provide signals for the 
differentiation of naive B cells into plasma cells and memory B cells along with the induction of 
class switching and somatic hypermutation (132,159,160, 182-186).
In the multi-valent pneumococcal conjugate vaccines, each capsular polysaccharide is 
independently conjugated to the carrier protein CRMi97, and this causes variability in 
immunogenicity and in the isotypes of antibody elicited (93, 157, 165,187-189).
Following the intra-muscular administration of a glycoconjugate vaccine the individual 
polysaccharide-protein conjugates either free or bound by local tissue dendritic cells are 
transported to the local draining lymph nodes. Here the polysaccharide and carrier protein may 
be bound directly by antigen specific B cells via the B cell receptor leading to direct activation or 
they are taken up and processed by DCs and B cells, both professional antigen presenting cells 
(APC), and the protein carrier presented to local T cells in the context of MHC class II.
Naive T cells are primed only by DCs expressing processed carrier protein peptides. Primed T 
cells are able to interact with activated B cells presenting carrier protein peptides on MHC class
II. Thus previous exposure to carrier proteins, such as tetanus and diphtheria toxoid, enhances 
immunogenicity o f conjugate vaccines and can boost carrier specific responses in previously 
immunised individuals (190).
However the cytokines produced by the activated T cells within the GC can determine the isotype 
and therefore biological function of the antibody induced following immunisation (figure 1.11).
47
Following BCR ligation by specific antigen, two further signals are required for initiation of class 
switch recombination (CSR). One is the interaction of CD40L (on the T cell) with CD40 (on the 
B cell). The second is that provided by cytokines that induce signals for B cell proliferation, 
differentiation and CSR to particular isotypes (191-193).
Following glycoconjugate immunisation the desired outcome is the generation of high avidity 
IgGl(102) although there is generally a mixed ratio of IgGl:IgG2 that is dependent on age and 
vaccine formulation (101, 102). Plain capsular polysaccharide and conjugate vaccines induce 
IgA2 production from polysaccharide specific B cells (98, 99, 194). Previous studies have shown 
differences in Ig isotype induction and immunogenicity of the individual polysaccharide-protein 
conjugates (188, 189, 195). In a recent murine study serotypes-19F and 14 were conjugated with 
CRM and the antibody isotypes induced were identified. The 19F-CRM conjugate induced high 
anti-CRM responses and an IgGl mediated anti-19F response. The serotype 14-CRM conjugate 
elicited a poorer anti-CRM response and an equal proportion of IgGl and IgG2a in response to 
the type-14 capsular polysaccharide (189). In a similar study, but in humans, the anti-CRM T cell 
response was equally robust for all of the CRM-polysaccharides combinations, while the anti­
polysaccharide antibody responses were variable (188). Therefore it was suggested that the 
cytokine environment within the germinal centre, induced by the individual polysaccharide 
protein conjugates may differ depending on the polysaccharide conjugated to the protein (188). 
One of the mechanisms contributing to this was suggested by McCool et al (93) where 
polysaccharides could alter the peptide specificity of the T cell response as a result o f altered 
antigen processing pathways for individual serotype polysaccharides. This was also confirmed 
by Leonard et al (196) who showed that unconjugated CRMi97 or CRMi97-serotype 14 or 18C 
were processed and presented more efficiently than the other vaccine type conjugates. Finally, in 
a study from 2004 it was shown that serotype 14 polysaccharide conjugated to PspA protein 
induced CD4+ T cell ap TCR specific responses to both the protein and polysaccharide 
components of the conjugate (132).
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Blocking of the signals between B and T cells either by monoclonal antibodies or by using gene 
knock out (k/o, -/-) mice have proven that CD40-CD40L interactions are essential for TD 
antibody responses (182, 193, 197-203). The main outcome of these experiments in murine 
models was a block in naive B cell differentiation into plasma cells and immunoglobulin 
synthesis (201, 204). More specifically there was no production of IgGl or IgG2a in mice (203). 
Natural Killer (NK) cells are also capable of providing the CD40-CD40L interaction to B cells, 
mainly to the innate CD5+ B cells leading to IgM production (198).
Therefore in the presence of the appropriate co-stimulatory signals cytokines secreted by T, B and 
NK cells direct the antibody response. In mice and humans there exist different CD4+ T cell 
subsets that are identified by the cytokines they secrete. Figure 1.11 shows how the 
differentiation of these CD4+ T cell subsets is induced. Production of IL-12 and IL-27 by APC 
induces T helper type 1 (Thl) CD4+ T cell differentiation while the secretion of interleukin (IL)-4 
by APC in the germinal centre environment can induce a T helper type 2 (Th2) response in the 
absence of interferon-gamma (IFNy) (205). In humans the subsets o f CD4+ T cells includes 
Thl, Th2, Thl7 and T regulatory (Treg) cells, figure 1.11 (206). Thl cells secrete IFNy, tumour 
necrosis factor (TNF), IL-2 and granulocyte macrophage-colony stimulating factor (GM-CSF). 
Thl cytokines in humans induce antibody isotypes IgGl and IgG3 while in mice IgG2a and 
IgG2b result. Th2 cytokines induce IgG2 and IgG4 in humans and IgGl in mice (191, 203). 
Figure 1.11 shows how the Thl and Th2 responses interact to regulate one another so that IFNy 
suppresses Th2 responses and IL-4 suppresses Thl responses (191, 206, 207).
IL-10, produced by CD4+ Treg, is a major Ig-gene CSR factor (192, 193, 199, 208). In 
conjunction with CD40-CD40L co-stimulation the targeted naive B cell differentiation into 
memory B cells is blocked by IL-10 with preferential differentiation into plasma cells(209, 210) 
that secrete IgM, IgA and IgGl, 2, 3 and 4 (192, 193, 208). However, IL-10 in the presence of
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IL-4 increased CSR from IgM to IgG but there was no secretion of antibody, while IL-4 alone 
induced IgE CSR and secretion (192, 193). IL-10 with IL-13 resulted in no Ig CSR while IL-13 
with IL-4 resulted in IgE and IgG (192, 193). Therefore it appears that IL-10 negatively regulates 
Th2 TD responses (211). TGF(3 alone or in combination with IL-10 results in IgAl and IgA2 
production (192, 193).
Thl cytokines IL-2 (212, 213) and IFNy enhance IgG synthesis and B cell growth and 
differentiation.
Another regulatory cytokine, IL-21, has recently been implicated in B cell differentiation (200, 
214-216). It is produced by peripheral blood CD4+ T cells (200, 216) and NKT cells (216) along 
with follicular CD57+CXCR5+ T cells (200, 217). The receptor for IL-21 (IL-21R) is expressed 
highly on naive and to a lesser extent on memory B cells (214) and is also found on MZB (215), 
some T cells and NK cells (200, 216). The effect of this cytokine is to enhance proliferation, 
differentiation and CSR in B cells, particularly naive B cells, but again requires B cell co­
stimulation via CD40-CD40L (200, 214). Thl cytokines (IL-2) enhance the activity o f IL-21 
while Th2 cytokine (IL-4) inhibit it (200) and in combination with B-lymphocyte stimulation 
protein (BAFF), IL-21 induces MZB differentiation into plasma cells (215).
Finally a subset of CD45RO+ T cells that secrete IL-17 (called Thl7 cells) have an unknown role 
in immunoglobulin synthesis but are known to have a proinflamatory role inducing IL-6, IL-8, 
TNFa and GM-CSF production (218). IL-23 is essential for IL-17 secretion (219). This entire 
process can be blocked by the presence of IL-27 that in combination with IL-12 is a potent 
inducer of Thl cell differentiation (220). Therefore it seems that IL-27 promotes beneficial 
production of Thl cytokine responses to specific antigens such as tetanus toxoid and purified 
protein derivative, while IL-23 promotes a more pathogenic inflammatory process mediated IL- 
17 mediated production of inflammatory responses in organs and neuronal tissues (in the absence 
of IFNy) without promoting Thl responses (218, 220). Thus in figure 1.11 the balance o f 
cytokine production is described with Thl and Th2 pathways being important for antibody class
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switching and regulated by Treg produced IL-10. Further discussion of cytokine involvement in 
vaccine responses can be found in chapter 3.
T cells have also been shown to recognise carbohydrate antigens. T cell clones that were specific 
for the carrier protein (tetanus toxoid) and also to the meningococcal group C polysaccharide 
(MCPS) were generated in response to immunisation with a meningococcal group C-tetanus 
toxoid conjugate in mice. While the TT clones were found to be conventional MHC class II 
restricted CD4+a(3 TCR clones the MCPS clones were also CD4+aP TCR phenotype but 
unrestricted by MHC class II although requiring direct contact with APC for in vitro proliferation 
(221 ).
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1.11 Factors that help determine the differentiation of naive, CD4+ T cells into four major subsets 
(Treg, T h l7, Thl and Th2 cells) (206).
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1.5 Host immune response to initial pneumococcal 
exposure
1.5.1 Recognition of colonising bacteria
Interaction between the pneumococcus and the host occurs initially in the nasopharyngeal mucosa 
during transient carriage. Colonising bacteria at the mucosal surface are detected via pathogen 
recognition receptors (PRRs) that bind highly conserved bacterial components, or pathogen 
associated molecular patterns (PAMPS) (15, 222). A family of PRRs called the Toll Like 
Receptor (TLR) family have a role in the innate immune response to pneumococci.
TLR-2,4, and 9 have been identified as having synergistic roles in immunity to IPD (11, 223). 
TLR-2 is the receptor for lipoteichoic acid and peptidoglycan and mediates the immune response 
to pneumococci by enhancing the response in synergy with other TLRs (223). Challenge o f TLR- 
2 knock-out mice resulted in increased bacterial cell numbers in the brain (18) when compared to 
control mice.
TLR-4 is involved in inflammation induced by pneumolysin (45, 224, 225) and absence o f TLR- 
4 increases susceptibility to NP colonisation.
TLR-9 binds un-methylated cytosine-phosphate-guanosine (CpG) DNA sequences that are 
released during bacterial cell lysis and induce B cell activation (226, 227). TLR-9 expression is 
localised to the endosomal compartment of epithelial cells and APC such as dendritic cells and B 
cells but expression is only up-regulated by naive B cells following antigen receptor cross-linking 
(228, 229) and then remains expressed by memory B cells. Therefore phagocytosis and lysis of 
bacteria allows CpG-DNA to bind TLR-9, enhancing the activation signals to the immune cells 
(230). A particular synthetic CpG sequence called CpG2006 (CpG motifs in bold) (5’ TCG- 
TCG-TTT-TGT-CGT-TTT-GTC-GTT 3’) has been identified as ideal for activation of human B 
cells in vitro (229, 231, 232).
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1.5.2 Mucosal IgA response to pneumococcal carriage
Pneumococcal colonisation of the nasopharynx generates a predominantly IgA mediated response 
(233). IgA binds to pneumococci or the breakdown products of lysed bacterial cells and these 
are then targeted for phagocytosis via the FcaRl on macrophages or the antigen-antibody 
complexes are transported to the mucosal surface via the plgR transcytosis mechanism (41). 
Therefore IgA appears to be a critical evolutionary first line of defence against colonisation (234) 
and pneumococcal protein-specific IgA can be detected in saliva of children as young as 6 
months of age, possibly induced by carriage (61). IgA can be induced in a T cell independent 
manner, via secretion of transforming growth factor-beta (TGF-J3) from non-lymphoid cells 
which is able to induce class-switch recombination in IgM+IgD+ B cells toward IgA expression 
(235).
1.5.3 Clearance from the mucosa
Until recently it had been assumed that anti-capsular antibody mediated clearance of 
pneumococci from the nasopharynx. This inference was based on the correlation of serum 
antibody levels increasing with age and frequency of carriage while IPD rates decreased. Also, 
pneumococcal vaccines induced elevated serum antibody concentrations that correlated with 
reduced carriage (37, 55, 236,237).
However, it has recently been proposed that clearance o f pneumococci from the nasopharynx 
involves mechanisms that are independent of capsule specific antibody. The proposed 
mechanism is a combination of innate immune responses, anti-surface protein antibody and CD4+ 
Thl cells (38, 49, 224, 238-241).
McCool et al demonstrated that in humans exposure to and subsequent carriage o f an attenuated 
serotype 23F pneumococcal strain was unaffected by the hosts serum antibody level. However
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they did find that NP exposure to the same strain induced anti-PspA IgG in the serum and 
secretary IgA at the mucosa. They also found that those who did not carry the serotype already 
had higher levels o f pre-existing anti-PspA IgG and IgA than those who did develop carriage 
(238). In a later study this group also demonstrated that only the more variable surface proteins 
(PspA and CbpA) were accessible to the host immune system and that these proteins induced 
antibody that correlated with protection from carriage (239).
1.5.4 Immunity to blood borne pneumococci
Once the pneumococcus enters the blood stream the PCh residues in the CwPS bind to CRP (222) 
which, in turn, activates the classical complement pathway leading to opsonisation (47). 
Complement bound to CwPs is able to cross-link the B cell Receptor (BCR)-co-receptor complex 
and complement receptors (CD21 and CD35) on B cells, leading to enhanced activation signals 
and natural antibody production by the specific B cell (242, 243). The anti-CwPs and anti-PCh 
antibody can be IgM or IgG and accumulate with age (6, 244) induced by the repeated exposure 
to pneumococcal serotypes through NP carriage (244).
Natural IgM antibody binding the bacterial cell surface induces classical complement activation 
and deposition of C3b and blocking of this mechanism in mice leads to rapid septicaemia (245). 
Therefore, anti-CwPs-Ab provides a first line o f defence against blood borne IPD, though the 
mechanisms involved in this protection are unclear since the ability o f these antibodies to 
opsonise and target the bacterium for phagocytosis is poor (16). One possibility is that antibodies 
directed against CwPS neutralise the inflammatory effects induced by the breakdown o f this 
molecule (6) thereby decreasing pathogenicity.
Another PRR-PAMP innate mechanism for clearance of blood borne pathogens involves 
mannose-binding lectin (MBL). MBL fulfils the role of capsule specific Ab, opsonising the 
polysaccharide capsule and activating complement, while the bacterium is in the spleen or liver, 
and induces phagocytosis. LPS binding protein (LBP) also has a role in protection of the host
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against IPD since it binds to the peptidoglycan, a component o f all bacteria providing broad, non­
species specific immune recognition (11).
1.5.5 The role of dendritic cells
The innate immune system provides a regulatory pathway for the adaptive immune response to 
pneumococcal infection through the role of DC (246). DCs recognise non-self molecules 
(PAMPs) via the TLR mediated recognition of danger signals, such as heat shock proteins (hsp), 
bacterial DNA and surface antigens (247).
Invading pneumococci activate epithelial cells, NK cells and mast cells that are then induced to 
secrete hsp. DCs constantly survey the mucosal surfaces and become activated in response to 
these danger signals (246). They are phagocytic cells that engulf invading bacteria or bacterial 
cell breakdown products and then migrate to the local secondary lymphoid tissues. In the 
nasopharynx the local lymphoid tissues are the tonsils or adenoids, while for blood borne 
pathogens, such as pneumococci, the major lymphoid organ is the spleen (248).
It has been suggested that different DC subsets will determine the outcome of the T cell response 
(247). For example, DCs that home to the Peyers patches of the gut or those in the respiratory 
tract may help prime a Th2 response, while those in the spleen may skew the response of T cells 
toward a ThO/Thl. DCs interact with MZB in mice to induce Tl-responses, which may also be 
the case in humans (248). DCs are also involved in the response of memory B cells. Myeloid 
DC express BAFF that allows the survival of peripheral naive B cells and memory B cell derived 
plasma cell survival(249). This allows CD40-independent Ig class switching in response to TD 
and TI antigens.
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1.6 B cell subsets mediating T cell independent 
responses to pneumococcal polysaccharides.
1.6.1 IgM memory
IgM memory is an important immunological mechanism that provides rapid natural and antigen 
specific memory responses. Initial protection from encapsulated bacteria such as S. pneumoniae,
H. influenzae and N. meningitidis and other blood borne infections such as Borrelia hermisii, is 
mediated by IgM. IgM memory increases from birth, peaking during young adulthood and 
declining again in the extreme elderly (fig 1.12) (144, 250-253).
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Figure 1.12 Frequency of IgD+IgM+CD27+ B cells (CB2 or MZB) in human peripheral blood.
PBMCs were isolated from 140 healthy donors aged (0-99years). From Y. Shi et al, figure 6(250).
Following primary exposure to carbohydrate antigens activated B cells differentiate into non­
proliferating, short-lived plasma cells (PC) that secrete antibody (predominantly IgM), with 
germline gene arrangements, by day 5 of the immune response (145, 254-258) and disappear 
from the peripheral blood by two weeks after vaccination (259-262). These cells re-circulate 
through the peripheral blood, reside mainly in the spleen or peritoneum and have a half-life of 3-5 
days (263). This early phase of the humoral response occurs in the absence of germinal centre 
formation and without direct interaction with T cells. Therefore there is no generation of classical
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memory B cells, although there may be some class switching of secreted antibody to low avidity 
IgGl or IgA (256-258, 263-266). Furthermore, repeat immunisation of adult humans with plain 
polysaccharide vaccine does not result in enhanced immune responses or new generation of 
antibody forming cells (AFC) (108, 267). Pneumococcal polysaccharide-protein conjugate 
vaccines on the other hand induce B and T cell memory and long term antibody production by 
recruiting T cells in a TD response(93,188, 189).
There are three main B cell lineages, the B la  cells, B ib cells and the B2 cells that interact to 
control the early stages of infection, providing long term immune memory to protect from re­
infection (268-271). B la  and B ib cells mediate the innate immune system, while the B2 cells 
(marginal zone and follicular B cells) provide the adaptive immune response.
BCR signalling is required for survival of all B cells (272) and it is the strength of antigen 
receptor signalling that determines the pathway along which the B cell precursors develop. 
Strong signalling through the BCR generates B IB  cells, while signalling of intermediate strength 
leads to FO B cell development and weak signalling, involving the Notch2 pathway, induces 
MZB development (272, 273). Baker et al (274) suggested that the concentration and quality of 
the naturally occurring IgM can regulate the B cell subset that differentiates from immature B cell 
precursor in the spleen. In their murine studies, high concentrations of polyclonal, cross-reactive 
IgM results in a reduction in the numbers of B1 and MZ B cells and an expansion of FO B cells 
as a result of enhanced BCR signalling (123). Other surface molecules help to regulate 
differentiation of these subsets. Those that inhibit or impair BCR signalling select for MZB cells 
development, for example CD22 which inhibits antigen receptor signalling (275) and CD21 
(complement receptor (CR)2)(276). An absence o f CD22 allows the development of FO B cells 
(277, 278) while the absence of CD21 leads to MZB cell development (276). Likewise, CD19 
enhances BCR signalling and absence leads to MZB development impairment (279).
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1.6.2 B1 cells (CD5+/‘ B cells).
The B1 cells appear earliest in mammalian B cell development, arising from progenitor cells in 
the foetal liver. They are maintained as a self replenishing population in the peritoneal and plural 
cavities of mice and humans throughout adulthood (280). Studies in asplenic mice revealed that 
the spleen may also be essential for survival and self-replenishment of B1 cells in mice (281). In 
mice, the expression of CD4510 (B22010) IgMhl CD23'CD43+IgD1° (282) distinguishes the B1 cells 
from conventional B2 cells. The B1 cell population is then further subdivided in mice and 
humans, based on the surface expression of the CD5, into B la  (CD5+) and B ib (CD5') cells (283, 
284).
The developmental lineage of B1 cells was clarified more recently by Montecino-Rodriguez et al 
2006 (270) who identified B1 cell progenitors in mice with the phenotype o f Lin'CD45Rl0‘ 
ne8CD19+ (B1 cell progenitor) while the conventional B2 cell progenitor is Lin+CD45R+CD19'. 
They found the B1 progenitors were present at high frequencies in murine foetal liver but at very 
low frequency in adult bone marrow (figure 1.13). They were also able to show that the B1 
progenitor isolated from adult bone marrow only differentiated into B ib cells not B la  cells thus 
confirming three separate B cell lineages in mice (269-271).
The role played by the B1 cell subset as a whole is rapid generation of poly reactive IgM antibody 
(and also IgA and IgG3 (282)), that targets highly conserved, PAMPs, such as PCh residues 
found in CwPS of all pneumococcal serotypes, phosphatidyl choline (PtC), lipopolysaccharides 
(LPS) and influenza virus antigens (282, 285). B1 cells do not express terminal deoxynucleotide 
transferase (TdT), thus immunoglobulin heavy and light chain genes are expressed as germline 
sequences with no somatic hypermutation (SHM) (282). As well as recognising PAMPs, the 
antibody produced by B1 cells can also react with specific antigens such as the polysaccharide 
capsules of encapsulated bacteria like Streptococcus pneumoniae (282, 286, 287). B la  cells are
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thus, responsible for the rapid and early production of natural antibody specific for PAMPs, the 
role of which is probably to mediate complement-antibody mediated opsonisation and 
localisation of capsular polysaccharide antigens to the marginal zone, allowing cross-linking of 
the BCR co-receptor (CD19/CD21) complex (288). The B ib  cells then generate antibody in 
response to antigen challenge, providing a longer lasting response to specific antigens such as 
pneumococcal polysaccharides, influenza virus proteins and Borellia hermisii antigens (268, 289, 
290). Further still, in a murine study, natural IgM antibody specific for influenza haemagglutinin 
was detected prior to infection (the B la  cell response) but did not increase following infection, 
while IgM produced by B2 cells rose by days 7-21 (290) suggesting that the innate and adaptive 
arms of the humoral response interacted to provide protection from influenza virus infection.
The expression of CD5 and CD 19 surface molecules are thought to act independently to regulate 
the development of the B la  and B ib cell responses. CD 19 knock out mice only develop B ib  
cells and are susceptible to infection in the absence of prior exposure of the mouse to the specific 
antigen (268). CD5 expression provides a mechanism for stimulation of B la  cells that is 
independent of BCR signalling, maintaining survival in the absence of proliferation of the B la  
cells (291, 292) and this may be related to NFkB expression levels (293, 294). It was also 
suggested that CD5 is an activation marker rather than a lineage marker (291, 295) that targets B 
cells for apoptosis following BCR ligation (296). In a recent human study it was shown that CD5 
was down regulated by Epstein Barr Virus (EBV) infected B la  cells preventing apoptosis o f the 
transformed B cell (296). On the other hand, higher levels of CD5 expression have been noted on 
B cells offflV* individuals (297).
Proliferation and differentiation of B1 cells into Ig-secreting cells is also maintained by IL-5 
secreted by helper T cells and mast cells (285). In mice stimulation of B1 cells and IgD+ splenic 
B cells by IL-5 induced the production of IgGl (298). Importantly, since B1 cells mediate the 
innate humoral response to invasive bacterial and viral pathogens, TLRs are thought to regulate
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the activation and migration of this B cell subset without the need for BCR ligation (299, 300), 
providing a mechanism for maintenance of natural IgM and mucosal IgA levels.
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Figure 1.13 A scheme of B cell subset development from specific progenitor cells in mice, that may be 
similar in humans.
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1.6.3 The B2 cells (marginal zone and follicular B cells).
MZB cells and follicular (FO) B cells are separate developmental B cell lineages that, in mice, 
appear to originate from the same precursor cell (274). The newly formed (NF) B cell precursor 
(also called Tl), develops in the marginal sinus of the spleen and then migrates to the follicle 
under the influence of CXCL13 (the ligand for CXCR5/3). Here the NF B cell precursor 
differentiates into T2-FP precursor that, in turn, becomes a follicular B cell 
(IgMhlIgDh,CDldloCD21intCD23+) or into a second, very similar precursor T2-MZB that becomes 
a MZB (IgMhiIgDl0CD21hiCDldhiCD23l0) (273, 301).
Thus, in the spleen and lymph nodes of mice there are two or three subsets o f B cells with the 
IgDhlCD23hl phenotype (FO, T2-FP and T2-MZB in the spleen and FO, T2-FP in the lymph 
nodes). It is possible that this may also be the case in humans were the MZB cell phenotype is 
CD27hlIgMhlIgDloCD21hlCD23'CDlchi. In mice and in humans the MZB and FO B cells can be 
identified by the level of surface IgD expression where FO B cells are IgDhl and MZB are IgD10 
(252, 302, 303). MZ and FO B cells are also distinguished by the expression of surface CD9 and 
Fc receptor homolog (FcRH)-3(304).
1.6.3A Marginal zone B cells
The MZB cells have recently been associated with responses to TI-2 antigens such as 
pneumococcal polysaccharides (123, 252). They contribute to the initial, rapid formation of 
plasmablasts in response to blood borne pathogens such as pneumococci, providing a first line of 
defence against blood borne pathogens (123, 305). MZB cells exist in a highly activated state 
compared to FO B cells, including higher levels of Blimp-1(306) that is required for rapid 
differentiation into plasmablasts (123). Human MZB cells are also distinguished by the high 
level expression of CD38, CD9, CD25, and migratory markers such as 02 integrin, LFA-1 and 
a4(31 integrin (301, 307). Expression of these markers further confirms that MZB cells are not a 
resting cell but are poised to mount rapid responses to invasive pathogens (301, 307).
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MZB cells have been identified in rodents and humans but in rodents these cells are limited to the 
spleen and do not re-circulate (273), while in humans the MZB cells reside in and home to the 
marginal zone of the spleen, but re-circulate through peripheral blood and are found in other 
secondary lymphoid organs (252, 253).
The TI-2 response is dependent on the presence of a mature and functional spleen (308). It has 
previously been demonstrated in mice and humans that loss of the spleen, splenic hypofunction or 
congenital asplenia leads to a loss of the IgM+memory population (144, 309) resulting in higher 
rates of disease caused by encapsulated bacteria (281).
Therefore residence of MZB cells in the splenic marginal zone means that they are ideally 
situated to respond to blood borne pathogens. In humans, the marginal zone separates the outer 
red and inner white pulp of the spleen and has been subdivided into inner and outer areas based 
on the presence of specialised fibroblasts and helper T cells (146). Lymphocytes re-circulate 
through the spleen, via the central arterioles that open into the perifollicular zone, between the 
marginal zone and outer red pulp (figure 1.14).
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Figure 1.14 Structure of the secondary lymphoid tissues of the lymph node and spleen
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Reticular fibres arise from the central arterioles, forming bridging channels between the red and 
white pulp. Specialised marginal DC reside there while blood derived DC (C D llc10) and 
neutrophils that bind whole bacteria or soluble bacterial polysaccharides (among other antigens) 
on their surface migrate to the bridging channels of the spleen where they present the 
polysaccharide antigen to the MZB cells (248). It has recently been demonstrated that the 
capsular polysaccharides are preferentially sequestered in the marginal zone of the spleen (139). 
Surface lectins on DCs bind the carbohydrate antigens and enhanced migratory capacity allows 
these cells to re-locate to the spleen. Exposure of these particular DCs to pneumococcal antigens 
has been shown to induce up-regulation of B lymphocyte stimulator (BlyS or B cell activation 
factor, BAFF) and APRIL (A proliferation-inducing ligand), that interact with BAFF-R (receptor) 
and TACI (transmembrane activator and calcium modulator cyclophilin interactor) and BCMA 
(B cell maturation factor) on the B cell. BLyS and APRIL are soluble factors that bind to BAFF- 
R, TACI or BCMA and this is required for plasmablast formation (310-314). The interaction of  
MZB cells with DCs induces rapid proliferation and differentiation of the MZB into antibody 
secreting plasmablasts.
In response to viral infection in mice it was shown that the MZB (CD23h,CD21hl) rapidly 
responded with class switched IgG specific for the virus by day 5 after challenge while the 
follicular B (CD23l0CD21l0) cells did not exceed the MZB contribution until three weeks after 
challenge (307, 315). This process has also been shown in mice where the MZB provide rapid 
ASC formation that switches from IgM to IgG by day 8 post challenge while the FO B cells 
rapidly form germinal centres but no ASC appear until day 8 after challenge (123, 301).
Marginal zone macrophages (in rodents) also play an important role in retaining antigen specific 
lymphocytes in the marginal zone. They present polysaccharide antigens via surface receptors 
such as sialic-acid binding lectins (Siglecs), presenting conformational epitopes to the B cells. 
However, this mechanism has not been demonstrated in humans (146).
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MZB cells increase in frequency with age (figure 1.12), but have an immature phenotype in 
infants under the age of two years. The functional difference between MZB in the under 2 year 
olds and adults involves the lack of CD27 and CD21 expression in the marginal zone (144, 316). 
Before the age of 2 years children have an immature splenic marginal zone structure that is 
unable to support CD27+ MZB cells, (the lack of CD27 expression in the marginal zone of infant 
spleens has been demonstrated in several studies (316, 317)), and renders infants incapable of 
mounting rapid secondary responses (316). CD21 (complement receptor 2) is highly expressed 
on mature MZB cells but not on MZB from children <2 years of age. CD21 binds the C3d 
component of complement that opsonises bacterial capsular polysaccharides and failure to engage 
CD21 at the same time as BCR ligation reduces the activation signal received by IgD+IgM+ B 
cells and may induce apoptosis of MZB cells binding polysaccharide via the BCR(316, 318).
The combination of low MZB frequency in this age group with reduced MZB responsiveness 
may be among the reasons for elevated rates of IPD caused by blood borne pathogens (317).
CD27 and also CD 148 are markers for human memory B cells (319) and approximately 40% of 
human peripheral blood B cells are memory (CD27+) B cells and within this memory population 
50% express class-switched (IgG, IgA, IgE), immunoglobulins. The remaining 50% of peripheral 
blood memory B cells consist mainly of IgM+IgD+CD27+ B cells with a small number of IgM 
only or IgD only memory cells (146, 252, 273, 320, 321). On FO B cells CD27 indicates 
previous germinal centre development and it is required for Ig class switching and somatic 
hypermutation. However, as already described, CD27 is expressed by mature MZB cells in the 
adult splenic marginal zone (146, 322). The peripheral blood MZB cells resemble IgM+ memory 
cell phenotype (IgM+IgD+CD27+), and express somatically mutated surface IgM (320).
The immunoglobulin produced by MZB cells undergoes CSR more rapidly (by day 5 after 
antigen challenge (307)), than is seen in FO B cell switched (IgG+) and IgM-only memory
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populations, (3 weeks post challenge, (307, 323)), and there is also enhanced switching to IgA 
production in mice (324).
Although CSR is more rapid in MZB, SHM occurs more slowly and in a smaller percentage of 
cells than is observed in FO B cells following immunisation (325). Willenbrock et al (325) and 
Weller et al (321) were able to demonstrate that activation induced cytidine deaminase (AID), 
that is required for SHM to occur was expressed at levels 20 times less than was seen in switched 
memory FO B cells.
MZB cells (IgD+IgM+CD27+ memory cells) with somatically mutated Ig are present in patients 
with X-linked hyper-IgM syndrome, where cognate T cell interactions required for B cell 
differentiation, germinal centre formation and isotype switching are absent (125, 252). The lack 
of T cell help is the result o f CD40L deficiency, preventing signalling between the B and T cell 
which drives class switch recombination and somatic hypermutation. The presence of MZB 
which are still able to mutate their immunoglobulin receptors, suggests an alternative pathway 
exists for TI CSR (252, 267, 324). Weller also found that although infant MZB cells were 
expanded and mutated, they were still incapable of making TI responses.
As well as responding to Tl-antigens MZB cells respond to TD-antigens as well. Protein antigens 
are processed and presented in the context of MHC class II (expressed at high levels on MZB). 
Following antigen up take and presentation by MZB cells the expression o f costimulatory 
molecules CD80/86 (B7.1/2) is rapidly upregulated, turning them into potent APC for CD4+ T 
cells. Attanavanich et al (326) showed that this skewed the T cell response towards a Thl 
cytokine secretion pattern in mice. Despite the interaction with T cells the response of MZB to 
TD antigens remained extrafollicular, occurring in the absence of germinal centre formation, at 
the T cell zone-red pulp interface. There is some CSR and SHM but not to the same extent seen 
following a germinal centre reaction (123, 315).
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1.6.3.U The follicular B cell response.
Following immunisation with either a glycoconjugate or plain polysaccharide vaccine tissue 
resident, immature DC encounter antigen as immune complexes (ic), capture it via complement 
and FcR and become activated, adopting a mature phenotype (327, 328). These mature DC 
migrate to the secondary lymphoid organs such as spleen and lymph node (figure 1.14) (327,
328). These DC are able to recycle antigen to and away from the cell surface so that it can be 
presented to B and T cells and is retained for long periods of time (130, 329). Expression of high 
affinity BCR on the surface preferentially selects a B cell for extrafollicular differentiation into 
plasma cells while lower affinity BCR selects the B cell for GC development (127, 330). 
Extrafollicular differentiation of B cells into plasma cells provides early antibody that can bind 
antigen, creating more ic for capture by follicular dendritic cells (FDC) (331, 332).
Germinal centre formation occurs in the B cell areas of secondary lymphoid organs (333), and 
they are comprised of a dark zone where antigen specific B cells rapidly proliferate and a light 
zone (basal and apical) where centrocytes undergo SHM and CSR (334).
Germinal centre precursor B cells migrate to the B cell follicles under the influence of CXCL13, 
expressed by reticuloendothelial cells in the B cell follicles (217, 335, 336), where they localise at 
the border of the T cells zone (328, 337). Here the GC precursors become follicular mantle zone 
(FM) B cells (IgD+CD38'CD40+CD23+/‘) that are activated following interaction of the surface 
immunoglobulin (slg) with specific ic bound to interdigitating DC (iDC) (130). The naive 
follicular mantle zone B cells become IgD+CD38+IgM+/' GC founder cells that undergo intense 
proliferation but very little immunoglobulin variable (V)-gene mutation(130, 329). The 
proliferating focus of B cells becomes the GC dark zone and the GC founder cells lose IgD 
expression and become CD77+ centroblasts that continue to proliferate intensively. Thus GC 
formation is antigen dependent beginning with the clonal expansion of just a small number of B 
cells and also T cell dependent (130).
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The interaction of specific antigen with slg leads to up-regulation of CD80/86 on the B cell 
surface that provides the initial co-stimulatory contact with CD28 on primed GC T cells brought 
in to close proximity with the B cells via the iDC. Re-circulating, antigen specific T cells become 
trapped either by MHC class II plus peptides on iDC (for nai've T cell priming), or on newly 
activated B cells.
The B cell-T cell interaction intum, leads to the up-regulation of CD40 ligand (CD40L/CD154) 
on the T cell surface and this interacts with CD40 on the B cell. CD40-CD40L interaction is 
essential for B cell selection and death, proliferation, differentiation of B cells, SHM and CSR of 
immunoglobulin genes (130, 329). The proliferating centroblasts also up-regulate surface CD27 
expression(130, 329). The interaction of B and T cells via CD40-CD40L occurs at 2-3 days 
following antigen encounter, such as glycoconjugate immunisation(202, 338) and is the signal for 
the GC reaction to begin by day 4. The expression of CD40L is transient and disappears within 
72 hours, thereby providing the initial stimulus for B cell clonal expansion and germinal centre 
formation (129). CD27 is essential for continued germinal centre reactivity, memory B cell and 
plasma cell differentiation (under the influence o f IL-10) and antibody secretion (182, 183, 339). 
It enhances the interaction with GC T cells and is found in both the germinal centre and splenic 
marginal zone. CD27+ B cells have higher rates of somatic mutation and class switching, 
especially to IgG (340). This period of intense proliferation in the GC dark zone and up- 
regulation of co-stimulatory molecules ensures that a large number of progeny are generated that 
then undergo the selection processes based on the affinity of the mutated Ig for the antigen(130,
329).
Naive B cells receiving stimulation via CD40-CD40L interaction predominantly differentiate into 
memory B cells with some plasma cell formation. If naive B cells do not receive BCR 
stimulation and CD40-CD40L interaction then they are likely to undergo apoptosis, particularly 
after the FM B cell stage when Bcl-2 (a survival factor), is lost and apoptosis factors such as Fas,
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Bax, p53 and c-myc are up-regulated. Centroblasts express particularly high levels of c-myc (331, 
332, 341).
Some GC B cells undergo a permanent switch from constant(c)p to c5 (IgD^gM') phenotype 
and express high levels of Fas/CD95 following which they undergo antigen affinity based 
selection based on the BCR affinity for the antigen. High affinity interactions leads to clonal 
expansion and differentiation and no or very low affinity induced apoptosis (130, 329).
Shortly after this selection stage the ability to undergo SHM with each cell division is acquired by 
the centroblasts (130, 329). During this phase the Ig V-gene sequences acquire random mutations 
so that the expressed slg has an altered sequence from the original clones (130, 329). The IgD+ 
IgM' CD38+ B cells have much higher rates of V-gene mutations than seen in the later gamma 
gene sequences (130, 329).
Following affinity maturation of the antigen receptor and down regulation of c-myc and the up- 
regulation of p53 the cells leave the cell cycle to become CD77' slg+ centrocytes (130, 329, 331, 
332, 341-343).
The centrocytes progress to the basal light zone, expressing fully mutated antigen receptors and 
associate with a sparse population of T cells (333). The centrocytes are then selected on the basis 
of the affinity of the slg for specific antigen captured on the surfaces of FDC and also molecules 
expressed on the surfaces of GC T cells (327). Here the B cells then localise with FDC (CD23hl) 
that form a network for the capture of free ic from the lymph through out the apical light zone 
that is processed and presented on the FDC surface. High affinity receptor centrocytes are also 
positively selected by capturing free ic via their slg. (127, 130, 329, 330) that is processed and 
presented to follicular T helper (TFh) cells (CXCR5+CD57+) that populate the apical light zone. 
GC T cells (CXCR5+CD4+CCR7+) initially reside at the T cell border but migrate to the B cell 
follicles in response to CXCL13, the ligand for CXCR5 (217, 335, 336). In the GC light zone the 
sparse TFH cell population localises with the centrocytes around FDC, providing CD40L
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interactions, secretion of IL-4, IL-10 and IL-21, TGFp, and FasL expression, all of which provide 
even more efficient help for centrocyte antibody synthesis (217, 335, 336) and differentiation into 
memory B cells or back to centroblasts in the dark zone (130, 329, 343). The sparsity of these 
TFH cells limits B cell-T cell interactions preferentially selecting high affinity B cell clones that 
express processed antigen on their surface (344).
There is still a high rate o f apoptosis at this stage because centrocytes either; 1) do not meet their 
specific antigen, or 2) the mutated BCR is no longer avid enough, or is autoreactive, and undergo 
deletion due to Fas-Fas-ligand (FasL) interaction or low signal strength in the absence o f T cell 
help as very few are present at this location (130, 329, 343). The centrocytes apoptose and are 
removed by tingible body macrophages(130, 329, 343).
It is at this stage that class switching of the surface Ig occurs. Thus, B cells with unsuccessful Ig- 
V-gene mutations are sensitive to apoptosis and only B cells with high avidity slg for the 
immunising antigen emerge from the germinal centre to differentiate into memory or plasma 
cells.
1.6.3.Hi Products of the germinal centre
The GC reaction then lasts for approximately 3 weeks (appearing by day 4 and involuting by day 
21-28) relying on either the continued presence of antigen on FDC surfaces for its maintenance or 
on the decay of the B cell proliferation stimulus to limit the GC reaction (333, 334, 345, 346). 
The peak in GC activity occurs during the second week after antigen challenge (days 7-10) (333, 
334, 346) following secondary immune responses or booster immunisations and results in the 
formation of 3 subsets of B cells: Long-lived plasma cells expressing CXCR4 that home to the 
bone marrow in response to CXCL12; Non-secreting plasma cell precursors that remain in the 
secondary lymphoid tissue; and memory B cells that express switched Ig molecules and are 
CXCR5+ which allows homing to the B cell follicles so that they can re-circulate between blood 
and lymph (145, 217, 254, 263, 347, 348).
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Generation of long lived plasma cells and memory B cells is the basis for maintenance o f long 
term antibody production(142, 143, 145, 255-258, 264, 299, 338, 348-360). These studies have 
all demonstrated the importance of long term survival of plasma cells in the bone marrow for 
maintaining antibody levels. In infants and young toddlers the microenvironment o f the spleen is 
not mature enough to maintain the plasma cell survival for long (142, 143, 350, 356). However 
once the bone marrow environment is able to support survival of these plasma cells it is still 
possible for them to be dislodged from their niches (257, 348). Down regulation of CXCR4 on 
bone marrow plasma cells means that they are unable to re-circulate and they eventually die in the 
periphery. Constant arrival o f cells of new specificity without renewal o f the old specificity cells 
may eventually lead to depletion of plasma cells of some specificities (257, 348).
Another mechanism for maintaining long term memory is the polyclonal activation of memory B 
cells by bystander T cell activation of through polyclonal stimulants such as PAMPs or bacterial 
DNA (228, 351, 359).
1.7 Quantification of the humoral response to 
pneumococcal vaccine
A rapid rise in specific Ab following booster immunisation with a polysaccharide vaccine at 12 
months of age demonstrates that primary immunisations with glycoconjugate vaccines in the first 
few months of life generate memory responses (165, 361). Sustained levels of capsule specific, 
serum IgG Ab (>0.2 pg/ml) (362) may indicate persistence of protection (187). However little is 
known about maintenance o f protection if serum IgG concentrations fall below this putative 
threshold (0.2mcg/ml). In very young infants, after primary immunisation, levels of capsule 
specific antibody may fall below the limits o f detection. Low levels of antibody may be present
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but undetectable by conventional assays. However memory B cells may be present and provide 
protection at earlier ages than when antibody is first detected (37).
The quality of the antibody produced is also important and antibody avidity for solid phase 
antigen is another method for assessing vaccine effectiveness, with a rise in avidity demonstrating 
generation of B cell and T cell memory via germinal centre development and somatic 
hypermutation (97, 150, 363-366). Opsonophagocytic activity of serum prior to and following 
immunisation is also another parameter that can be assessed as it mimics the natural clearance 
mechanism of pneumococci and shows good relationship to ELISA based IgG avidity 
measurements (103, 104,120, 367-369).
More recently antigen specific B cell responses have been studied in humans and mice. 
However, there is very limited human data tracking these responses following immunisation in 
humans. Existing data includes studies of smallpox, tetanus, diphtheria and pneumococcal 
vaccines (111, 188, 370-373). Antigen specific, spontaneously secreting B cells appeared in the 
peripheral blood between days 5 and 8 after immunisation in all of these studies (106, 111, 261, 
374, 375).
It is suggested that these spontaneously secreting, antigen specific AFC are probably derived 
from memory cells residing in secondary lymphoid tissues after primary immunisations (145). 
Booster immunisation induces activation and rapid proliferation of vaccine specific, memory B 
cells (260) with both extrafollicular and germinal centre responses. The extrafollicular response 
results in a rapid efflux of antigen specific AFC into the peripheral blood, peaking on days 6-7 
after immunisation providing initial protection from infection while germinal centres develop 
(145, 256, 264).
In-vitro stimulation of isolated B cells has allowed the detection of low frequency, antigen 
specific AFC which are putative memory or precursor plasma cells that persist for some time 
after antigen exposure. These cells, present in the peripheral blood, are distinct from 
spontaneously secreting cells and require added stimulation via the BCR and co-stimulatory
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molecules before Ig is secreted (228, 259, 354). In-vitro stimulation with Staphylococcus aureus 
Cowan 1 strain (SAC) which cross-links the BCR, and IL-2 provides the signals necessary for the 
expansion of these antigen specific memory B cell populations, facilitating their detection by 
ELISpot (183, 372, 376, 377).
There is little data available on the kinetics of plasma and memory B cell responses following 
primary immunisations or primary exposure to infectious agents, therefore this thesis examined 
the phenotype and kinetics of B cell populations appearing in peripheral blood in relation to the 
isotype and magnitude of the specific serum immunoglobulin response following primary and 
booster immunisation with Pnc7.
1.8 Aims
The primary aims of this thesis were;
1. Could polysaccharide specific memory B cells be isolated from the peripheral blood of 
toddlers prior to immunisation with Pnc7 vaccine? Would immunisation with a 
glycoconjugate vaccine induce detectable increases in the frequency of these B cells?
2. Are the kinetics of the appearance of polysaccharide specific memory B cells and plasma 
cells in adult peripheral blood in response to immunisation with Pnc7 vaccine similar to 
those reported in previous studies?
3. What are the phenotypes of spontaneously secreting plasma cells and memory B cells 
induced in adults by glycoconjugate vaccines? Does this alter with increasing age?
4. Does age at time of immunisation affect the frequency of plasma cells and memory B 
cells generated in response to the polysaccharides contained in the Pnc7 vaccine?
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Chapter 2: Materials and Methods
2.1 Antibodies
2.1.1 The ELISpot assay
2 .1 .L i  Coating the ELISpot plates (refer to section 2.5.1-2.5.3):
The capture antibody for total immunoglobulin (Ig) control in the ELISpot assay was a polyvalent 
goat-anti-human Ig (Caltag, HI7000, Buckingham, UK) used at lOpg/ml in phosphate buffered 
saline (378).
2 .1 .1 .U  Antibodies for the detection of IgG, IgA or IgM antibody secreting 
cell spots (refer to section 2.5.4):
The detection antibodies were goat anti-human IgG, y-chain specific -alkaline phosphatase 
conjugate (#401442), goat anti-human IgA, a-chain specific-alkaline phosphatase conjugate 
(#401132), goat anti-human IgM, p-chain specific-alkaline phosphatase conjugate (#401902; 
Calbiochem-Novabiochem, Nottingham, UK), all diluted at 1:5000 for use in the ELISpot 
development.
2.1.2 Fluorescent activated cell sorting (FACS) (refer to 
section 2.8).
All of the monoclonal antibodies (MAb) were raised in mice against human lymphocyte surface 
antigens and were of the murine IgGl or IgG2a isotype. The fluorescent labels used were 
Fluorescein isothiocyanate (FITC), phycoerythrin (PE), Peridinin chlorophyll protein (PerCP), 
BD-Cy-chrome™ (PE-Cy5). All antibodies for FACS were obtained from Becton Dickinson
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(BD Biosciences Ltd), Oxford, UK, except for anti-IgA-FITC, which was obtained from 
Calbiochem-Novabiochem.
2 .1 .2 .1 Isotype controls for non-specific binding;
Antibody isotype controls used were Becton Dickinson (BD) SimulTest™-isotype control (anti- 
IgGl-FITC plus anti-IgG2a-PE), and anti-IgGl-PerCP.
2 .1 .2 .H  Antibodies against the following lymphocyte markers were used: 
FITC-labelled anti-CD3, anti-CD27, anti-IgA, anti-CD21, anti-CXCR4 and anti-CD62L. 
PE-labelled anti-CD27, anti-CD38, anti-IgG, anti-IgD. PerCP-labelled anti-CD20, anti-CXCR5, 
anti-CCR7 and PE-Cy5 labelled anti-IgM.
2.1.3 Detection antibodies for the pneumococcal serotype 
ELISA (refer to section 2.10).
IgG, IgA and IgM serum antibodies specific pneumococcal serotypes 4 ,14 and 23F were detected 
using the following enzyme conjugates from Biosource CA. USA. All of the MAb were raised in 
goat against human serum IgG, IgA and IgM and all were conjugate to alkaline phosphatase 
(AP).
Goat-anti-human-IgG-AP (AHI0305), Goat-anti-human-IgA-AP (AHI0105) and Goat-anti- 
human-IgM-AP (AHI0605). The IgG-AP conjugate was used at 1:2000 and the IgA-AP and 
IgM-AP conjugates were used at 1:1000 as predetermined by prior dilution experiments.
2.2 Buffers
2.2.1 Phosphate buffered saline xlO concentration (PBSxlO) 
for the ELISpot and pneumococcal serotype ELISA.
Sodium Chloride (NaCl, 80g/litre); potassium dihydrogen orthophosphate (KH2P 04, 3.14g/litre); 
di-sodum hydrogen phosphate -  heptahydrate (Na2HP04-7H20 , 20.6 g/litre); potassium chloride
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(KC1, 1.6 g/litre). All the powders were dissolved in 800ml of sterile, pyrogen free water and 
then the volume made up to 1 litre. The pH was then adjusted to 1.2-1 A, using 6M sodium 
hydroxide (NaOH) or 10M hydrochloric acid (HC1) and then stored for up to 6 months at room 
temperature.
2.2.2 PBSxl for coating of ELISpot and pneumococcal ELISA 
plates.
The PBSxlO was diluted 1:10 using sterile pyrogen free water to make the required volume for 
the coating of either ELISpot or ELISA plates. The pH was then adjusted to 1.2-1 A, using 6M 
NaOH or 10M HC1 and then stored for up to 6 months at room temperature.
2.2.3 Wash buffer for the ELISpot assay: PBSxl+Tween20(T) 
0.25% (PBS-T0.25).
The wash buffer was made from PBSxl plus the required volume of Tween20 to give a final 
concentration of 0.25% Tween20. For example 100ml of PBSxlO mixed with 900ml of sterile, 
pyrogen free water plus 2.5ml of Tween20. The pH was then adjusted using 6M NaOH or 10M 
HC1 to 1.2-1 A and the buffer was stored for up to 1 month at room temperature.
2.2.4 Pneumococcal serotype ELISA wash buffer: Tris- 
phosphate buffered saline with 1% Brij-35 solution (TBS- 
Brij35xl0).
Sodium chloride (NaCl, 160g/2 litres); potassium chloride (KC1, 3.20g/2 litres); Trizma hydrogen 
chloride (Tris-HCl, 29.12g/2 litres); Trizma base (Tris-Base, 1.88g/2 litres) ; Brij-35 solution 
(1%, 66mls in 2 litres). All of the salts were dissolved in 1934ml of sterile pyrogen free distilled 
water. To this was added 66mls of the Brij-35 detergent solution, making up the final volume of
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2 litres. The pH was then adjusted using 6M NaOH or 10M HC1 to 1.2-1 A  and the buffer was 
stored for up to 1 month at room temperature.
2.2.5 Substrate buffers and stop solutions
2 .2 .5 . i  Substrate buffer for the ELISPot assay
Alkaline phosphatase substrate kit -  2 components (Biorad Laboratories 170-6432) made as per 
manufacturers instructions. The reaction was stopped with 200pi per well o f sterile, pyrogen free 
H20 .
2 .2 .5 .U  Substrate buffer for the pneumococcal serotype ELISA 
1M diethanolamine with 0.5 mM MgCl2 (Don Whitley Scientific E00016) used with Phosphatase 
substrate 5mg tablets (4-Nitrophenyl phosphate disodium salt hexahydrate, Sigma S0942 tablets). 
The reaction was stopped with 50pl 3M NaOH per well.
2.2.6 RPMI for peripheral blood mononuclear cell (PBMC) 
isolation.
The RPMI medium was made using a 500ml bottle of RPMI-1640 medium with phenol red 
indicator, 25mM hepes modification with sodium bicarbonate (RPMI, Sigma R5886). This was 
supplemented with 5ml of L-glutamine at 2mM (Sigma G7513), and 5ml o f penicillin and 
streptomycin (Sigma P4458) at 50U/ml and 0.05g/ml respectively. The medium was stored at 
4°C until use, when it warmed to room temperature before use.
2.2.7 RPMI+newborn bovine serum (NBBS) at 10% 
(10%NBBS).
The 10%NBBS was made by supplementing the RPMI described above with 50ml of heat
inactivated NBBS (Sigma N4637). This 10%NBBS was used for all cell culture medium and for
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the ELISpot plate blocking step and cell incubations. The 10%NBBS was stored at 4°C until use 
when it was warmed to room temperature.
2.2.8 RPMI+human AB serum (HABS) at 10% (10%HABS).
The 10% HABS was made to the required volume by diluting the HABS 1:10 in RPMI under 
sterile conditions. This medium was stored at 4°C until use when it was warmed to room 
temperature.
2.2.9 PBS with 2mM Ethylenediamine tetraacetic acid (PBS- 
EDTA): Rinse buffer for the AutoMACS™ procedures.
Five PBS tablets (Sigma P4417) were dissolved in 1 litre distilled H20  and then EDTA 2mM 
(0.744g EDTA/litre of PBS) was added. Once dissolved, the pH was corrected to 1.2-1 A  using 
6M NaOH or 10M HC1 and then was autoclaved. The rinse buffer was stored at room 
temperature for up to 6 months.
2.2.10 PBS-EDTA+0.5%NBBS: Cell wash buffer for cultured 
PBMC harvesting and also for the AutoMACS™ procedures.
A 1 litre bottle of sterile PBS-EDTA was opened in the laminar flow, cell culture hood and a 5ml 
aliquot of NBBS was added to a final concentration of 0.5%NBBS. The wash buffer was stored 
at 4°C and kept sterile for use.
2.3 Subjects and clinical procedures
2.3.1 Vaccines
A heptavalent pneumococcal-CRM197 conjugate vaccine (Pnc7, Wyeth Vaccines, Pearl River, 
MA), given by intra-muscular injection in the left deltoid. The 0.5ml dose of the vaccine 
contained polysaccharide concentrations of 2.0pg/ml o f serotypes-4, 9V, 4, 18C, 19F, 23F and
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4pg/ml of 6B. Each oligosaccharide is conjugated to CRMi97 (mutant diphtheria toxoid) and 
adsorbed on aluminium phosphate.
Purified pneumococcal polysaccharide vaccine (23PnV, Pneumovax™, Merck) containing 25pg 
of each of the capsular polysaccharides for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F.
2.3.2 Blood draw volumes
In the adult studies, venous blood samples of 20mls were split as follows, 18mls were collected in 
sterile, preservative free heparin tubes at each time point and 2mls were collected as a clotted 
sample, from which serum was obtained and stored at -80°C.
For the toddler studies, 5ml o f venous blood was collected at each time point, 4mls into heparin 
and 1 ml for serum.
Informed consent was obtained from the volunteers and the protocol was approved by the 
Oxfordshire’s Research Ethics Committee (OxREC number C02.005 (toddlers and young adults 
and OVG2006/01 (elderly adults)).
2.3.3 Age groups
The age of individuals enrolled into the studies conducted for this thesis fell into three groups. 
There were toddlers aged 12 to 14 months o f age, young adults aged (32 (23-49) and elderly 
adults with a mean age of 58 (47-66) years old.
Details of the study groups can be found in the subjects and clinical procedures sections for each 
of the results chapters.
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2.4 Density gradient separation of PBMCs from whole 
blood
PBMCs were separated from whole blood using the density gradient medium Lymphoprep™ 
(Axis-Shield). Fresh, whole blood was diluted 1:2 for 18ml blood volumes and 1:3 for the small 
infant blood sample volumes of l-4ml using RPMI. The diluted blood was then layered over half 
its volume of Lymphoprep™. The layered blood was then centrifuged, with the break off, for 30 
minutes at 2200rpm (1 lOOxg). Following centrifugation the buffy coat was carefully removed to 
a clean tube and then washed again in RPMI for 20 minutes at 1800rpm (700xg). Following this 
wash step the cell pellet was re-suspended in the appropriate culture medium for counting or was 
washed a further three times in PBS+EDTA+0.5%NBBS for use in the ex vivo ELISpot, before 
counting.
2.4.1 Cell counts
Prior to use in the cell culture assay or ELISpots or FACS assays, the PBMCs were counted on a 
haemocytometer. For counting and exclusion of dead cells 50pi of cell suspension were diluted 
with 50pl of PBS and 50pl of trypan blue (0.4%). Following gentle mixing lOpl was removed 
and added to the haemocytometer. The number of cells per ml of suspension was then calculated 
as follows. Cells within 5 squares of the central haemocytometer grid were counted and then 
multiplied by 5 to give the number of cells in 25 squares. This was then multiplied by 3 to 
account for the (trypan blue+PBS+cells) dilution. This figure was then multiplied by 104 to give 
the number of cells/ml of PBMC suspension. The number of cells/ml was then divided by the 
required concentration of cells for the assay (e.g. 2x106 cells/ml), to give the total volume of the 
cells at 2xl06cell/ml. The initial volume of the PBMC suspension was subtracted from this total 
volume to give the volume of 10%NBBS to be added.
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2.5 The ELISpot assay for the detection of antigen 
specific IgG, IgA and IgM-antibody forming cells 
(AFC).
2.5.1 Control antigens
The assay positive controls were anti-Ig polyvalent antibody (section 2.1.1) for detection of the 
total IgG, IgA or IgM AFC and tetanus toxoid (tet) (606117ml or 1515pg/ml stock, Statens 
Seruminstitute, Copenhagen, DK) as a non-vaccine related antigen control (a negative control for 
the ex vivo assay and a positive control for the memory B cell assay). PBS alone was used as the 
background control for non-specific binding to the membranes and any spots detected were 
subtracted from the antigen specific well spot counts.
An unstimulated control was not included in the final assay based on previous evaluation. 
Spontaneous formation of IgG-AFC was evaluated during prior development o f the ELISpot 
assay. PBMCs from ten unimmunised donors were cultured for five days to compare 
unstimulated (10%-NBBS) with stimulated (SAC+CpG+PWM) cells for IgG-AFC formation. 
The result of the unstimulated cultures was some spontaneous IgG-AFC formation in the total 
IgG control wells of the ELISPot with a median spot count 0 (0-500) IgG-AFC/million cultured 
PBMCs. None were detected in wells coated with serotype 4, 14 or 23F tetanus or diphtheria 
toxoid. Therefore the cut off for total IgG was set at >1000 spots per million IgG-AFC and for 
the specific antigens a positive response was >1 spot per million IgG-AFC.
2.5.2 Vaccine of vaccine related antigens
The vaccine related antigens used were diphtheria toxoid (dip) (20051f/ml or 5012pg/ml stock), 
(Statens Seruminstitute, Copenhagen, DK), to show the CRM 197 carrier response and 
pneumococcal purified polysaccharides from serotypes-4, 14, 23F (LGC Promochem, 
Teddington, UK), conjugated to mHSA (National Instititute for Standards and Controls, Potters
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Bar, UK). Since availability o f PBMCs was limited only 3 of the seven pneumococcal vaccine 
serotypes were studied.
2.5.3 Antigen coating concentrations
The ELISpot plates used in this assay were 96-well Multiscreen™ plates with hydrophobic 
polyvinylidene fluoride (PVDF), membranes at the base of the wells (Millipore, Watford, UK). 
The polysaccharides were mixed with equal concentrations and volumes o f mHSA as in the 
comix method described by Nelidia Concepcion et al 1998(379). All of the antigens were coated 
at 10pg/ml in PBS except tet and serotype-23F which were coated at 5 and 20|ig/ml respectively. 
The plates were then sealed and incubated overnight at 4°C and then stored as such for up to one 
month.
2.5.4 The ELISpot assay
Before use, the plates were washed three times with 200pl/well of lxPBS. The wells were then 
blocked with 200pi of 10%-NBBS for at least 30 minutes at 37°C in 5% C 02 and 95% humidity. 
PBMCs were prepared as in section 2.4 to give a final suspension of 2xl06cells/ml. The cells 
were then seeded at 2xl05cells/well in then antigen specific wells and at 2x104, 2x103 and 
2xl02cells/well for the anti-Ig control wells. The cells were then incubated for 16-20 hours at 
37°C in 5% CO2 and 95% humidity. Following the cell incubation the wells were washed four 
times with 200pl/well PBS-TO.25% and then once with 200pl/well lxPBS. The bound antibody 
secreted by the cells was then detected by incubating the plates with one or all o f anti-IgG, IgA or 
IgM alkaline phosphatase conjugates (all diluted at 1:5000), at 50pl/well, for 4 hours at room 
temperature. The wells were then washed four times with 200pl/well PBS-TO.25% and then three 
times with 200pl/well water. The bound conjugate was then revealed using 50pl/well of the AP- 
conjugate substrate kit (nitroblue tetrazolium + 5-Bromo-4-chloro-3-indolyl phosphate in 
dimethylformamide, Bio-Rad Laboratories, Hemel Hempstead, UK), and stopped using
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200pl/well o f water. The plates were then dried and scanned for counting using an AID ELISpot 
reader ELR02 and software version 3.2.3. (Cadama Medical Ltd, Stourbridge, UK). The 
parameters for accepting spots were preset following optimisation of the spot counts prior to 
counting all plates in the studies. The spot characteristics were set to include thresholds o f the 
following parameters: Spot intensity (minimum of 10), spot size (minimum of 40), spot emphasis 
(tiny). The well saturation level was set to a maximum of 70% before the well was uncountable. 
Debris was edited out o f the wells manually to avoid false positive readings. Any spots detected 
in the PBS control wells were subtracted from the total-IgG control and the antigen specific wells. 
Samples were only accepted when the total-IgG control spot count was >1000 spots/106 PBMCs.
2.6 In vitro, polyclonal stimulation of PBMCs for the 
expansion of memory B-cells
PBMCs were isolated from peripheral blood using density-gradient centrifugation as described in 
section 2.4 and re-suspended at 2x106 cells/ml in 10%-NBBS as described in section 2.4.1.
The polyclonal stimulants used were combinations o f Staphylococcus aureus cowan 1 strain plus 
IL-2 (SAC+IL-2) or SAC plus CpG-2006 plus pokeweed mitogen (PWM) (SAC+CpG+PWM). 
The final well concentrations o f the stimulants were as follows; SAC at 1:5000 dilution o f the 
Pansorbin™ commercial cell suspension (Calbiochem-Novabiochem, Nottingham, UK), IL-2 at 
50U/ml (Roche Diagnostics stock concentration 10,000U/ml, Mannhiem), CpG-2006-ODN at 
2.5pg/ml (Autogen Bioclear, UK) and PWM at 83ng/ml (Sigma L-9379, UK). The stimulants 
were diluted in 10%-NBBS and 100pi volumes were added to an appropriate number of wells in a 
round bottom, 96-well culture plate. Following this the PBMCs were added in lOOpl volumes 
giving a final cell density of 2xl05cells/well. The PBMCs were then stimulated, in vitro for 5 
days at 37°C in 5% C 02 and 95% humidity.
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2.7 Preparation of in vitro stimulated PBMCs for IgG, 
IgA and IgM ELISpot assays.
Following 5 days of stimulation the PBMCs were harvested by gentle re-suspension and transfer 
to a clean tube where the contents o f the wells for each individual sample were pooled. The cells 
were washed once in PBS+EDTA+0.5%NBBS at 2000 rpm (900xg) for 20 minutes to remove 
cell culture supernatant. The cells were then washed three times in PBS+EDTA+0.5%NBBS at 
1800rpm (700xg) for 15 minutes to remove residual antibody secreted during the 5 day 
stimulation culture. Following this the cells were resuspended in 1ml of 10%-NBBS and counted 
as in section 2.4.1. The cells were then resuspended to 2x106 cells/ml and were then put in to the 
ELISpot assay described in section 2.5.
2.8 Flow Cytometric phenotyping of PBMCs
PBMCs separated as in section 2.4, were assessed for expression of surface markers CD3, CD4, 
CD 16, CD 19, CD27, CD56, CD62L, CCR7, IgD, IgM and IgG (see section 2.1.2 for details). A 
standard procedure was used for labelling the cells. Briefly, 1x105 PBMCs were incubated with 
pre-determined volumes of the above antibodies in three colour combinations that would allow 
analysis o f memory B-cell subsets as well as general lymphocyte populations. The cells were 
labelled for 15 minutes in the dark, at room temperature. The cells were then incubated in BD 
FacsLyse™ for 5 minutes and then washed at 1500rpm (475xg) for 5 minutes, followed by a 
wash in BD CellWash™ (PBS+EDTA), at 1500rpm (475xg) for 5 minutes. The cells were 
finally fixed in 200pl of BD CellFix™ (1% formaldehyde).
The labelled cells were then run on a BD FacSCAN™ (three colour flow cytometer), that was 
able to detect green, red-orange and far-red fluorescence. The data was collected and analysed 
using BD CellQuest™ software version 3.1. The number of events collected was 10,000 unless
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the sample was too small and then the count was stopped manually at 3-5000 events. A gate was 
set on the lymphocytes and the subsets within the lymphocyte gate were subsequently analysed.
2.9 Separation of PBMCs for the detection of Ig- 
secreting cells by ELISpot.
PBMC subsets were positively selected using an AutoMACs™ cell separator (Miltenyi Biotec 
Ltd. Bisley, UK), on the basis of CD20, CD27, CD38, IgA, IgD, CXCR4 or CXCR5 expression 
using the microbeads as per manufacturer’s instructions (Miltenyi Biotex Ltd, Bisley, UK). 
Briefly the PBMCs (between lxlO6 and lxlO7 cells depending on the sample size), were 
incubated with the antibody coated magnetic beads for 15 minutes at 4°C. The bead-cell mixture 
was then washed once with PBS+EDTA+0.5%NBBS at 1500rpm (475xg) for 10 minutes. The 
bead-cell pellet was then resuspended in 500pl of PBS+EDTA+0.5%NBBS in preparation for 
passing through the AutoMACS™ column. The programme used was a positive selection, 
double column separation (Posselds) preset by Miltenyi Biotec. This programme involved 
passing o f the positively selected sample through a second separation column for extra purity of 
the cell fraction. Both the negative and positive fractions were counted and resuspended to 
known concentrations that varied due to the size o f the pre-exisiting subset in the whole PBMC 
fraction. The separated fractions where then seeded on to antigen coated ELISpot wells as 
described in section 2.5. The results were expressed as the percentage spots/well to take into 
account to differing cell fraction sizes. The un-separated PBMC fraction was always run along 
side the separated fractions as a control.
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2.10 An ELISA for the detection of pneumcoccal 
polysaccharide capsule specific immunoglobulins in 
human serum.
The World Health Organization standard protocol was used for detection of human IgG, IgA and 
IgM antibodies against S. pneumoniae capsular polysaccharides (380), 
http://www.vaccine.uab.edul. In brief, serum or plasma samples were pre-absorbed with lOpg/ml 
of CPS (Statens Seruminstitut, Copenhagen, DK) and 10pg/ml of a non-vaccine related serotype 
polysaccharide, 22F (LGC Promochem, Teddington, UK). The standard serum, 89SF (supplied 
by the Federal Drug Administration) was used to create the standard curve for the ELISAs and 
control sera were obtained from NIB SC, Potters Bar, UK. Table 2.1 shows the predetermined 
IgG, IgA and IgM levels contained within the international standard (89SF).
89SF pg/ml
IgG IgA IgM
4 4.1 1.2 1.4
14 27.8 1.9 1.2
23F 8.1 1.3 0.7
Table 2.1 The concentrations of serotype 4,14 and 23F antibody in the international pneumococcal 
standard (89SF) for ELISA (supplied by the FDA).
A control serum was established (QC080806) by taking 20ml blood samples from previously 
immunised adults, pooling the serum and quantifying the IgG, IgA and IgM levels for serotypes 
4, 14 and 23F against the 89SF standard curve and NIB SC control sera. Table 2.2 shows the 
geometric mean concentrations (GMC) for the new QC080806 control serum (+/- 2 standard 
deviations of the mean antibody concentration) for each serotype based on thirteen assay 
repetitions for each serotype and isotype. The assay acceptance criteria involved achieving a 
standard curve fit (r) of at least 0.97 and that the value for QC080806 fell within the +/- 2 SD 
range shown in table 2.2.
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QC080606 pg/ml of antibody
IgG IgA IgM
4 1.24 0.44 0.27
(0.86-1.63) (0.05-0.49) (0.15-0.39)
14 20.55 478 1.76
(17.14-23.96) (0.40-0.56) (1.13-2.39)
23F 10.48 0.19 0.40
(8.74-12.22) (0.18-0.21) (0.26-0.55)
Table 2.2 Geometric mean (+/- 2 standard deviations) for QC080806.
An in-house control serum established from a pool of serum obtained from four adults who had previously 
received one or two doses of the Pnc7 vaccine.
IgG, IgA and IgM Antibodies specific for the capsular polysaccharides 4, 14 and 23F were 
detected using alkaline-phosphatase conjugates diluted 1:2000 for IgG and 1:1000 for IgA and 
IgM (section 2.1.3), and antibody concentrations were calculated in ng/ml from a four point, 
sigmoidal plot using Revelation™ softwear (ThermoLabs Inc., Basingstoke, UK). All the data 
were then subsequently converted to pg/ml for analysis.
2.11 T-cell stimulation and supernatant collection
PBMCs separated as described in section 2.4 and resupended to 2xl06cells/ml in 10%-HABS and 
100pl of the suspension were added to the culture well giving a final well density o f 2x105 cells. 
The antigens for T cell stimulation were Tet (5fig/ml) dip (10pg/ml) CbpA and PspA at 2.5pg/ml 
(obtained from Dr James Paton, Adelaide, Au) and phytohemagglutinin (PHA) at 5pg/ml (Sigma, 
UK) were used in quadruplicate in round bottom culture plates, (Coming, UK). The cells were 
incubated with antigens for seven days at 37°C in 5%C02 and 95% humidity.
On day seven the supernatants were harvested from the wells and frozen at -80°C for subsequent 
detection of cytokines by ELISA. The remaining PBMCs were then harvested, washed in 10%- 
NBBS and then allowed to secrete IFNy in the ELISpot assay described in section 2.12.
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2.12 IFNy ELISpot
The ELISpot for IFNy secreting cells was carried out using the MABtech human IFNy antibody 
kit as per the manufacturer’s instructions (MABtech, Sweden). The kit contained anti-human 
IFNy capture monoclonal antibody (Mab) (1-D1K), a biotinylated anti-human IFNy detection 
Mab (7-B6-1) and a streptavidin-alkaline phosphatase enzyme conjugate. The same substrate and 
ELISpot plates were used as for the B-cell ELISpot, section 2.4. Briefly, the PVDF ELISPot 
plate (Millipore), was coated with 50pl/well of the anti-human IFNy-Mab which was then 
incubated overnight at 4°C. The plate was then washed once with PBS and blocked with 10%- 
NBBS for at least 30 minutes at 37°C in 5%C02 and 95% humidity. The harvested cells from 
section 2.11, were added to the ELISpot wells in triplicate, at lxlO5 and 5xl04 cells/well and 
allowed to secrete IFNy for 16-20 hours. Spots were enumerated using using an AID ELISpot 
reader ELR02 and software version 3.2.3. (Cadama Medical Ltd, Stourbridge, UK), using the 
preset IFNy spot count settings from AID.
2.13 ELISA for IL-5 and IL-10 quantification
The concentrations of the cytokines IL-5 and IL-10 were quantified in the T cell culture 
supernatants using Becton Dickinson OptEIA ELISA antibody and buffer sets for detection of 
human IL-5 and IL-10, as per the manufacturer’s instructions (BD Biosciences, Oxford UK). The 
T cell supernatants were defrosted and 50pi was added to duplicate wells, and the final 
concentration of cytokine was expressed in pg/ml.
2.14 CFSE dye dilution for quantification of B cell 
proliferation.
The cytoplasmic dye, 5-(and-6)-Carboxyfluorescein diacetate succinimidyl ester (CFSE), was 
used to label PBMCs isolated at each time point after immunisation. The PBMCs were isolated
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as in section 2.4 and resuspended to 2xl06cell/ml. Then 1ml of cell suspension was removed 
prior to CFSE labelling and kept as the unlabelled cell control and also for ex vivo FACS analysis 
prior to culture.
The remaining cells were diluted in PBS+EDTA+0.5%NBBS to give lxlO6 cells/ml. These cells 
were then labelled with a final concentration of 2pM CFSE by incubation at 37°C in 5% C 02 and 
95% humidity for 10 minutes. Following this incubation the reaction was quenched with ice cold 
PBS+EDTA+0.5%NBBS and washed at 2000 rpm (900xg) for 20 minutes. The pellet was 
resuspended in PBS+EDTA+0.5%NBBS and washed 2 times at 1800 rpm (700xg) for 15 
minutes. Finally, the cells were resuspended in 1ml 10%NBBS, counted as in section 2.4.1 and 
then resuspended to 2xl06cells/ml and put into culture as in section 2.6.
Following 5 days of stimulation the cells were harvested for ELISpot as in section 2.7 and a small 
fraction was labelled with antibodies to IgD, IgM, IgG, CD27, CD 19, and CD3 (see section 2.1.2 
and section 2.8) The CFSE proliferation data was analysed by BD CellQuest™ software (see 
chapter 5).
2.15 Statistics
Comparison between individuals and time points was carried out using the Wilcoxon Signed 
Rank test and the Mann Whitney test in SPSS vl2, GraphPad Prism V4 and Microsoft Excel.
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Chapter 3: The T and B cell responses to a 
heptavalent pneumococcal conjugate 
vaccine at 12 months of age.
3.1 Abstract
To evaluate the response to a pneumococcal conjugate vaccine at 12 months of age, toddlers were 
immunised with a heptavalent pneumococcal protein-polysaccharide vaccine and blood samples 
obtained before and after immunisation. The B and T cell responses were evaluated by analysis of 
immunoglobulin and cytokines produced by PBMCs and surface phenotyping of the 
lymphocytes. There was a rise in frequency of diphtheria specific plasma cells following 
immunisation. In vitro culture with SAC+IL-2 revealed a rise in frequency of diphtheria and 
serotype 4 specific IgG memory B cells following immunisation. At different time points after 
immunisation there was variation in the number of memory B cells detected. The frequencies of 
polysaccharide specific memory B cells were higher at day 9 after immunisation than at day 11, 
while there was no difference in the number of the diphtheria specific cells at these two times. 
There was a significant rise in serum IgG antibody following immunisation to serotype 4 and 23F 
but not to serotype 14, although pre-existing IgG levels were higher to serotype 14.
Toddler lymphocytes expressed a predominantly naive phenotype (CD27' B cells and CD45RA+ 
T cells). All o f the toddler B cells expressed co-stimulatory molecules such as HLA-DR and 
CD38 and the T cells were CD28+, suggesting a state of pre-activation and that they may respond 
rapidly even though they are naive.
Pnc7 immunisation significantly increased the concentration of IL-5 and IL-10 in cell culture 
supernatants following in vitro stimulation of PBMCs with diphtheria toxoid. No such effect was 
seen with IFNy-secreting cell frequency.
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Prior nasopharyngeal carriage of pneumococcus (positive culture at dO) and increased risk of  
exposure to respiratory infections (exposure to siblings or peers in nursery) was associated with 
increased secretion of IL-5 and IL-10 by PBMCs cultured with diphtheria toxoid following Pnc7 
immunisation. There was no change in the frequency of IFNy-SC following immunisation and no 
difference between groups.
Conclusion
Toddlers responded well to a single dose of Pnc7 vaccine with plasma cells and memory B cells 
being generated in response to diphtheria toxoid and serotype 4. The cytokine response to the 
carrier protein appeared to be predominantly Th2 (IL-5) although the toddler’s PBMCs were 
capable of secreting IFNy. However, the time points chosen in the study may not have been ideal 
for optimal detection of plasma cells, memory B cells or for cytokine responses. While the data 
in this chapter have shown that it is possible to detect these B cell populations in vitro even in 
very young children, a number of questions have been raised. For instance, what are the optimal 
time points for plasma cell and memory B cell detection following immunisation?
3.2 Introduction
The heptavalent pneumococcal conjugate vaccine (Pnc7) is highly efficacious in children under 
the age of 2 years. However following immunisation with Hib and Men C conjugate vaccines at 
2,3,4 months o f age, the levels of serum IgG antibody have been shown to wane rapidly during 
the following 12-15 months (381). This was also shown to be true in infants primed with the 
Pnc7 vaccine, although the decline in antibody was serotype dependent (187). In some cases 
antibody concentrations may fall below the levels of detection by ELISA, yet boosting at a later 
date generates a rise in antibody concentration, indicating that priming for an immune memory 
response has occurred during the intervening time between priming course and booster dose.
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The isolation and subsequent quantification of the B cells involved in the generation and 
maintenance of serum antibody may be of benefit in predicting future protective immunity 
induced by primary immunisation with glycoconjugate vaccines. This same process may also 
allow identification of individuals with pre-existing memory for the vaccine antigens. Antigen 
specific plasma cells have been isolated from the peripheral blood of human adults immunised 
with pneumococcal vaccines (106-108, 111, 113) and Hib vaccines (382). The presence o f these 
cells in the circulation has also been demonstrated in pre-school children and toddlers, although 
direct comparisons with adults are few (113, 383). It has been suggested that toddlers 
predominantly generate non-secreting plasmablasts in response to pneumococcal polysaccharides. 
These cells migrate to the bone marrow before maturing into terminally differentiated plasma 
cells that secrete antibody for prolonged periods of time (256, 257, 354, 384-386). In order to 
detect non-secreting plasmablasts or pre-exisiting memory B cells, polyclonal stimuli are used to 
activate peripheral blood B cells, inducing the proliferative processes required for differentiation 
into IgG-antibody forming cells (IgG-AFC) (376, 387). The frequency of memory B cell derived 
IgG-AFC in the circulation of toddlers following immunisation with Pnc7, and comparison with 
adults, has not yet been established.
It is not only the B cell response that needs to be considered in response to protein conjugated 
polysaccharides. The success of the glycoconjugate vaccines in children under 2 years o f age has 
been attributed to the recruitment of T cell help by the protein-carrier (in this case CRM197, a 
mutant of diphtheria toxoid). These CD4+ T-helper cells (Th-cells) provide co-stimulatory help 
to B-cells responding both to the polysaccharide and also to the protein carrier. These signals 
include IL-5 that is produced by activated Th2 cells and mast cells and acts on B1 cells, 
stimulating proliferation and differentiation into AFC (285). However, the T cell help is affected 
by the cytokine environment in which the response to the vaccine antigens occurs (188, 189). 
This may be either the pre-existing cytokine environment or that induced by immunisation. The 
cells producing the cytokines may be non T cell and non B cell, therefore not specific for the
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vaccine antigens at all. Previous studies have shown that priming immunisation schedules during 
the first 6 months of life can skew infant cytokine responses towards a Th2 phenotype (IL-5, IL- 
10 and decreasing IFNy), that generates mainly IgM and IgGl antibody (195, 388, 389). In older 
children and adults the response to immunisation is skewed towards a Thl (IFNy) or ThO (IL-5, 
IL-10, IFNy) response leading to IgG2 antibody. Factors which may affect the cytokines 
produced in response to immunisation include 1) the maturational stage of T cell development 
(390-392), 2) exposure to respiratory pathogens or nasopharyngeal carriage o f commensal 
organisms (393, 394) and 3) maturational stage of accessory cell development such as natural 
killer (NK) cells (395) and defective maturation of dendritic cell IL-12 production (388). 
Exposure to Bordetella pertussis or immunisation with component pertussis vaccines during early 
infancy has been demonstrated to skew the T cell response towards a Thl phenotype (396), while 
other childhood immunisations induce a Th2 phenotype (195, 388, 389) or a ThO phenotype (189) 
which subsequent vaccination then drives toward either Thl or Th2 phenotype depending on age. 
At 12 months of age, toddler T cell responses are already programmed toward a Th2 like 
phenotype in response to immunisations with tetanus toxoid and Hib. T cells from this age group 
have a steady state Th2 response and decreased IFNy response. The new heptavalent 
pneumococcal conjugate has been shown to induce Th2 responses in adults, with respect to the 
carrier protein (373).
3.3 Aims
The main aim of this pilot study was to determine whether it would be possible to detect IgG- 
ASC specific for pneumococcal capsular polysaccharides in the peripheral blood of 12-month old 
toddlers following immunisation with a single dose o f Pnc7. In particular it was o f interest 
whether it would be possible to isolate these cell populations from the very small paediatric blood 
volumes of 4ml or less.
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The secondary aim was to determine the frequency of interferon-gamma secreting cells (IFNy- 
SC) as a measure of the Thl cytokine response along with the levels of the Th2 cytokine IL-5 and 
regulatory cytokine IL-10 prior to and following immunisation in the same group of toddlers. 
Antibody data obtained from the main study(397) would then be compared to the cytokine data to 
see if  there was an affect of Th2 skewing on antibody generation in response to immunisation.
3.4 Methods
3.4.1 Subjects and clinical procedures
A study was undertaken in the Oxford area in 12-month old toddlers. The aim of the study was to 
determine differences in serum IgG induced by immunisation with of Pnc7 in toddlers with or 
without risk factor for increased exposure to nasopharyngeal carriage of pneumococci (397). In 
the Salt et al study toddlers were grouped on the basis of risk factors for exposure to 
nasopharyngeal carriage of pneumococci during the first year of life. These risk factors were 
either a toddler’s attendance of a day care facility or the presence of siblings in the family home, 
or both of these or neither of these.
For this study the grouping was simplified into two groups based on the increased risk (group 1) 
or reduced risk (group 2) of exposure to respiratory pathogens (Table 3.1).
The laboratory staff remained blinded to the toddler grouping until all o f the study samples had 
been analysed. All o f the participants received the same vaccine at 12 months of age.
Serum samples were collected prior to and 9-11 days following immunisation and a 
nasopharyngeal swab was obtained prior to immunisation. In order to study the B cell response 
in the same cohort ethical permission was sought from the Oxfordshire Research Ethics 
Committee (OxREC number C02.005), to obtain 4ml of heparinised blood prior to and following
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immunisation. Following this approval 5ml of blood was obtained from each child (1ml for 
ELISA and a maximum of 4ml for B cell studies, with the ELISA taking priority).
Therefore from a total o f 160 toddlers enrolled and visited during the study, a small subset of 17 
toddlers (14 paired samples), had sufficient sample for the successful detection of either ex vivo 
(plasma cells) or memory B cell derived IgG-AFC by ELISpot (table 3.1).
Cytokine (IL-5 and IL-10,) and IFNy-SC (in vitro stimulated) responses were investigated in a 
further subset of twenty-nine 12-month old toddlers (table 3.1).
Blood volumes of less than 800pl were deemed to small to yield enough PBMCs for memory B 
cell culture and ELISpot, although they were sufficient for some T cell cultures since fewer cells
were needed.
Study assay
Total
no.
toddlers
tested
increased or reduced 
risk o f exposure to a 
respiratory pathogen
isolation o f a pneum ococcus 
from nasopharyngeal swabs 
obtained prior to 
imm unisation
Group 1 
(increased)
Group 2 
(reduced)
Positive N egative
Plasma Cells 7 n/a n/a n/a n/a
M em ory B cells 14 n/a n/a n/a n/a
IFNy-SC 29 17 12 17 12
IL-5 21 11 11 14 7
IL-10 21 11 11 14 7
Table 3.1 The number of toddlers included in the analysis for each of the parameters tested in the 
study.
For each of the study assays the total number of toddler samples analysed is shown in the second column. 
For the cytokine assays the toddler samples were analysed for increased risk (group 1) and reduced risk 
(group 2) of exposure to respiratory pathogens. The cytokine data was also analysed based on whether 
nasopharyngeal isolates were culture positive or negative for detection of a pneumococcal serotype. ( n/a = 
sample numbers were to small to perform the subgroup analyses for the B cell study).
3.4.2 B cell ELISpot for the detection of vaccine induced 
memory
PBMCs were isolated, as described in Chapter 2, section 2.4, from 12-month old toddlers (n=17) 
prior to and 9,10 or 11 days post-immunisation with a single dose of Pnc7.
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The PBMCs were then either incubated directly in antigen coated ELispot wells or were cultured 
for 5 days in the presence of SAC+IL-2 as described in Chapter 2, sections 2.5-2.6.
The ex vivo elispot was carried out as in Chapter 2, section 2.5 and the data were expressed as 
IgG-AFC/106 PBMCs. For the memory B cell assay, following 5 days o f in vitro stimulation 
with SAC+IL-2, the PBMCs were harvested, washed and seeded on to ELISpot plates (2x105 
PBMCs/well), coated with PBS, tetanus toxoid, diphtheria toxoid and polysaccharides from the 
capsules of pneumococcal serotypes 4, 14 and 23F (See chapter 2 section 2.7).
Due to the small number of samples obtained for this part of the study it was not possible to 
determine the effects of nasopharyngeal carriage exposure on pre-existing memory B cell 
frequency. Statistical analysis was used to compare the difference in frequency of the IgG-ASC 
prior to and following immunisation for the ex vivo assay and also the memory B cell assay 
(Wilcoxon sign rank test for paired, non-parametric analysis). Analysis was also carried out on 
the effect of post immunisation time point (day 9, 10 or 11) on detectable memory B cell 
frequency specific for each of the antigens tested (Mann-Whitney U test for un paired, non- 
parametric analysis).
3.4.3 Determination of vaccine induced IFNy-SC frequency 
and secreted cytokine concentrations
The frequency of IFNy-secreting PBMCs was determined by ELISpot after 7 days o f in vitro 
stimulation with tet, dip, CbpA and PspA (see chapter 2, sections 2.11 and 2.12). Tet was a 
positive, non vaccine related control antigen and dip was used to represent the CRM 197 carrier 
protein response. CbpA and PspA were pneumococcal surface proteins to which toddlers may 
have been exposed during nasopharyngeal carriage o f pneumococci.
The levels of the Th2 cytokine IL-5 and regulatory cytokine IL-10, in the cell culture supernatants 
were determined by ELISA as per manufacturers instructions (see chapter 2, section 2.13). 
Statistical analysis was used to compare the frequency of IFNy-SC and IL-5 and IL-10
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concentrations prior to and following immunisation (Wilcoxon sign rank test for paired, non- 
parametric analysis). Subgroup analysis was also carried out for the effect of exposure to 
respiratory pathogens and also whether carriage o f a pneumococcus was detected prior to 
immunisation (Mann Whitney U test for un-paired, non-parametric analysis).
3.5 Results
3.5.1 A single dose of Pnc7 induced a rise in plasma cell 
frequency
Following immunisation a rise in the median frequency of spontaneously secreting IgG-AFC 
(plasma cells) was induced in response to the CRM197 carrier component o f the vaccine 
(represented by dip). This was observed in 100% of the 12-month old toddlers 9-11 days after 
immunisation (table 3.2). A rise at day 9-11 was also seen in response to serotype-4 with 100% 
of participants responding to immunisation, though this was not significant, and to a lesser extent 
in response to serotype-14, but not in response to serotype-23F (table 3.2 and figure 3.1). The 
rise in frequency of IgG-AFC was highly significant for diphtheria toxoid (fig 3.1, p=0.006). 
Although there appeared to be a trend for a rise in frequency of IgG-AFC specific for the capsular 
polysaccharides (4,14 and 23F,) this difference was not significant.
median frequency o f ex vivo IgG-AFC/10 PBM C s
tet dip 4 14 23F
,. . . dayO  
time point , « - - day 9-11
1
0
4
20
0
5
0
5
0
0
responders ^
3/7
43%
7/7
100%
7/7
100%
5/7
71%
1/4
25%
Table 3.2 The percentage of toddlers with an ex vivo, plasma cell response to a single dose of Pnc7.
The data represent the median frequency of ex vivo AFC prior to (day 0) and following (day 9-11) 
immunisation of toddlers with a single dose of Pnc7. Also shown is the percentage of toddlers where a rise 
in frequency was seen following vaccination (% responding) with the actuall numbers of participants and 
responders in parenthesis.
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Figure 3.1 Spontaneously secreting IgG-AFC detected in the peripheral blood of 12-month old 
toddlers prior to (blue open circles) and 9-11 days after (green open circles) a single dose of Pnc7.
PBMCs were isolated and incubated for 16 hours on ELISpot plates coated with tet, dip and serotype-4, 14 
and 23F polysaccharides. Spots per well were calculated and the data were expressed as the number of 
antigen specific IgG-AFC/106 PBMCs.
3.5.2 Immunisation with Pnc7 did not lead to increased 
frequencies of Memory B cell derived total IgG-AFC.
The total frequency of all IgG-secreting cells isolated from the peripheral blood of toddlers was 
quantified by coating ELISpot wells with anti-human Ig and then detecting the AFC secreted 
antibody with an anti-human IgG-alkaline phosphatase conjugated antibody. Total IgG-AFC was 
used as a control for the in-vitro differentiation of memory B cells into IgG secreting plasma 
cells. The cut off frequency was >1000 IgG-AFC/106 cultured PBMCs. Samples were excluded 
if the frequency fell below this since the assay sensitivity for the low frequency polysaccharide 
specific memory B cells may have been insufficient. Figure 3.2 shows that it was possible to 
detect memory B cell derived IgG secreting cells in the peripheral blood of 100% of 1 2 -month
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old toddlers prior to immunisation. The lowest frequency detected was 2798 IgG-AFC/106 
cultured PBMCs. Following immunisation there was no significant alteration in the frequency of 
total IgG-secreting cells. The range in total IgG-AFC/106 cultured PBMCs, both before and after 
immunisation, was wide (2798-62,500 total IgG secreting cells before and 7500-40,000 9-11 day 
after immunisation).
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Figure 3.2 The frequency of total-IgG-AFC in the peripheral blood of toddlers prior to (dO) and 
following (d9-ll) a single dose of Pnc7.
PBMCs were isolated and stimulated with SAC+IL-2 for 5 days. The cells were then harvested and 
washed 3 times in 10%-NBBS before being seeded (at concentrations of 2xl04, 2x l03, 2xl02 cells/well), 
into anti-human Ig coated ELISpot wells. The cells were then left to secrete IgG overnight at 37°C in 
5% C02 and 95% humidity. Following development of the spots, the data were expressed as the median 
number of IgG-AFC/106 cultured PBMCs. The effect of immunisation on the frequency o f total-IgG AFC 
was calculated in a non-parametric, paired analysis using the Wilcoxon signed rank test.
98
3.5.3 A single dose of Pnc7 increased the frequency of 
antigen specific memory B cell derived AFC.
Tetanus toxoid (tet) was used as a positive control to check that in vitro stimulation of PBMCs 
drove the differentiation of antigen specific memory B cells in to plasma cells. There were 
detectable numbers of tet specific IgG-AFC in 93% of toddlers prior to immunisation and this 
was unaltered following administration of the Pnc7 vaccine (figure 3.3). The median number of 
tetanus toxoid specific cells detected prior to immunisation was 12 IgG-AFC/106 cultured 
PBMCs while following immunisation this fell to 8  IgG-AFC/106 cultured PBMCs (p=0.808).
p=0.0001 o  dO 
o  d 9 -1 1
p=0.808
p=0.001
tet dip 4  14
coating antigen
2 3 F
Figure 3.3 The frequency of antigen specific IgG-AFC, derived from memory B cells from the 
peripheral blood of toddlers.
PBMCs were isolated on day 0 (blue open circle) and then days 9-11 (green open circle) following 
immunisation with a single dose of Pnc7. The PBMCs were stimulated with SAC+IL-2 for 5 days, and 
then harvested, washed 3 times in 10%-NBBS and seeded (at 2xl0"cells/well), into ELISpot wells coated 
with tet, dip, and serotypes 4, 14 and 23F polysaccharides. The cells were incubated overnight at 37°C in 
5% C02and 95% humidity. Following development of the spots, the data were expressed as the number of 
IgG-AFC/106 cultured PBMCs. The Wilcoxon signed rank test was used to calculated the significance of 
differences in the median cell frequency between day 0 and day 9-11.
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The frequency of memory B cells specific for the vaccine related antigens were determined prior 
to immunisation. The CRM197 carrier response was determined using diphtheria toxoid as the in 
vitro antigen and, before immunisation, 79% of the toddlers had detectable diphtheria toxoid 
specific memory IgG-AFC, (median of 4 IgG-AFC/106 cultured PBMCs). Pre-existing memory 
B cell frequency specific for the polysaccharide antigens was much lower. Only 29% of toddlers 
had detectable memory B cells specific for serotypes-4 and 14 and 43% for serotype-23F (table 
3.3). This translated into median spot counts of zero for all three polysaccharides.
Following immunisation, memory IgG-AFC specific for diphtheria and serotype-4 increased 
significantly in frequency by days 9-11 (fig 3.3), with 100% of toddlers showing a boosted 
memory response to diphtheria and 79% for serotype-4 (table 3.3). There was no significant 
alteration in the frequency of IgG memory to serotypes-14 and 23F. The percentage o f toddlers 
with detectable IgG-AFC following immunisation was higher for all of the antigens at days 9-11, 
though the actual number of individuals showing an increase in frequency (% responders) did not 
change for serotype-14 and showed only a marginal rise for serotype-23F (table 3.3).
The low level of detection for some of the serotypes suggested that perhaps the timing of the 
blood samples was too late and that the peak in circulating antigen specific memory B cell had 
been missed. Therefore the data were split to show the frequency of cells detected on days 9 
(n=4), 10 (n=7/8) and 11 (n=7) following immunisation (fig 3.4).
It is clear from figure 3.4 that there was no significant alteration in the detection of the IgG-AFC 
to the positive control (fig 3.4a tetanus) at any of the time points, while for diphtheria toxoid the 
frequency of IgG-AFC remained significantly elevated above baseline at each of the time points 
(fig 3.4b). For each of the capsular polysaccharide antigens there was a trend to decreasing 
frequency of IgG-AFC as time post immunisation increased with day 9 yielding the highest rate 
of detection (fig 3.4c-e), although this was only significant for serotype-4 (fig 3.4c).
100
m edian frequency o f  
IgG -AFC/106 cultured PBM Cs
dip 4 14 23F
median frequency  
day 0 n-pre
% pre-existing m emory
4
11/14
79%
0
4/14
29%
0
4/14
29%
0
6/14
43%
 ^ „ median frequency 
day 9-11 *J n-post
30
14/14
4
12/14
0
5/14
2
9/14
responders n-resp
%
14/14
100%
11/14
79%
4/14
29%
7/14
50%
Table 3.3 The frequency of memory B cell derived IgG-AFC in the peripheral blood of toddlers 
prior to and following a single dose of Pnc7.
The median frequency of IgG-AFC are shown for day 0 and day 9-11, expressed as the median IgG-
AFC/106 cultured PBMCs. Underneath this is the number of individuals (n-pre) with pre-existing memory 
IgG-AFC at day 0 plus the percentage. At day 9-11 the number of toddlers with detectable IgG-AFC (n- 
post) is shown. Finally the overall percentage of toddlers with a rise in frequency of IgG-AFC to each of 
the antigens (% responders) and also the absolute numbers (n-resp) following immunisation with Pnc7 
vaccine is shown.
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3.5.4 Pnc7 immunisation induced a rise in pneumococcal 
capsule specific serum IgG antibody.
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Figure 3.5 Serotype capsular polysaccharide specific IgG in the serum of 12 month old toddlers prior 
to and following a single dose of Pnc7.
Serum IgG antibody was quantified by the ELISA protocol as described in Chapter 2, section 2.10. This 
data represents a subset o f 18 individuals from the larger study of 160 subjects, the results of which were 
published recently by P. Salt et al (397). The individuals included here were the same individuals included 
in the memory B cell study. The data represents the serum concentration of IgG (pg/ml) at day 0 (blue 
circles) and day 9-11 post immunisation (green circles) with a single dose of Pnc7. The red bar represents 
the GMC with. ***p=<0.0001, **p=0.0067, ns=not significant, p=0.1134.
Prior to immunisation there were barely detectable levels of IgG to any of the three serotypes 
with GMCs for serotypes 4, 14 and 23F of 0.068pg/ml (0.01-1.06), 0.201jig/ml (0.114-0.354) and 
0.07pg/ml (0.04-0.118) respectively (figure 3.5). These levels increased significantly for 
serotype 4 (p=<0.0001), and 23F (p=0.0067), following immunisation while in response to 
serotype 14 the rise in GMC of IgG was not significant (p=0.1134, fig.3.5). The post 
immunisation levels of IgG were similar for each of the serotypes while the actual rise in IgG 
specific for serotype 4 was greater than for serotype 14 which was greater than that induced by
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23F. There were no correlations between antibody levels and memory B cell frequencies at any 
time point for any of the three serotypes.
3.5.5 A single dose of Pnc7 had no effect on the phenotype of 
toddler B and T cells.
Toddler PBMCs were isolated and the cells labelled for expression of CD3, CD19/CD20 along 
with activation and co-stimulatory markers CD28, CD38, CD69 and CD80 as described in 
chapter 2, sections 2.1.2 and 2.8. The mean expression of B-cell activation and memory markers 
are show in fig.3.6a-b, while the general characteristics of the CD3+ T cells are shown in figure 
3.6c.
The percentage of CD19+ and CD20+ B cells was identical (fig.-3.6a-b), which allowed for more 
versatility in combinations of antibodies used for further analysis of phenotypes. Toddler B cells 
were predominantly naive (CD27‘) but positive for the MHC class II molecule HLA-DR 
(fig.3.6b). The B cell expression of the co-stimulatory marker CD80 and the activation marker 
CD69 was also low. Most toddler B cells were CD38+, and the mean CD38+CD19+ B cell 
population increased following immunisation, though not significantly.
The T cell phenotype (fig 3.6c) shows that almost all of the T cells expressed CD28 and CD38. A 
small percentage of the T cells express the IL-2 receptor (CD25) and 50% expressed CD45RA (a 
marker o f naive T cells), and 10% express CD45RO (a memory T cell marker). The activation 
marker CD69 was not detected. Thus the toddler T cells were predominantly naive but expressed 
co-stimulatory markers (CD28 and CD38). Therefore immunisation of toddlers with a single 
dose of Pnc7 had no observable effect on the mean percentages o f the B cell or T cell populations 
(fig.3.6a-c).
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Figure 3.6 The phenotype of peripheral blood B and T cells isolated from toddlers prior to (blue) and 
9-11 after a single dose of the Pnc7 vaccine (green).
B cells were gated on either CD 19 or CD20 surface marker expression (total). The within the CD19/CD20 
populations of B cells the percentage expression of CD27, CD38, HLA-DR, CD80 or CD69 was 
determined (a-b). The T cells were gated based on the expression of CD3. The percentage of CD3+ T cells 
expressing CD25, CD28, CD38, CD45RA/RO, and CD69 was then quantified (c). The bars represent the 
mean percentage surface expression within the CD19/CD204 or CD34 populations plus the 95% confidence 
intervals.
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3.5.6 Reduction in spontaneous I F N y  secretion by PBMCs 
isolated following immunisation with Pnc7.
The frequency of IFNy-SC was quantified following in vitro stimulation of PBMCs isolated prior 
to and 9-11 days after immunisation of toddlers with Pnc7. A group of twenty-nine 12-month 
old toddlers were included in the analysis but the limited size of blood samples obtained meant 
that not all of the culture antigens were used for all o f the subjects and the number of paired 
samples was much lower than the 29 individuals recruited into the study (figure 3.7).
There was a wide variation in the frequency of IFNy-SC between individuals in response to 
stimulation with all of the antigens before and after immunisation (figure 3.7).
In vitro stimulation of PBMCs with tet, dip (vaccine CRM 197 carrier protein related antigen), 
PspA and PHA induced higher frequencies of IFNy-SC than was seen with medium alone figure 
3.7 (p=<0.0001), while there was no difference in the frequency of CbpA induced IFNy-SC 
compared to medium alone (p=0.109).
Following Pnc7 immunisation there was a significant decline in the spontaneous secretion of 
IFNy in the medium only PBMC cultures (fig. 3.7a, p=0.017) but no change in IFNy-SC 
frequency following PBMC stimulation with specific antigens or PHA (fig.3.7a-b).
Therefore immunisation did not alter the IFNy response to stimulation with dip (the CRM 197 
carrier protein related antigen), nor to the other antigens or PHA but there was a reduction in 
spontaneous IFNy secretion in the medium only cultures.
Table 3.4 shows the proportion of toddlers where immunisation with Pnc7 increased the 
propensity o f stimulated PBMCs to secrete IFNy. There was a rise in IFNy-SC frequency in 
28%-53% of toddlers following in vitro culture of post immunisation versus pre immunsation 
PBMCs.
106
a ) p=0.909
12500- o o
10000-
o
7500- o
5000- o
oO o Oo
g o ° °
o
0 0 
o 
o
2500-
0-
p=0.0174
OOOO® O «
1°boo
oofo 
0 0
OO 
CO
0? o
O d O  
O d9-11
medium
(n=29)
</)
o
§
m
0-
■aa>
O
C/)
b)
3000-
2000 -
1000-
p=0.558
o  o 
o °J o V .  OO a*£
«o° 2°°
M
tet
(n=28)
PHA
(n=23)
p=0.799
p=0.978
’oo
°o
o
OO
o  <Sb
p=0.578 'oo
o
>o
Oo
rftrrg
dip
(n=29)
CbpA
(n=7)
PspA
(n=15)
cell culture antigens
Figure 3.7 The effect of immunisation on the frequency of spontaneous and antigen specific IFNy-SC.
PBMCs isolated prior to immunisation (blue) and 9-11 days after immunisation with a single dose o f  Pnc7 
(green) were stimulated for seven days with medium or antigens and three days with PHA. The resulting 
cells were then harvested and seeded into anti-IFNy-Mab coated ELISpot w ells where they were allow ed to 
secrete IFNy for 16 hours. IFNy-SC were then enumerated and the data expressed as IFNy-SC/106 cultured 
PBMCs. Fig 3.7a shows the frequency o f  IFNy-SC obtained from unstimulated PBM Cs (medium alone), 
and polyclonaly stimulated PBMCs (PHA). Fig.3.7b shows the frequency o f  IFNy-SC obtained follow ing  
stimulation o f  PBMCs with tet, dip, CbpA and PspA. The red lines represent the median number o f  IFNy- 
SC.
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antigens used for in vitro stimulation o f PBM Cs 
isolated 9-11 days after immunisation with Pnc7
cytokine responders medium tet dip PspA CbpA PHA
IFNy-SC
% 28%* 36% 48% 29% 53% 48%
n= 8/29 10/28 14/29 2/7 8/15 11/23
IL-5
%
n=
10%
2/21
40%
8/20
80%*
16/20
IL-10
%
n=
19%
4/21
29%
6/21
60%*
12/20
Table 3.4 The percentage of toddlers where a single dose of the Pnc7 vaccine lead to an increased 
propensity of in vitro stimulated PBMCs to make IFNy, IL-5 or IL-10 9-11 after immunisation with 
Pnc7.
PBMCs were isolated following immunisation and stimulated in vitro with tet, dip, PspA, CbpA, PHA or 
medium only. IFNy-SC frequency was enumerated by ELISpot and concentrations of IL-5 and IL-10 in the 
culture supernatants were measured by ELISA. The data shown are the percentage responders (%) with 
actual numbers of toddlers tested and responding (n=). *p<0.05.
3.5.7 Increased IL-5 and IL-10 secretion by PBMCs isolated 
following immunisation with Pnc7.
Determination of IL-5 and IL-10 cytokine levels in cell culture supernatants was only possible in 
response to in vitro stimulation of PBMCs with tet and dip (figure 3.8 and table 3.4).
The concentration of IL-5 induced following in vitro stimulation of PBMCs with tet or dip was 
higher than that of IL-10. PBMCs stimulated with tet or dip secreted more IL-5 and IL-10 than 
those cultured in medium alone (fig 3.8a-b). Levels of IL-5 and IL-10 were highest in response to 
in vitro stimulation with tet although immunisation of toddlers with Pnc7 did not alter this. 
However, the Pnc7 vaccine contains CRM 197, a mutant diphtheria toxoid, and following Pnc7 
immunisation the levels of IL-5 and IL-10 secreted following in vitro stimulation of PBMCs with 
dip increased significantly (IL-5, p=0.027 and IL-10, p=0.016 respectively, fig.3.8a-b) with 80% 
and 60% responders respectively (table 3.4).
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Figure 3.8 IL-5 and IL-10 secretion by PBMCs isolated before and after immunisation of toddlers 
with a single dose of Pnc7.
PBMCs were isolated from toddlers on day 0 (blue open circles) and on day 9-11 after immunisation (green 
open circles). The PBMCs were then cultured for seven days in the presence of medium only, tet or dip. 
The level of IL-5 (a) or IL-10 (b) in the supernatant was measured by ELISA and is presented in pg/ml with 
the median concentration shown as a red bar.
3.5.8 The effect of post immunisation blood sample time 
point on frequency of IFNy-SC
When the dO samples were grouped based on the timing of the post vaccination sample (d9, 10 or 
11), it was possible to see that there was no difference in the propensity of PBMCs to secrete 
IFNy at day 0 between the groups or between each group compared to the study population as a 
whole (fig.3.9a-c).
Following immunisation the frequency of IFNy-SC cells induced by in vitro stimulation of 
PBMCs with tet and dip was unaffected by the timing of the post immunisation sample (fig.3.9e- 
f). However, PBMC cultured with medium alone showed significantly higher frequencies of 
IFNy-SC at day 11 than at day 9 (p=0.024, fig 3.9d) but there was no significant difference 
between dO and d9, 10 or 11. This data suggests that frequencies of IFNy-SC may rise above 
baseline at a time later than day 11.
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3.5.9 Exposure to respiratory pathogens had no effect on the 
IFNy-SC frequency but enhanced diphtheria toxoid induced 
IL-5 and IL-10
The toddlers recruited into this study were grouped according to risk factors for exposure to 
respiratory pathogens. These risk factors were i) presence of siblings in the household and ii) 
attendance of daycare. For the purposes of this thesis analysis the toddlers were grouped as 
follows: Group 1 = increased risk of exposure to respiratory pathogens and Group 2 = reduced 
risk (no siblings or daycare). The frequency of IFNy-SC and also the concentrations o f IL-5 and 
IL-10 in the supernatants of the PBMC cultures were compared between the groups both before 
and after immunisation with Pnc7 (fig 3.10).
Immunisation with Pnc7 had no effect on the frequency of IFNy-SC following in vitro stimulation 
of PBMCs with medium, tet or dip (fig.3.10a-c). There was also no difference in IFNy-SC 
frequency between group 1 and group 2.
The concentrations of IL-5 (fig.3.10d-f) and IL-10 (fig.3.1 Og-i), in the PBMC culture 
supernatants, was similar between group 1 and group 2. This was true both before and after 
immunisation. Within group 2 however, following immunisation with Pnc7 there was a 
significant rise in the concentrations of IL-5 (p=0.027) and IL-10 (p=0.016) in the culture 
supernatants following in vitro stimulation with diphtheria toxoid than was seen prior to 
vaccination (fig.3.10.f+i).
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3.5.10 Carriage of pneumococci prior to Pnc7 immunisation 
increases the diphtheria toxoid specific IL-5 secretion by 
PBMCs.
As part o f the larger study, 159 toddlers were shown to have had cultures, positive for 
pneumococcus isolated from nasopharyngeal swabs obtained prior to immunisation. For this 
portion of the study the percentage of positive versus negative cultures is shown in table 3.5. The 
main observation from this data was that more children were positive for pneumococcal carriage 
(59-70%) than were negative for carriage at the time of immunisation (30-43%).
This data shows that there were similar proportions of pneumococcal culture positive and 
negative toddlers in each of the cytokine analysis groups. The IFNy-SC frequencies for the two 
groups (culture positive or negative,) are shown in figure 3.1 l(a-d) along with the concentrations 
of IL-5 (fig. 3.1 le-h) and IL-10 (fig. 3.1 li-1).
Antigen uset 
medium
for in vitro s 
tetanus
imulation
diphtheria PH A
culture (+/- 
)
+ + + - +
IFNy-SC
IL-5
IL-10
59% 41%  
67% 33%  
65% 35%
57% 43%  
70% 30%  
70% 30%
59%  41%  
65% 35%  
67% 33%
61%  39%  
62.5%  37.5%  
59%  41%
Table 3.5 Percentage of toddlers with detectable pneumococcal carriage prior to immunisation with 
Pnc7.
Nasopharyngeal swabs were obtained from all of the toddlers in the main study (397) and the percentage of 
cultures positive or negative for the detection of pneumococci was established. This data represents the 
proportion of toddlers included in each of the cytokine-antigen analysis groups, that were either positive or 
negative.
Following in vitro stimulation of the PBMCs isolated both before and after Pnc7 immunisation 
there was a higher concentration of IL-5 than IL-10 present in the culture supernatants. This was 
true following stimulation with tetanus (fig.3.11f+j), diphtheria (fig.3.11g+k) and PHA 
(fig.3.11h+l). There were no significant differences between the culture positive and culture 
negative groups at either time point (dO or d9-l 1). However immunisation with Pnc7 did result in
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a significant increase in the IL-5 secretion by PBMCs isolated from the culture positive group 
following in vitro stimulation with diphtheria toxoid (fig.3.11g, p=0.017). The frequency of 
IFNy-SC obtained from the same in vitro PBMC cultures was similar in the culture positive and 
culture negative groups (fig.3.11.a-d). Therefore, only the IL-5 response o f PBMCs appeared to 
be affected by prior exposure to pneumococci.
3 . 5 . 1 1  Toddler rather than adult PBMCs made a greater I L - 5  
and I F N y  response to diphtheria toxoid stimulation.
In order to determine whether baseline levels o f IL-5, IL-10 and IFNy-SC were affected by age 
the baseline levels of IL-5, IL-10 and frequency of IFNy-SC in the toddlers were compared with 
that found in a group of five young adults (figure 3.12a-c). There was no difference in IL-10 
concentration between toddlers and adults, irrespective o f the stimulatory antigen used 
(fig.3.12b). The concentrations of IL-5 were lower in the adult group than in the toddler group, 
particularly in response to stimulation with diphtheria toxoid (fig.3.12a, p=0.013). There were 
also differences in the frequency of tetanus and diphtheria toxoid specific IFNy-SC between the 
two age groups with toddlers having significantly higher IFNy-SC frequencies. No such 
difference was seen in response to stimulation of PBMCs with PspA or PHA.
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Figure 3.12 Inducible IL-5 and IL-10 concentrations and IFNy-SC frequency from in vitro cultures 
of PBMCs obtained from toddlers and adults prior to immunisation with Pnc7.
PBMCs were isolated and stimulated for seven days with either medium only, tetanus or diphtheria toxoid, 
PspA and PHA. The supernatants were collected and IL-5 (a) and IL-10 (b) concentrations were quantified 
by ELISA. The cultured cells were harvested and allowed to secrete IFNy on to anti-IFNy coated ELISpot 
wells for 16 hours. The frequency was then determined and expressed as the number of IFNy-SC/106 
cultures PBMCs (c).
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3.5.12 Correlation between serum IgG and frequency of 
memory B cells
Serum IgG concentrations specific to each of the capsular polysaccharides (4, 6B, 9V, 14, 18C, 
19F and 23F), were quantified as part o f the larger study and the data published recently (397). 
The data for the three serotypes used in the B cell studies (4, 14 and 23F) were compared with the 
memory B cell frequency. No correlation was found either prior to or following immunisation 
except for serotype 23F. At day 0 there was a very weak, negative correlation between serum 
IgG and memory B cell frequency (r=-0.4977, p=0.042).
3.5.13 Correlation between serum IgG concentrations and 
inducible IFNy-SC frequency
For PBMCs isolated prior to immunisation with Pnc7 and stimulated with PHA there was a weak 
correlation between the IFNy-SC response and post immunisation levels o f IgG specific for 
serotype 4 (r=0.4472, p=0.032). Stimulation of the same PBMC samples with tetanus toxoid 
generated an IFNy-SC response that weakly correlated with serum IgG specific for serotype 9V 
(r=0.4545, p=0.017) and 23F (r=0.4329, p=0.021). There was also a weak association with post 
immunisation levels of IgG specific for 14 (r=0.4028, p=0.034) and 23F (r=0.5547, p=0.0022). 
Following Pnc7 immunisation, stimulation of PBMCs with tetanus toxoid generates IFNy-SC 
frequencies that were weakly associated with post immunisation IgG specific for serotype 19F 
(r=0.3846, p=0.04). Stimulation with diphtheria toxoid induced IFNy-SC frequencies that 
correlated with IgG specific for serotype 14 (r=0.4048, p=0.029).
3.5.14 Correlation between serum IgG concentrations and 
inducible IL-5 and IL-10
As with IFNy-SC the correlations between serum IgG and IL-5 or IL-10 were weak.
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The main relationships found involved spontaneously induced IL-5. For example the levels of 
IL-5 found in unstimulated cultures prior to immunisation negatively correlated with baseline 
serum IgG specific for serotype 6B (r=-0.614, p=0.004,) and 9V(r=-0.5549, p=0.011). Baseline 
IL-5 from unstimulated cultures also negatively correlated with post immunisation IgG specific 
for serotype-6B (r=-0.7922, p=<0.0001).
Following immunisation the IL-5 produced in unstimulated cultures still showed the same 
correlations with serum IgG. Overall, spontaneously secreted IL-5 negatively correlated with IgG 
levels while antigen induced production of IL-5 positively correlated with serum IgG levels.
The levels of IL-10 spontaneously secreted in unstimulated PBMC cultures did not correlate with 
serum IgG concentration. However, IL-10 induced in response to PBMC stimulation with PHA 
correlated with IgG prior to immunisation for serotype 6B (r=0.5283, p=0.029).
Prior to immunisation, stimulation of PBMCs with tetanus toxoid induced levels o f IL-10 that 
positively correlated with serotype 9V specific IgG (r=0.4940, p=0.027), 19F (r=0.4619, 
p=0.035), and 23F (r=0.4985, p=0.021).
Following immunisation, stimulation of PBMCs with tetanus toxoid resulted in IL-10 levels that 
weakly correlated with IgG specific to serotype 9V (r=0.6223, p=0.0034), 23F (r=0.5062, 
p=0.019), 23F (d9-ll) (r=0.5100, p=0.018.) While IL-10 produced by PBMCs stimulated with 
diphtheria toxoid correlated with IgG specific for 23F (pre and post immunisation (r=0.4395, 
p=0.046; r=0.4420, p=0.045 respectively).
3.6 Discussion
3.6.1 A single dose of Pnc7 induced elevated frequencies of 
both plasma cells and memory B cells
The data from this study show that it was possible to detect both plasma cells ex vivo and memory 
B cell derived IgG-AFC isolated from small (<4ml o f whole blood), paediatric whole blood 
samples.
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Pnc7 immunisation induced a significant rise in plasma cell frequency in response to the carrier 
related protein (diphtheria toxoid, fig.3.1). There was also a rise in frequency of polysaccharide 
specific plasma cells specific for serotypes 4 and 14, though these were not significant), but no 
such rise was seen in response to 23F (fig.3.1).
The frequency of memory B cell derived AFC also rose significantly in response to diphtheria 
toxoid and serotype 4 after immunisation with Pnc7, but no increase was seen in response to 
serotype 14 and 23F.
There was no correlation between the memory B cell frequency and post immunisation antibody 
level. However, the largest fold rise in antibody titre was seen in response to serotype 4 and this 
was the only serotype with a significant rise in frequency of memory B cells. The antibody data 
obtained from this subset o f individuals followed the trends described in the paper by Salt et al 
2007 (397) on the complete cohort of 160 12 month old toddlers. Here they found that serotype 4 
was the most immunogenic (100% of toddlers achieved titres >0.2pg/ml), followed by serotypes 
14 and 23F (99% and 81% of toddlers achieving IgG titres >0.2pg/ml).
The serum antibody response and the frequency of memory B cells, although not correlated, show 
similar patterns of response. The significant rise in memory B cells following immunisation in 
response to serotype 4 mirrors the antibody response at the same time point. However, there was 
minimal polysaccharide specific memory detected in peripheral blood before immunisation. So 
where did the pre-existing antibody derive from? This result argues for persistence of long-lived 
plasma cell maintenance in the bone marrow of these 12 month old toddlers from prior exposure 
to pneumococci or following diphtheria toxoid immunisations (258, 354, 385, 398). However, if  
this is the case then why were the responses to the polysaccharides from serotypes 14 and 23F not 
as efficient? One reason for the discrepancy may be a lack of nasopharyngeal carriage o f these 
serotypes prior to immunisation? However, the carriage data from this and other studies show 
that infact serotypes 23 F and 14 are detected more frequently in carriage isolates than serotype 4 
(59, 79, 92, 397). The numbers in this pilot study were far too small to complete a subset analysis
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for the influence of prior nasopharyngeal carriage on the B cell response, but Salt et al (397) did 
report differences in the magnitude of the antibody response for some of the vaccine serotypes in 
toddlers who had been exposed to carriage and those who had not. From data presented here it is 
only possible to conclude that differences in the immunogenicity o f the capsular polysaccharides 
themselves are responsible for the variation in the immune responses.
The frequency of antigen specific memory B cells peaked significantly above baseline at day 9 
for the polysaccharide antigens but in response to diphtheria this elevation remained by day 11 
post immunisation. It was not possible to carry out a similar analysis on the plasma cell response 
since the number of individuals was too small. However, higher frequencies o f spontaneously 
secreting cells have been observed during the first seven days following antigen challenge. 
Studies in the 1980’s showed that following immunisation of adults with pneumococcal 
polysaccharide vaccine there was a rise in spontaneously secreting IgG-AFC during the first week 
after immunisation, followed by a rise in antibody(106-108, 261). However, it has not been 
shown when memory B-cell derived IgG-AFC peak in the peripheral blood of toddlers or adults 
after immunisation with a glycoconjugate vaccine.
The dynamics of the extrafollicular and germinal centre reactions suggest that antigen specific 
antibody secreting cells appear in the peripheral blood from day 6 post immunisation, however 
spontaneously secreting plasma cells tend to disappear from the periphery by day 8-9 (254, 259, 
354, 399). Thus the timing of the post immunisation samples in this pilot study in relation to 
previously described kinetics suggests that the frequency of spontaneously secreting plasma cells 
(fig.3.1), was probably on the wane and this may be the sole reason for the low frequencies 
detected.
A population of non-secreting plasma cell precursors (plasmablasts) has also been described 
exiting the lymphoid tissues after antigen exposure (254, 257, 354, 400). These cells migrate to 
the bone marrow under the influence of CXCR4-CXCL12 interactions were they mature into
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terminally differentiated plasma cells and secrete antibody in the long term (348, 350, 354, 357, 
401). These cells are highly proliferative and will differentiate into mature immunoglobulin 
secreting cells after in vitro stimulation with SAC+IL-2 (400-402). Therefore between the ex 
vivo plasma cell and in vitro stimulated memory B cell assay it is probable that these data 
represent the early response mixture of mature plasma cells and non-secreting plasmablasts which 
can evolve from naive B cells, MZB, FO B cells and memory B cells(385).
The germinal centre reaction reaches a peak of B cell numbers by days 10-14 after immunisation 
(401) therefore it is likely that some of the AFC detected at days 9-11 in this study are derived 
from a newly generated memory B cell response.
There were no correlations between in vitro derived IgG-AFC and the concentration of IgG 
antibody detected in the serum. One reason for this lack of correlation may be the mixed source 
of plasma cells, secreting antibody in the short term and plasmablasts that are non secreting.
Figure 3.13 shows a scheme which describes the kinetics of the B cell subsets and their 
relationship to the serum antibody being secreted during the early response to a single 
immunisation with Pnc7, a T cell dependent vaccine.
Following immunisation there are two waves of B cell proliferation and differentiation. One is 
extrafollicular and independent of direct T cell interaction and the second is dependent on T cells 
and germinal centre formation (figure 3.13). The blue boxed area shows how the samples 
obtained in this pilot study relate to the kinetics o f the different B cell response.
Spontaneously secreting plasma cells are the product of the extrafollicular response and are short 
lived, peaking in frequency by day 7 (green filled curve), thus at the time points in this study the 
frequency of PC was probably waning, based on findings in previous studies (106-109, 145, 259, 
261).
When PBMCs were stimulated in vitro with SAC+IL-2 the cells differentiating into AFC were 
most likely non secreting plasmablasts produced during the initial extrafollicular response (red
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line). Plasmablast migration has been shown to continue for some days (up to five weeks in mice 
(259)), following immunisation. So at the time points in this study, although spontaneously 
secreting plasma cells were disappearing from the peripheral blood, accounting for the low AFC 
frequency in the ex vivo ELISpot, the in vitro stimulation of PBMCs enabled continued detection 
of IgG-AFC by day 11 after immunisation.
The germinal centre reaction involves the recruitment o f T cells by FDC expressing specific 
antigen, allowing co localisation of B cells and T cells for appropriate co-stimulation and help. 
By days 9-11 after immunisation the germinal centre activity is reaching its peak and the resulting 
cells exiting the germinal centre include newly generated plasmablasts (solid and dotted red line) 
and memory B cells (dotted blue line). The kinetics of these cells are uncertain and it is unlikely 
that there will be spontaneous antibody secretion, hence the waning, antigen specific ex vivo 
response. However the germinal centre plasmablasts and memory B cells induced, by SAC+IL-2, 
to differentiate in to AFC will contribute to the frequency of cells detected in the memory B cell 
ELISpot.
The antibody response is represented by the green line and is initially produced by the wave of 
extrafollicular, short lived plasma cells (green filled curve) present in peripheral blood in the first 
week after immunisation. In a secondary response IgG, IgA and IgM antibody accumulates in the 
serum, peaking by day 15 and remaining elevated for up to 1 month before declining gradually in 
the absence of re-stimulation (187). Plasmablasts migrate to the bone marrow where they mature 
into long-lived plasma cells so, in vivo, do not contribute to the initial antibody response.
Thus the lack of correlation between serum antibody on days 9-11 and the in vitro memory B cell 
frequency is because these B cells are not responsible for producing the antibody.
To better understand the kinetics o f the response to the pneumococcal conjugate vaccine in more 
detail a pilot study in a small group of adults was undertaken to look at the frequency of  
spontaneously secreting plasma cells and also memory B cell derived IgG-AFC (Chapter 4.)
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Figure 3.13 The source of serum antibody produced during the initial immune response to a single 
dose of Pnc7 vaccine.
In the initial phase of the immune response to a TD glycoconjugate vaccine naive B cells, marginal zone B 
cells (MZB) and follicular B cells (FO) undergo rapid extrafollicular proliferation and differentiation in 
response to B cell receptor cross-linking (1). The survival of these B cells is aided by signals provided by 
dendritic cells (DC). The result of this initial B cell response is the production of short lived, antibody 
secreting plasma cells (PC) and non-secreting plasmablasts (PB). The kinetics of the PC response is shown 
by the green, filled curve and the proposed PB kinetics by the red line. The lime green line shows what 
happens to the serum IgG response during the first month after immunisation. Most o f this initial antibody 
is secreted by the short lived plasma cells and peaks by day 15 after immunisation. In the first few days, 
low avidity antibody is produced by MZB but by the second week, FO B cells differentiate into higher 
avidity IgG secreting PC. T cells are recruited into the response by the carrier protein in the vaccine and 
this leads to the formation of germinal centres (2), from which arise memory B cells and non secreting PB. 
The blue line shows the proposed kinetics for detection of the memory B cell response in vitro while the PB 
frequency in peripheral blood may eventually wane in the absence of antigen, while serum IgG is 
maintained by PB differentiation into long lived PC in the bone marrow. The blue boxed area shows the 
time points covered by the samples in this pilot study.
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3.6.2 Peripheral blood lymphocytes in toddlers are 
predominantly naive in phenotype
The B cells isolated from 12 month old toddlers were mainly CD27- and the T cells CD45RA+ 
showing that the immune system was still immature. B cells expressing CD38 were predominant 
in toddler peripheral blood. CD38 is differentiation marker that is up or down regulated during 
different stages of B-cell development, and is highly expressed in terminally differentiated plasma 
cells. It has previously been described that 6 days after secondary immunisation with tetanus 
toxoid that there was an increase in CD38+ cells in peripheral blood in mice and humans (262). 
This was not seen in this study, perhaps because the time points o f the blood draws were too late. 
There was a small population of CD80+ B cells both before and after immunisation with no 
change in the percentage. It has previously been demonstrated that children aged 2-20 months 
express low to negative levels of co-stimulatory molecules such as CD80 on the surface o f their 
resting B cells as is seen in adults (403). However a subset of memory B cells has been described 
in adult humans that express CD80 even when resting. It is suggested that these CD80+CD27+ B 
cells may be involved in rapid secondary responses as they secrete large amounts o f switched 
immunoglobulins (361, 404). Within the CD20+ B cell population in this study the expression of  
CD27 and CD80 were quite similar and it may be that these were the same cells (fig 3.6b), 
although double staining was not possible at this point to confirm this. If these cells were 
CD80+CD27+ then is would show that the toddlers possessed such a population of rapidly 
responding, switched memory B cells that may be involved in early responses to infection or 
immunisation.
3.6.3 Toddler T cell responses are skewed to Th2
In this study the T cells isolated prior to immunisation could be induced to secret IFNy, IL-5 and 
IL-10. When compared to adult baseline levels the frequency of IFNy-SC cells induced by 
stimulation with diphtheria and tetanus toxoid was significantly higher in the toddler group. This
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is likely to be the result of more recent tetanus and diphtheria immunisations in the toddlers. 
There were no age related differences in the frequency of IFNy-SC stimulated by PspA or the 
mitogen PHA. A number of studies have shown that IFNy responses increase with age and 
number of vaccine doses, reaching adult levels by 12 months of age (391, 392).
There were equivalent levels of inducible IL-10 in both adult and toddler PBMC cultures while 
IL-5 levels in cultures of toddler PBMCs were higher than in adult cultures. Together with the 
IFNy-SC results, this suggests that prior to immunisation, toddler PBMCs were already more 
skewed toward a ThO (IFNy and IL-5) cytokine phenotype than were adults.
Studies in humans of all ages have a revealed a gradual maturation of the neonatal T cell response 
through to toddlers and young children that is increasingly skewed towards a Thl response, but 
with stable levels of Th2 cytokine expression (390-392, 395). This increasing production of IFNy 
is thought to be related to the gradual acquisition of a memory CD4+ T cell phenotype 
(CD45RO+CD45RA) with age (390). The gradual rise in the Thl responsiveness o f toddlers T 
cells may account for the non-polarised cytokine pattern seen here compared to adults.
3.6.4 The Response to a single dose of Pnc7 vaccine
Immunisation of toddlers with a single dose of Pnc7 only enhanced the amounts of IL-5 and IL- 
10 (fig 3.6) produced in response to in vitro stimulation with diphtheria toxoid (the representative 
antigen for the CRM197 carrier protein in Pnc7 vaccine). There was no alteration in the 
frequency of IFNy-SC and infact the spontaneous secretion of IFNy-SC from unstimulated PBM 
cultures decreased following vaccination with Pnc7 (fig 3.5). Previous studies o f tetanus 
immunisation in neonates followed through to 12 months o f age showed that although infants 
made IFNy responses they were short lived and waned by 6 months of age, even using polyclonal 
stimuli in the cell cultures. Th2 cytokine responses remained stable and boosted with re­
immunisation (389). A similar effect was seen in response to hepatitis B vaccine, Hib-CRM197 
conjugate vaccine and measles vaccine (195, 388, 405). The data from this study also show that
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immunisation did not boost the in vitro IFNy response but did boost the in vitro IL-5 response to 
diphtheria toxoid.
The Pnc7 vaccine contains aluminium hydroxide as an adjuvant and this in itself can alter 
cytokine responses, generally toward increased IFNy production by activated phagocytic cells or 
NK cells (373). Adjuvants used in a murine study of pneumococcal conjugate vaccines found 
similar effects with QuilA and with CpG plus dimethyl dioctadecyl ammonium bromide. In both 
cases a Thl profile of cytokines was induced along with IgG2a and IgG2b (Thl associated in 
mice) (406). In a previous study of adults immunised with pneumococcal conjugate vaccines 
containing seven polysaccharides conjugated to tetanus toxoid or one containing four 
polysaccharides conjugated to diphtheria toxoid showed there was a rise in tetanus or diphtheria 
specific IL-5 respectively following immunisation (373). In adults, however, there was also a 
significant rise in IFNy production that was not seen in the toddlers in this study, further 
emphasising the skewing to Th2 in the 12 month old age group.
3.6.5 Risk of exposure to respiratory infections induced Th2 
cytokine responses in toddlers PBMC cultures
There is mixed data about the effect that prior respiratory infections have on the balance of 
cytokines in young children. In this study it was not apparent that there was any detrimental or 
enhancing effect when toddlers were thought to be at increased risk of exposure to respiratory 
infections as a result of social mixing with other children in day care or at home. Mahalingham et 
al-2006 suggested that exposure to respiratory syncytial virus (RSV) increases the skewing 
towards a Th2 response and even increases the risk of developing allergic diseases. The number 
and severity of infectious episodes with a particular virus, such as RSV, may be the key factor to 
the development o f a Thl or Th2 like cytokine environment (407). However, infection with other 
organisms, such as Bordetella pertussis, can skew the immune response toward a definite Thl
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phenotype and this has also been seen in response to the primary immunisation with whole cell 
pertussis vaccine (396).
The data on the effect o f nasopharyngeal carriage on the cytokine balance in young children is 
also varied. In this study, known carriage of pneumococci prior to immunisation did not appear 
to alter the pattern of cytokines secreted when PBMCs were stimulated in vitro. It has previously 
been shown that nasopharyngeal carriage of Neisseria meningitidis induced ThO responses in 
teenagers with both IL-5 and IFNy secreted by activated CD69+CD4+ T cells (394). In the case of 
pneumococcal carriage the cytokines induced by carriage are serotype dependent. In a mouse 
model of carriage, sepsis and pneumonia the levels of cytokine mRNA expression were compared 
for different serotypes (408). Following inoculation of serotypes 6B or 14 there was a rise in the 
levels of IL-12 expression, while carriage or pneumonia caused by these serotypes induced TGF|3 
expression. IL-10 was induced by nasopharyngeal carriage of serotype 14 while carriage o f 6B 
induced TNFa expression which is inhibited by IL-10. The differences in the patterns o f cytokine 
secretion are thought to be one reason for the differences in the invasiveness of the serotypes 
(408).
The fact that the different serotype capsules can induce different cytokine secretion patterns has 
also described during the germinal centre reaction following immunisation of mice and humans 
with pneumococcal vaccines (189, 195). One important aspect of the cytokine profile induced by 
the serotype capsule is that cytokines affect the ability o f memory B cells to migrate back to 
lymph nodes. It has been previously described that IFNy (but not IL-4, IL-lp, IL-6 or TNFa,) is 
required for the up-regulation of CXCR3 on the surface of memory B cells that express IgGl as 
part of a Thl mediated antibody response (257, 348). Thus the cytokine profile induced 
following episodes of nasopharyngeal carriage of pneumococci or by immunisation with 
pneumococcal vaccines may either enhance the B cell response or be detrimental depending on 
the serotype involved and the maturational status of the immune system.
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3.7 Conclusion
The data from this pilot study in 12 month old toddlers have confirmed the appearance o f antigen 
specific plasma cells in the peripheral blood following a single dose of Pnc7-CRM197 vaccine. 
The in vitro stimulation of PBMCs revealed the presence o f antigen specific AFC that were non 
secreting in vivo and may be derived from memory B cells or plasmablasts. So the B cell 
response in 12 month olds appears quite similar to that described in adults to polysaccharide 
vaccines. The cytokine balance in this age group was still more Th2, though there was IFNy 
production. The lymphocyte populations consisted mainly o f naive cells expressing co 
stimulatory molecules such as CD38, HLA-DR on B cells and CD28, CD38 on T cells.
Two main questions have arisen from this work though and one is whether earlier time points 
would be better for the detection of vaccine specific plasma cells in peripheral blood? To 
determine this, a small study in adults was designed to fill in the gaps between day 0-6 and day 
10-15 and day 28. The second question was whether it was possible to identify the subsets o f B 
cells involved in the response to Pnc7 immunisation.
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Chapter 4: The kinetics of the adult human 
peripheral blood B cell response to either a 
single or booster dose of Pnc-7 vaccine.
4.1 Abstract
Young adults received either primary or a booster dose o f Pnc7 and PBMCs were isolated for the 
detection of antigen specific plasma cells. Memory B cells were detected by in vitro stimulation 
of PBMCs with SAC+IL-2. B cells were phenotyped by magnetic cell separation in depletion 
experiments to identity the subsets responsible for IgG secretion.
A primary dose of Pnc7 induced a significant increase in frequency of diphtheria specific and 
pneumococcal polysaccharide specific plasma cells and memory B cells in young adults. In 
response to booster immunisation a peak in IgG, IgA and IgM plasma cell frequency was seen at 
days 6-7 following immunisation. The IgA response was only significant in response to serotype 
4. There was also a rise in the frequency of SAC+IL-2 induced memory B cells at day 6 for 
serotype 4 and diphtheria toxoid and days 6-15 for serotype-23F. Immunisation did not result in 
elevated levels of serotype 14 specific IgG-AFC.
PBMCs isolated 6/7 days after immunisation were identified as either CD20+CD27+sIg+CD38+ or 
CD20'CD27+sIglo/'CD38+ and antibody secretion was restricted to the CD38+, CD27+ or CD20+/‘ 
fractions following magnetic cell sorting. Further analysis of plasma cell phenotype showed that 
more IgG secretion occurred in CXCR4' or CXCR5+ fractions than in CXCR4+ or CXCR5' 
fractions. These markers distinguish re-circulating plasma cells (CXCR5+) and bone marrow 
bound plasma cells (CXCR4+) from one another and also newly formed plasma cells (CXCR4+) 
from plasma cells ejected from bone marrow niches (CXCR4'). It was also possible to show that
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diphtheria specific plasma cells were CD5' and secreted IgG while serotype 4 specific plasma 
cells were predominantly CD5+ rather than CD5‘ and secreted IgA more the IgG.
The antibody response to serotype 4, 14 and 23F polysaccharide was predominantly IgG in 
response to 23F, a mixture of IgG and IgM to serotype 14 and a combination of IgG, IgA and 
IgM to serotype 4. Serotype 23F induced the highest IgG response, followed by serotype 14 then 
4. The IgA response was greatest in response to serotype 4.
Overall, the Pnc7 booster did not alter the serotype 14 IgG response compared to the primary 
immunisation, but lowered the IgM and IgA response. There was a slightly earlier IgG response 
in the booster response to 23F and the response to serotype?? was similar after either primary or 
booster immunisation. By day 28 after a primary or booster dose there was no significant 
difference in the IgG concentrations, plasma cell frequency or IgG memory B cell frequency 
between the primary and booster dose groups.
Conclusions
This data clearly shows that plasma cells appear and disappear during a very small window o f the 
early response to vaccination and that this remains unaltered by primary or booster immunisation. 
There was some evidence of antibody class switching when post booster antibody was compared 
to post primary antibody isotype distribution. Also the cells isolated on days 6/7 had the 
phenotype of either mature plasma cells or plasma blasts, showing that Pnc7 immunisation results 
in the circulation of at least two antibody secreting cell subsets.
4.2 Introduction
Studies of the immune response against the polysaccharide capsule of the pneumococcus have 
focused largely on the generation of specific serum antibody following immunisation of infants, 
the elderly or individuals in groups at high risk o f pneumococcal sepsis. The original studies 
using 23 valent polysaccharide vaccine showed that serum antibody was generated but was often
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of low avidity and waned over time, providing some protection against invasive disease in elderly 
adults (92, 94-97). More recent studies using new glycoconjugate vaccines have been less 
conclusive about the benefits of immunising adults with these new generation vaccines than has 
been observed in infants (90, 409,410).
The limited human data tracking the cellular responses following immunisation includes studies 
of smallpox, tetanus, diphtheria and pneumococcal polysaccharide vaccines (106-108, 111, 181, 
188, 261,370-372).
These studies demonstrate the appearance o f antigen specific plasma cells, spontaneously 
secreting immunoglobulin, in the peripheral blood of humans and mice, at days 5 to 8 after 
immunisation(106, 107, 111, 261, 374, 375).
The new pneumococcal glycoconjugate vaccines induce T cell dependent responses as is seen 
following immunisation with protein antigens, such as tetanus toxoid. The studies mentioned 
above, utilising T independent and dependent antigens, described peaking plasma cell responses 
seven days after immunisation irrespective of the antigen suggesting that the early stages of the 
immune response are not affected by antigen type. Thus differences in the quality o f the immune 
response to glyconjugate versus polysaccharide vaccines may be more to do with the type o f B 
cell recruited during later stages of the immune response. Marginal zone B cells are now known 
to be the main mediators of anti-polysaccharide responses in humans. These cells are more 
rapidly activated than conventional follicular B cells (301) because of the strong BCR cross- 
linking and co-stimulation via complement receptor CD21 (315). Thus polysaccharide antigens 
preferentially co localise with MZB in the splenic marginal zone under the influence of 
complement (C3d) opsonisation but it has recently been reported that by conjugating the 
polysaccharide to a protein carrier this dependency is removed and B cells respond to 
glycoconjugates under the influence of T cell help (411). Infant MZB have low levels o f CD21
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expression, inhibiting the MZB response to polysaccharides so by conjugating the polysaccharide 
with protein this deficiency is overridden by recruitment o f T cell help and is the basis behind the 
enhanced efficacy of the glycoconjugate vaccines in the young age groups (316, 318, 411, 412). 
In adults however, where both the thymus dependent and independent immune responses are 
intact in is not certain whether use of glycoconjugates will be of benefit?
In Chapter 3 it was shown that plasma cells could be detected in the ELISpot assay directly ex 
vivo following immunisation of 12 month old toddlers with Pnc7. It was also possible to detect 
IgG-AFC following in vitro stimulation of PBMCs with SAC+IL-2 for 5 days. However, 
uncertainty regarding the kinetics of plasma cell and memory B cell migration through peripheral 
blood of toddlers, suggested that sampling should be more frequenct and begin at time points 
earlier than days 9-11.
Therefore, the studies described in this chapter involved the regular sampling o f the peripheral 
blood of adults during the first 15 days after immunisation enabling characterisation of the plasma 
cell response to Pnc7 vaccine in relation to the vaccine studies mentioned above.
The in vitro stimulation of PBMCs enabled the detection of low frequency, antigen specific AFC 
derived from circulating memory B cells and precursor plasma cells that persist for some time 
after antigen exposure. These cells, present in the peripheral blood, are distinct from 
spontaneously secreting cells and require in vitro stimulation via the BCR and co-stimulatory 
molecules before Ig is secreted (228, 259, 354). In-vitro stimulation with SAC (which cross-links 
the BCR,) and IL-2 (stimulates proliferation of activated B-cells and T-cells present in PBMC 
cultures,) provides the signals necessary for the expansion of these antigen specific memory B- 
cell populations, facilitating their detection by ELISpot (183, 372, 376, 377).
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The studies described in this chapter examine the kinetics of peripheral blood B cell populations 
in more detail and also attempt to identify the phenotypes of the immunoglobulin secreting cells. 
The effect of administering a single or booster dose of Pnc7 on the B cell and antibody response 
was also investigated.
4.3 Aims
The primary aim of the studies described in this chapter was to establish the kinetics and 
frequency of ex vivo plasma cells and cultured memory B cells in adult peripheral blood 
following either a single or booster immunisation with Pnc7.
The secondary aim of this study was to determine the phenotype o f the B cells involved at the 
peak of the ex vivo, plasma cell response to the Pnc7 conjugate vaccine.
4.4 Subjects and clinical procedures
Two studies were undertaken in adults to determine B cell responses. The first was a pilot study 
utilising a booster dose of Pnc7 (Booster study) and the second involved the administration of a 
single dose of Pnc7 (primary dose study).
4.4.1 The booster dose study
Ten healthy adult volunteers (aged 28 -  44 years, 3 male and 7 female,) received a primary dose 
of the heptavalent pneumococcal-CRMi97 conjugate vaccine (Pnc7, Wyeth Vaccines, Pearl River, 
MA,) by intra-muscular injection in the left deltoid. The 0.5ml dose of the vaccine contained a 
concentration of polysaccharides of 2.0pg/ml for each of serotypes-4, 9V, 4, 18C, 19F, 23F and 
4pg/ml o f 6B. Each polysaccharide is conjugated to CRMi97 (mutant diphtheria toxoid) and 
adsorbed on aluminium phosphate. Blood was drawn prior to vaccination and again seven days 
later for measurement of serum antibody.
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Six of the 10 original volunteers received a booster dose of Pnc7, 12-17 months after the initial 
dose. Two of these six adults participated in a detailed study of B cell kinetics during the first 2 
weeks after booster immunisation. A 20ml blood sample (2ml clotted for serum and 18ml 
heparinised for PBMCs,) was collected on days 0, 3, 5, 6, 7, 9, 11, 13, 15. The results from these 
first two subjects enabled a reduction in the number of blood draws, on days 0, 6, 7, 15 and at 4-6 
weeks, from the remaining four volunteers. The blood for PBMC isolation was processed as soon 
as possible after venepuncture. The plasma samples were stored, in aliquots, at -80°C. Informed 
consent was obtained from the volunteers and the protocol was approved by the Oxfordshire’s 
Research Ethics Committee (OxREC number C02.005).
4.4.2 The primary immunisation study
A second group of twenty adults was recruited to the study under the same ethical application 
(OxREC number C02.005,) following submission of a substantial amendment. The adults 
recruited in this study had no previous history of pneumococcal immunisation or disease and the 
age range was (aged 23 -  49 years, 8 male and 12 female.) Blood was collected as above, 20ml 
(2ml for serum and 18ml for PBMCs,) on days 0, 6, 7,15 and at 4-6 weeks after immunisation.
4.5 Methods
Serum or plasma antibody (IgG, IgM and IgA), to the polysaccharide capsule of serotypes 4, 14 
and 23F were measured by ELISA as described in Chapter 2, section 2.10.
PBMCs were isolated (as in chapter 2, section 2.4), from the adult donors at the above the time 
points prior to and following a booster dose of Pnc7 in the booster study and at the same time 
points in the primary immunisation study.
For the pilot, booster immunisation study IgG, IgA and IgM plasma cells specific for 
pneumococcal serotypes 4, 14 and 23F, diphtheria toxoid (dip) and tetanus toxoid (tet) were 
detected by enzyme linked immunospot assay (ELISpot) either directly ex-vivo (chapter 2,
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section 2.5), or following 5 days culture with Staphylococcus aureus Cowan strain (SAC) and 
interleukin (IL-) 2 (chapter 2, section 2.6 and 2.7). Flow cytometry (chapter 2, section 2.8), and 
AutoMACs™ magnetic cell separation (chapter 2, section 2.9), were used to phenotype the 
responding cells.
For primary immunisation study blood from ten of the twenty adults was studied in the ex vivo 
IgG plasma cell assay and ten samples were studied using the IgG memory B cell assay. The 
PBMC isolation, in vitro stimulation, Elispot and ELISA assays were as described above and in 
chapter 2.
4.6 Results
4.6.1 The IgG, IgA and IgM plasma cell response following a 
booster dose of Pnc7 in adults.
Prior to immunisation there was evidence o f plasma cell Ig secretion in the peripheral blood of  
the adults volunteers (median counts of between 5 to 7 IgG-AFC/106 PBCMs). There were also 
low levels of peripheral blood IgM and IgA plasma cells specific for tetanus and diphtheria 
toxoid, serotype 4, 14 and 23F (fig.4.4a-e). Median frequencies o f 0 to 3 IgM or IgA-AFC/106 
PBMCs equated to between 33%-66% of individuals with pre-existing, antigen specific plasma 
cells.
The data shown in fig.4.1a-e, show detailed time course of IgG secreting plasma cell frequency in 
two adult volunteers. Following booster immunisation the plasma cells appeared in peripheral 
blood by day 5, peaking in frequency by days 6-7 and a returning to baseline by day 15. When 
studied in all six individuals it was clear that this pattern was consistent in timing, with IgG-AFC 
frequencies rising significantly above baseline for all o f the vaccine related antigens at day 6-7 
(fig.4.2 b-e). The magnitude o f the response was variable between individuals and for each
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antigen (fig. 4.2 a-e). There were no detectable alterations in the frequency of tetanus toxoid 
specific plasma cells, except for 2 individuals, in whom there was a rise at day 6-7 (fig.4.1a and 
4.2a) though this was not significant.
Following booster immunisation the frequency o f IgM plasma cells specific for diphtheria toxoid 
(the carrier related antigen) increased from 3 to 8 IgM-AFC/106 PBMCs and the percentage 
responders was 80% at day 15 but this response was not significant (fig.4.4.b). There was a non 
significant elevation in frequency of IgM plasma cells specific for the capsular polysaccharides of 
serotypes-4, 14 or 23F on day 6, with a return to baseline levels by day 15 (fig.4.4c-e). The post 
booster IgA plasma cell response to serotype 4 (fig.4.4c), rose significantly 6-7 days after 
immunisation, peaking at 256 IgA-AFC/106 PBMCs, but waning again by day 15.
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Figure 4.1 The frequency of spontaneously secreting, IgG-AFC in the peripheral blood of two adult 
volunteers before and at various time points from 3 to 15 days post immunisation.
The IgG-AFC specific for tetanus toxoid (la), diphtheria toxoid (lb), serotype 4 (lc), serotype 14 (Id) and 
serotype 23F (le), were enumerated by ELISpot. The data are expressed as the number of antigen specific 
IgG-AFC / 106 PBMCs.
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Figure 4.2 The post Pnc7 booster frequency of IgG secreting plasma cells isolated from the 
peripheral blood of 6 adults on day 0 and on days 6, 7,15.
IgG-AFC specific for tetanus toxoid (a), diphtheria toxoid (b), serotype 4 (c), serotype 14 (d), and serotype 
23F (e), were enumerated by ELISpot. The data are expressed as the number of antigen specific IgG- 
AFC/106 PBMCs. (**p=<0.05, *p= <0.08). The box represents the 25th and 75th quartiles and the whiskers 
are the outliers.
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4.6.2 The IgG, IgA and IgM memory B cell response to a booster 
dose of Pnc7 in adults.
Prior to booster immunisation (day 0), in vitro stimulation of PBMCs with SAC+IL-2 revealed a 
low but detectable frequencies of memory B cell derived IgG-AFC specific for the three 
pneumococcal serotypes in the ELISpot assay with numbers of IgG-AFC/106 cultures PBMCs for 
serotype 23F>14>4 in frequency (fig. 4.3d-e). Diphtheria specific memory IgG-AFC induced by 
SAC+IL-2 were not detectable at day 0 (fig.4.3b).
There was evidence o f a strong baseline level of memory B cell derived IgM-AFC specific for 
tetanus, diphtheria, serotype 4, 14 and 23F, while IgA memory was at the limits o f detection for 
these assays (fig.4.4f-j).
Following administration of a booster dose of Pnc7 there was a non-significant rise in tetanus 
toxoid specific memory B cell derived IgG-AFC (fig.4.3a). Diphtheria specific IgG-AFC induced 
by SAC+IL-2 rose significantly, peaking at day 6, for all but one individual, where the rise in the 
frequency was delayed until day 15. Diphtheria specific IgG-AFC declined after day 15 but 
remained detectable even at days 28-42, with the exception of one individual (fig.4.3b). In 
response to the pneumococcal capsular polysaccharides there was a more gradual rise in the 
memory B cell IgG-AFC response than was seen in the plasma cell response. In response to 
serotype 14 there was an equal number of responders and non-responders by day 6 following the 
booster dose of Pnc7. This response returned to baseline by day 15 for all except two of the 
vaccinees (fig.4.3d). Most individuals responded with an increase in frequency o f serotype 4 and 
23F specific IgG-AFC (fig.4.3c+e). The response of one individual to serotype 23F was o f far 
greater magnitude than any of the other individuals, and coincided with also achieving the highest 
frequency of diphtheria specific IgG-AFC (fig.4.3b+e). The same individual responded less well 
to serotype 4 and 14.
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The memory IgM-AFC response induced by booster immunisation was elevated in response to 
the vaccine related antigens and also to tetanus toxoid by day 6 (fig.4.4f-j). The magnitude of 
IgM memory cell frequency, following SAC+IL-2 stimulation of PBMCs, was greater even than 
the IgG responses seen in fig.4.3. However the increases in IgM memory B cell frequency were 
not significantly elevated above baseline at any point. The IgA memory cell frequency was also 
elevated by day 6, most notably for serotype-4 where IgA cell frequency was elevated at day 
6(p=0.08) and reached significance by day 15 (p=<0.05, fig.4h). The magnitude o f the IgA 
memory response was lower than the IgM memory response and also the IgG memory response 
except for serotype 4 which induced a higher frequency of IgA secreting plasma cells and in vitro 
induced IgA-AFC than either serotype 14 or 23F.
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Figure 4.3 The post Pnc7 booster frequency of IgG memory B cells in the peripheral blood of 6 
adults on day 0 and on days 6, 7,15.
Following in vitro stimulation of PBMCs with SAC+IL-2 the IgG-AFC frequency in response to tetanus 
toxoid (a), diphtheria toxoid (b), serotype 4 (c), serotype 14 (d), and serotype 23F (e) was enumerated by 
ELISpot. The data are expressed as the number of antigen specific IgG-AFC/106 PBMCs. The box 
represents the 25th and 75th quartiles and the whiskers are the outliers. (**p=<0.05, *p= <0.08).
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Figure 4.4 The post Pnc7 booster frequency of spontaneously secreting and memory B cell derived 
IgM and IgA-AFC in peripheral blood of adults.
PBMCs were isolated on days 0, 6,7, 15 and at 4-6 weeks post immunisation for the detection o f IgM 
(black) and IgA (red) plasma cells by ELISpot (a-e), or were stimulated for 5 days with SAC+IL-2 before 
being incubated on antigen coated Elispot plates for the detection IgM and IgA memory B cell responses (f- 
j). Data are expressed as IgM or IgA-AFC/106 PBMCs or /106 cultured PBMCs. There were between 2 
and 6 individuals at each time point.
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4.6.3 The characteristics of IgG secreting cells isolated 7 days 
after booster dose of Pnc7 in adults.
PBMCs isolated on the peak day of the plasma cell response (day 7) to a booster dose o f Pnc7, 
were separated by AutoMACs™ on the basis of, CD20, CD27 or CD38 expression. The 
frequencies o f plasma cells, specific for tetanus (tet) and diphtheria (dip) toxoid and serotype 4, 
14, and 23F polysaccharides were quantified within each fraction and in the un-separated PBMC 
sample (fig.4.5a). Plasma cells specific for serotype 4, 14, 23F and diphtheria toxoid were 
present in both the CD20+ and CD20' fractions of the PBMC population, although they appeared 
to be more frequent in the CD20+ fraction. Tetanus toxoid specific plasma cells were present in 
the un-separated PBMC sample, but were undetectable after magnetic cell sorting. There was 
almost a complete absence o f plasma cells within the CD27' and CD38‘ fractions with all 
immunoglobulin secreting activity appearing within the CD27+ and CD38+ fractions.
The phenotype of these magnetically separated immunoglobulin secreting cells was investigated 
further by flow cytometry. Cell surface immunoglobulin expression was compared between the 
CD27+ secreting fraction and the CD27' non-secreting fraction (flg.4.5b). The percentage o f IgG, 
IgM and IgD expressing cells was higher in the non-secreting, CD27' fraction than in the CD27+ 
fraction.
Further phenotypic analysis was carried out on the CD20, and CD38 separated fractions. The 
presence or absence of both CD27 and surface immunoglobulin isotypes was assessed in the 
CD20 (+ and ‘) and CD38 (+ and ') fractions (fig.4.5c). The CD27‘ B-cells in all of the fractions 
expressed far more surface Ig than did the memory, CD27+ B cells. The CD20+CD27+ B-cells 
had higher expression of Ig than any of the other CD27+ populations. Overall, the fractions with 
antibody secreting activity in the ELISpot assay (CD27+CD20+/‘ or CD27+CD38+), had lower 
surface expression of Ig than the non-secreting fractions.
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Figure 4.5 The phenotype of IgG plasma cells isolated on day 7 after a booster dose of Pnc7 in adults.
The percentage of antigen specific IgG plasma cells detected in each magnetically sorted fraction is shown 
in (4.5a). The data represents the mean and standard error from 3 different donors and is expressed as the 
percentage of the total cells per well. Tetanus (tet) and diphtheria (dip) toxoid specific IgG-AFC are shown 
in (4.5ai) and polysaccharides 4, 14 and 23F IgG-AFC in (4.5aii). The expression of IgG, IgM and IgD in 
the CD27+ and CD27’ fractions is shown in 4.5b. The expression of IgG, IgM and IgD with and with CD27 
expression is shown for the CD20+/_ and C D 3 8 fra c tio n  in 4.5c. The data in 4.5b+c are representative 
data from one experiment of three.
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Figure 4.6 Separation of PBMCs on the basis of the chemokine homing receptors CXCR4 or CXCR5 
expression.
PBMCs were isolated from two adult donors on day 6 following a primary dose of Pnc7. The PBMCs were 
separated on the basis of CXCR4 or CXCR5 surface expression. These fractions, along with unseparated 
PBMCs were seeded on to antigen coated ELISpot wells for the detection of spontaneously secreting IgG- 
AFC in peripheral blood. IgG-AFC specific for tetanus and diphtheria toxoid and the capsular 
polysaccharides from pneumococcal serotypes 4, 14 and 23F were detected and the data are expressed as 
the number of IgG-AFC/106 PBMCs.
4.6.4 Depletion of CXCR4+ or CXCR5+ IgG secreting cells 
isolated 6 days after booster dose of Pnc7 in adults
On day 6 after immunisation PBMCs from two study subjects were separated by magnetic cell 
sorting on the basis of either CXCR4 or CXCR5 expression. The separated fractions were then 
re-suspended and seeded into ELISPOT plates and allowed to spontaneously secrete antibody 
overnight. The CXCR4- and CXCR5+ fractions contained a greater proportion of the antibody
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secreting activity (fig.4.6). There were IgG secreting plasma cells with specificity for diphtheria 
toxoid and the three pneumococcal polysaccharides (4, 14 and 23F) in all fractions. However, 
there were no IgG secreting plasma cells present in the sorted fractions that were specific for 
tetanus toxoid.
4.6.5 IgG secretion by cells sorted on the basis of CD5 
expression 6 days after a booster dose of Pnc7 in adults.
PBMCs from obtained from an adult donor, 6 days after booster Pnc7 immunisation, were 
depleted o f CD3+ T cells and then separated by AutoMACs™ magnetic cell separation on the 
basis o f CD5 expression (fig.4.7). Within each fraction (CD5+, CD5' and unseparated PBMCs) 
the percentage of the CD19+, CD3+, CD19+CD5+, CD27+ and CD27+ were determined by flow 
cytometry (fig.4.7a). The CD19+ B cell population was enriched in both the CD5+ (11% CD19+) 
and CD5' (18% CD19+) fractions compared to unseparated PBMCs (5% CD19+). The CD5‘ 
fraction was totally depleted of CD3+ T cells while 3% CD3+ T cells remained in the CD5+ 
fraction after depletion compared to unseparated PBMCs (70% CD3+ T cells). The percentage of  
CD19+CD5+ B cells was enriched in the CD5+ fraction (4%) while there was less than 1% in 
unseparated PBMCs and non in the CD5‘ fraction. The percentage of CD27+ B cell was less than 
10% in both the CD5+ and CD5' fractions while there were 40% CD27+ lymphocytes in the 
unseparated fraction. The proportion of the fractions that were CD27' was similar, approximately 
35-41%.
The secretion of IgG and IgA within the CD5+ and CD5' fractions and the unseparated PBMCs 
was quantified by antigen specific ELISpot. The number of IgG and IgA-AFC per/106 sorted 
cells was calculated and is presented in figure 4.7b. In the unseparated PBMCs no tetanus or 
serotype 4 specific IgG-AFC were detected but there were diphtheria specific IgG-AFC. IgG- 
AFC with specificity to all three antigens (tet, dip and serotype 4), were enriched in the CD5' 
fraction. The serotype 4 response was enriched to a greater extent in the CD5+ fraction but this
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was not so for the diphtheria and tetanus IgG response. More evident was that while no IgA 
response was detected in response to tetanus and diphtheria, there was a 7-fold increase in 
enrichment of IgA-AFC specific for serotype 4 in the CD5+ fraction compared to the unseparated 
fraction. Therefore the response to the polysaccharide capsule of serotype 4 was mediated by 
IgA-AFC to a greater extent than IgG and by CD5+ B cells than by CD5' B cells. From the 
phenotyping data in section 4.5.3 it can be assumed that the IgG-AFC are all CD27+ as there was 
no IgG secretion in the CD27' fraction.
4.6.6 The serotype specific IgG, IgA and IgM antibody response 
following a booster dose of Pnc7 in adults.
Adults received a booster dose of Pnc7 and the IgG, IgA and IgM serum anti-capsular antibody 
concentrations, against pneumococcal serotypes 4, 14 and 23F were quantified prior to 
immunisation (day 0) and on days 6, 7, 15 and 36-42 after immunisation (fig.4.8a-c). The GMC 
of IgG prior to administration of the booster dose (12-17 months after a primary dose), was above 
the protective threshold o f 0.20pg/ml(362) for serotypes 4, 14 and 23F (0.62pg/ml, 14.78pg/ml 
and 4.51pg/ml respectively). Following the booster immunisation there was a rapid and steady 
rise in IgG, IgA and IgM levels from day 6, peaking at day 15 and remaining elevated at days 36- 
42 for serotypes 4, 14 and 23F. Serotype 4 polysaccharide induced only a minimal rise in 
antibody peaking significantly above baseline by day 15 for IgA (p=<0.05), and IgM (p=<0.01). 
Serotype 14 polysaccharide induced no significant rises in antibody, but had the highest pre­
booster levels of IgG and IgM. Serotype-23F induced significant levels of IgG (p=<0.05), IgM 
(p=<0.001), and IgA (p=<0.01), by day 15 post booster. The elevated levels o f IgG, IgA and IgM 
antibodies were still maintained by days 36-42 for all 3 serotypes (fig.4.8a-c).
147
a ) Flow cytometric analysis of cell surface makers
100-1
c
O 75-|
50-
25-
J=L a
CD19+ CD3+
—  I~l
CD19+
■ l ll l
CD27+ CD27'
CD5+
b)
cell surface expression 
ELISPot on sorted fractions
450 
400 
350- 
300- 
250- 
200-  
150- 
( 3  100 -  
<  50
0
</>
O
2
QQ
0.
■D
O</)
coO
H
tet IgG tet IgA
J=L
dip IgG dip IgA
U U
T4 IgG T4 IgA
ELISpot antigen and antibody isotype
□  unseparated Q  CD5 negative Q  CD5 positive 
PBMCs fraction fraction
Figure 4.7 The phenotype and IgG or IgA-AFC frequency of PBMCs separated on the basis of CD5 
expression.
PBMCs isolated 6 days after a booster dose of Pnc7 were separated by magnetic cell separation based on 
the surface expression of CD5. T cells were depleted prior to CD5 separation by the use of anti-CD3 
magnetic beads and then the CD3 negative fraction was then separated into CD5+ (orange) and CD5 
(green) fractions. Unseparated PBMCs (blue) were retained as the control for surface marker expression 
and immunoglobulin secretion in the original sample.
4.7a) Purity and enrichment o f the separated fractions was analysed by flow cytometry on the basis o f 
CD l9+, CD3+ CD19+CD5+, and CD27+/' expression and the data represent the percentage of each fraction 
expressing the marker, b) The remaining cells from each fraction were seeded onto antigen coated 
ELISpot plates for the detection of IgG or IgA secreting cells specific for tetanus toxoid, diphtheria toxoid 
or pneumococcal serotype 4 polysaccharide. The ELISpot data is expressed as the mean number of IgG or 
IgA-AFC/106 PBMCs isolated on day 6 after immunisation.
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Figure 4.8 Pneumococcal serotype specific antibody in serum of adults before and after a booster 
(figures a-c) or primary dose (figures d-f) of Pnc7 vaccine.
Six adults received a booster dose of Pnc7 12 to 17 months after receiving a first dose of the same vaccine 
(a-c). A second group of twenty adult volunteers received a primary dose of Pnc7 (d-f). Blood was drawn 
on day 0 and then days 6, 7, 15 36-42 days after the booster dose or upto 28 days after the primary dose. 
IgG (♦) IgA (■) and IgM (A ) were measured against serotypes 4 (a+d) 14 (b+e) and 23F (c+f). Data 
represent the GMC with 95% confidence intervals.
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4.6.7 The serotype specific IgG, IgA and IgM antibody response 
following a primary dose of Pnc7 in adults.
A group o f twenty adults were immunised with a single dose o f Pnc7 and the serum antibody 
levels were quantified by ELISA. The kinetics of the antibody response to each of the serotypes 
(4, 14 and 23F), following the single dose of Pnc7 (fig.4.8d-f) were similar to those seen 
following the booster dose of Pnc7 (fig 4.8a-c). All three serotypes induced significant increases 
in IgG, IgA and IgM by day 6 and the concentrations continued to increase until day 15 where 
they then remained level until day 28.
Serotype 4 induced a small and mixed response of IgG/IgA/IgM (fig.4.8c), with significant rises 
in all isotypes by days 6 and 7 (p=<0.0001) post immunisation that remained above baseline even 
by day 28 (p=<0.0001). Antibodies directed against serotype 14 (fig.4.8e) were higher at baseline 
(IgG=1.92pg/ml, IgA=0.19|ig/ml and IgM=2.31pg/ml), than those against serotype 4 
(IgG=0.34pg/ml, IgA=0.11pg/ml and IgM=0.26pg/ml), and 23F (IgG=T.12pg/ml, 
IgA=0.07pg/ml and IgM=0.50pg/ml). The levels of IgG, and IgM remained higher against 
serotype 14 than those against serotypes 4 and 23F throughout the time course. From day 6 
onwards serotype 4 induced more specific IgA than seen in response to serotypes 14 and 23F, 
while serotype 14 induced the most IgM.
4.6.8 Comparison of the serum IgG, IgA and IgM antibody 
responses after either, a primary or booster dose of Pnc7 in 
adults.
At baseline (dO) there were some differences in antibody levels between the primary dose and 
booster group (fig.4.9a-j). For instance there were significantly higher pre-immunisation levels of 
IgG specific for serotype 4 and 14 in the booster group (fig.4.9a-c). The pre-immunisation levels 
of IgA (dO, fig.4.9d-f), were significantly higher for serotypes 4 and 23F in the booster group. 
There were no differences in pre-immunisation levels of IgM between the groups.
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Following immunisation there were no significant differences in the serum IgG response to any of  
the serotypes (4, 14 and 23F), whether a primary or booster dose was given (fig.4.9a-c). There 
was a trend for more rapid and higher IgG production in response to serotypes 14 and 23F in the 
booster group compared to the primary group but this was not significant. There was a trend for 
more IgA in the primary dose group and this was significantly higher than in the booster group 
for serotype 14 at day 15. The IgA response to serotype 4 was initially higher in the booster 
group but by day 15 after immunisation this was reversed and IgA remained higher in the primary 
dose group, though this was not significant (fig.4.9d). The IgM response was greatest for 
serotype 14 and was higher in the primary dose group compared to the booster dose group, 
significantly so at days 15 and 28.
Overall, figure 4.9 shows that the same isotype to serotype relationship was seen following either 
a primary or booster dose of Pnc7. In the IgG responses serotype 14>23F>4. In fig 4.9d-f, it can 
be seen that the IgA response was serotype 4> 14> 23F and the pattern for the IgM response was 
serotype 14>4>23F (Fig 4.9g-i).
4.6.9 The IgG plasma cell response in the peripheral blood of 
adults following either a primary or booster dose of Pnc7.
The kinetics o f the IgG plasma cell response in adults were the same following either a primary or 
booster dose of Pnc7 vaccine, with peak plasma cell frequencies at days 6 to 7 (fig4.10a-e). The 
magnitude of the diphtheria specific response (fig.4.10b), was significantly lower in the booster 
group, than in the primary dose group, suggesting that the CRM197 carrier response was not 
boosted by re-immunisation. There were no differences in the response to the capsular 
polysaccharides o f serotypes 4, 14 and 23F.
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Figure 4.9 Comparison of anti-capsular antibody isotype and kinetics in serum of adults following a 
primary or booster dose of Pnc7.
Serum was collected at each of the time points prior to and following immunisation of adults receiving 
either a primary (blue) or booster dose (red) of Pnc7. IgG, IgA and IgM anti-capsular polysaccharide 
antibodies against serotypes 4, 14 and 23F were quantified by ELISA and compared between the groups. 
The data are expressed as the geometric mean concentration of antibody with 95% confidence intervals. 
The significance levels were calculated using un-paired ttest function on Prism V4.
4.6.10 The peripheral blood memory B cell response following 
either a primary or booster dose of Pnc7 in adults.
Following in vitro stimulation of PBMCs with SAC+IL-2 at each time point the frequencies of 
memory B cell derived IgG-AFC were compared between the booster group and the primary dose 
group. There was no difference in tetanus toxoid specific memory B cell frequency between the 
groups at any of the time points (Fig 4.11a). There was a trend for higher frequencies of
1 5 2
diphtheria specific memory B-cells in the primary dose group than in the booster group 
(figA llb ), but this difference was not apparent prior to immunisation (dO) and was not 
significant. The frequencies of capsular polysaccharide specific memory B cells was higher were 
similar between the groups except in response to serotype-23F at day 6 post immunisation, where 
the booster group had a higher frequency of IgG-AFC (p=0.008, fig.4.1 le).
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4.7 Discussion
In this study the peripheral blood kinetics and phenotype of populations o f B cells appearing after 
immunisation of adults with the glycoconjugate vaccine, Pnc7 have been described. Plasma cells 
that spontaneously secrete antibody ex vivo appear briefly in peripheral blood, peaking on days 6- 
7 following immunisation, and are of two phenotypes (CD20+CD38+CD27+ or CD20' 
CD38+CD27+). Both o f these subsets have low surface immunoglobulin (Ig) expression. 
Furthermore, the appearance of these antibody secreting cells is accompanied by a more 
sustained, though lower magnitude, rise in appearance of a non-Ig secreting B-cell subset in the 
peripheral blood that have the in vitro characteristics o f memory B cells or plasmablasts.
4.7.1 Pnc7 immunisation induced elevated frequencies of 
vaccine specific plasma cells in adult peripheral blood.
This study has identified a population of spontaneous Ig-secreting cells that produce antibody to 
the capsular polysaccharides o f the Pnc7 vaccine. The cells appeared by day 5 and peaked at 
days 6-7 following booster immunisation, but had fallen to undetectable levels by day 15. There 
was a simultaneous rise in serum anti-capsular IgG, IgA and IgM antibodies from day 6 following 
the administration of the booster dose with a peak by day 15.
Similar kinetics have been described following immunisation of toddlers and adults with Pnc7 or 
23-valent pneumococcal polysaccharide vaccine (107, 111, 112, 261) and in mice (375).
In adult studies from the early 1980’s by Kehrl et al (108-110) the kinetics of the B cell response 
to a single dose of 14 valent pneumococcal polysaccharide vaccine were determined. This was 
achieved by quantifying the polysaccharide specific antibody both in vitro and in vivo. They 
found that in the absence of in vitro stimulation PBMCs isolated after immunisation 
spontaneously secreted, polysaccharide specific antibody of all isotypes into the supernatants of 
the in vitro culture. This system revealed a peak in spontaneous antibody production on day 8
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after immunisation. This was followed by a peak of in vivo serum anti-polysaccharide antibody 
by day 14(108). The data presented in this study describe a peak in plasma cell frequency by 
days 6-7 and this slightly precedes the peak of in vitro antibody seen in the Kehrl et al studies. 
This indicates that these authors were likely to be have been detecting the plasma cell response in 
the method used.
The reproducibility of the kinetics o f circulating antigen specific plasma cells and serum antibody 
between different individuals in this and other studies suggests that these responses are a 
programmed physiological response to immunisation in a primed individual. Other published data 
indicate that these responses are not limited to Pnc7 as similar responses have been described 
after immunisation against tetanus and influenza (106, 374).
The spontaneously secreting plasma cells seen in the adult peripheral blood in this study are 
probably derived from memory B cells residing in secondary lymphoid tissues (145) as a result of 
the initial immunisation given in the booster group. The booster dose of Pnc7 then resulted in 
activation and rapid proliferation of vaccine specific, memory B-cells (260). By 6-7 days after 
immunisation there is a rapid efflux of antigen specific plasma cells into the peripheral blood, as 
was seen in this study, leading to enhanced protection from invasive disease (145, 256, 264).
The booster immunisation also induced significant levels o f IgA-plasma cells in response to 
serotype 4, less so to serotype-23F and 14 and the diphtheria toxoid control. The peak of the IgA 
response matched that seen in the IgG response and both IgG and IgA may represent switched 
memory responses resulting from the first dose of Pnc7 administered to adults in the booster 
study, 12-17 months prior to boosting.
There was a low frequency of IgM-AFC detected post booster, that may represent plasma cells 
derived from the extrafollicular response of naive B cells, B1 cells or MZB cells, that occurs in 
the first week after immunisation (126). Some of the IgM plasma cells may also arise from 
primary immune responses to capsular polysaccharides previously unseen by the donor. In the
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primary immune response, B-cells activated by capsular polysaccharide differentiate into non­
proliferating, IgM secreting short-lived plasma cells that secrete antibody with germline V-gene 
arrangements early in the immune response (145, 254-258) and disappear from the peripheral 
blood by two weeks after vaccination (259-262). Although the frequencies o f IgM plasma cells 
described in this study were low, there was a trend towards a peak in the first week after the 
booster immunisation.
In previous studies it has been demonstrated that no memory B-cells are generated and no 
germinal centre reaction occurs in response to plain polysaccharide vaccines (256, 257, 263-266, 
399, 413).
In human immunisation studies it has also been shown that repeat immunisation of adult humans 
with plain polysaccharide vaccines (4 months after a primary dose), does not induce a new peak 
of plasma cell activity or any rise in spontaneous antibody in vitro or serum antibody in 
vivo{ 108).
The data in this study, comparing the IgG plasma cell responses to a booster dose or a primary 
dose of Pnc7 suggests that re-immunisation with a pneumococcal conjugate vaccine does not 
significantly enhance the IgG plasma cell response to the capsular polysaccharides.
4.7.2 Immunisation with Pnc7 induced a rise in polysaccharide 
specific memory B cell frequency
Administration of a booster dose of Pnc7 in adults resulted in the increase frequency of IgG-AFC 
specific for serotypes 14 and 23 F. Detection of these cells by ELISpot required in vitro 
stimulation of PBMCs by SAC+IL-2. The numbers o f these polyclonaly induced IgG-AFC 
returned to pre-booster levels 1 month after the booster dose.
These observations suggest that memory B-cells induced by the primary immunisation 12-17 
months earlier were mobilised to circulate in peripheral blood after the booster dose of Pnc7 was 
given. However, these cells may also be newly formed, non secreting plasmablasts that migrate
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to the bone marrow before terminal differentiation into mature plasma cells. Many studies have 
shown that it is possible, by stimulation of peripheral blood cells by various combinations of 
polyclonal stimuli, to induce B cells to differentiate into IgG-ASC of various maturational stages. 
(183,213, 372, 376, 377,414).
ELISpot analysis o f plasma cells ex vivo only allowed detection of fully differentiated plasma 
cells already secreting antigen specific antibody (415). Pre-existing, mature plasma cells only 
survive in culture for up to 48 hours and after 5 days stimulation with SAC+IL-2, only those B- 
cells entering culture as memory B-cells or plasmablasts remain (347). Analysis o f B-cell 
division by flow cytometry and CFSE labelling has shown that five days o f in vitro stimulation is 
sufficient for B cells to undergo at least 4 division cycles and that this number of division cycles 
is necessary for antibody secretion (260, 416, 417). This system preferentially activates memory 
B-cells (376, 377) and induces IgM memory B-cells (CD27+IgM+IgD+) to secrete IgM and IgG, 
while class switched memory B-cells (CD27+IgM'IgD') will secrete IgG and IgA (267, 418, 419). 
The data from the present study indicated that high frequencies of IgM-AFC were formed 
following in vitro stimulation with SAC+IL-2, but minimal IgA-AFC were seen except in 
response to serotype 4. Also the frequency of IgM-AFC was constant through out the 15 days 
studied, which suggests that the IgM production was not specific to the vaccine antigen, 
particularly as there was equivalent amounts induced in response to the non-vaccine antigen 
control, tetanus toxoid. The SAC+IL-2 system probably induces low avidity, cross-reactive IgM 
that is secreted by B1 cell or MZB cell derived plasmablasts that fully differentiate in culture to 
secrete antibody.
Migration of the plasmablasts occurs over a limited period before they become resident in the 
bone marrow(254, 256, 257, 338), and this may explain the observed peaks in SAC+IL-2 induced 
cells at days 6-7 and the return to pre-booster levels of detectable IgG-AFC at 4-6 weeks post 
immunisation. The failure of this method to stimulate higher levels of memory B-cells to 
differentiate into IgG-AFC, at later time points maybe overcome in future work by the addition of
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CpG-DNA and pokeweed mitogen to the culture medium (351, 370). Alternatively the numbers 
of pre-existing memory B-cells, detected in the peripheral blood may be maintained at a constant 
level (259).
In vitro stimulation of PBMCs with SAC+IL-2 also allowed the detection of memory B cell 
derived IgG-AFC that were of unrelated specificity to the vaccine (i.e. tetanus toxoid specific 
IgG-AFC). Although detectable throughout the study time course, the frequency of these cells 
remained steady, suggesting that IgG-AFC in the peripheral blood following immunisation were 
not only related to the administration of the Pnc7. There is evidence to suggest IgG-AFC of non­
vaccine specificities appear in the peripheral blood as the result of displacement of long-lived 
plasma cells from the bone marrow or bystander activation of B-cells during an immune response 
(145,254, 255,257, 259, 263, 338, 347, 348, 351, 353, 355, 356, 358, 400, 401, 420,421).
The migration of the plasmablasts and plasma cells is dependent on the expression of the 
chemokine receptor CXCR4 that has affinity for the chemokine CXCL12, secreted by bone 
marrow stromal cells (259). Up-regulation of plasma cells moving from the tonsils, through the 
blood to the bone marrow has been demonstrated in human(262). Once plasmablasts take up 
residence in the bone marrow, they terminally differentiate into mature plasma cells and lose the 
expression of CXCR4. In the event of displacement from their BM survival niche, the lack of 
CXCR4 expression renders these plasma cells incapable of returning from the periphery(257). It 
is thought that preference is given to newly arriving plasmablasts that still express the CXCR4 
molecule, enhancing their ability to remain in the bone marrow environment (348). Another 
possibility is that CXCR4- plasma cells are re-circulating through the blood(262).
The data described here from the cell sorting studies based on CXCR4 expression, showed that on 
day 6 after immunisation CXCR4 was expressed on plasma cells of vaccine related specificities, 
but there were also plasma cells that did not express this chemokine receptor. This may be o f  
relevance since the plasma cells at day 6 may have been a combination of both newly generated 
CXCR4+ plasma cells and also pre-existing plasma cells, pushed out o f bone marrow niches
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because they no longer express CXCR4. An alternative theory is that they represented the long 
lived (CXCR4+) migrating to the bone marrow and short lived CXCR4' plasma cells that re­
circulate during the first week after immunisation (257, 259, 262, 348). CXCR5 is expressed by 
plasma cells homing back to the lymph nodes and it may be that some plasma cells re-circulate 
back to the lymph nodes to undergo further somatic hyper mutation in a second round of germinal 
centre development.
4.7.3 Serum antibody levels remained elevated following 
immunisation with Pnc7.
In the booster group, serum IgG specific for serotypes 14 and 23 F remained elevated 12-17 
months after the initial dose o f vaccine and were enhanced following booster immunisation. 
However, there was no significant difference in the IgG concentration obtained in the booster 
group compared to the group who received only a primary dose. Therefore, although the number 
of doses did not appear to have an additive effect on antibody levels in adults, the antibody 
induced by Pnc7 was maintained for over 12 months.
The process behind maintenance of serum antibody is poorly understood. Three mechanisms have 
been suggested for the long term maintenance o f protective antibody levels (145); presence of 
long-lived plasma cells (354, 358); bystander or polyclonal activation of B-cells (351); and re­
stimulation of memory B-cells by antigen persisting on follicular dendritic cells (FDC) (422).
An alternative explanation in the case of pneumococcal antibody may be exposure to the 
organism through nasopharyngeal colonisation. Nasopharyngeal carriage of pneumococci was not 
investigated during this study but previous epidemiological studies, including one carried out in 
Oxford children, showed that 23F was among the most commonly detected serotype among 
nasopharyngeal isolates, while serotype-4 was the rarest and 14 was intermittently detected (58, 
79, 92). Similar observations were made in a multinational epidemiological study of 
pneumococcal disease and carriage rates, (31). It is possible, therefore, that frequent exposure to
161
serotypes-14 and 23F, via nasopharyngeal carriage has helped to boost the AFC and antibody 
responses seen for 14 and 23F polysaccharides, generating a response that is predominantly IgG 
and due to pre-existing memory B-cell formation in exposed individuals. Conversely, little or no 
exposure to the infrequently colonising serotype 4 means that a more naive response is generated 
following immunisation. This view is supported by data for the serotype 4 response, reported 
here, that showed no improvement in the magnitude of the response following the booster dose, 
although there was a switch to a more predominantly IgG response. In addition IgA and IgM were 
more apparent in the response to serotype 4 than in the immune response to serotypes 14 and 23F. 
These differences in antibody generation following immunisation are also reflected in higher rates 
of invasive pneumococcal disease caused by serotype 4 compared to 14 and 23F.
4.7.4 The phenotype of pneumococcal AFC
The plasma cell population in the peripheral blood on day 7 following immunisation included 2 
subpopulations, CD20+CD27+CD38+Ig1° and CD20‘CD27+CD38+Ig1°- The CD20' cells are 
possibly terminally differentiated plasma cells expressing high (hi) levels o f CD27 and CD38 
with concomitant down regulation of CD20 and surface immunoglobulin (Ig) (183, 255, 259,280, 
358, 423). The CD20+ subset probably represents intermediate plasmablasts with a more 
germinal centre phenotype, that are present in the peripheral blood and able to secrete antibody 
(263). The identification of the CD20+ subset as a plasmablast population was further confirmed 
by the low level, surface expression of immunoglobulin. The upregulation of CD38 has been 
associated with differentiation into mature plasma cells (384) with tonsil and bone marrow 
plasma cell precursors expressing very low levels of CD38 (424). CXCR4 and CXCR5 
populations may differentiate AFC populations migrating toward the bone marrow (CXCR4+) 
(348, 386) and recirculating to the lymph nodes (CXCR5+)(259). Plasmablasts migrate toward 
the CXCR4 ligand (CXCL12) expressed by bone marrow stromal cells(257, 348, 386) but mature 
plasma cells do not (386). Therefore the AFC detected at day 7 appear to be a mixture o f newly
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generated antigen specific (CXCR4+) plasma blasts leaving the lymphoid follicles for the bone 
marrow. Mature plasma cells are pushed out bone marrow niches into the blood, but are CXCR4- 
, therefore cant return to the bone marrow. This may explain the low frequency of tetanus toxoid 
specific cells seen in peripheral blood after immunisation with a heptavalent vaccine. CXCR5 
expression by B cells is essential for follicular responses to occur (425). CXCR5+ AFC may 
recirculate to the lymphoid tissues since CXCR5 knock-out mice show impaired class switching 
and antibody production in the long term(425).
CD27+/'IgM+IgD+ B-cells were the predominant subset identified by flow cytometry in these 
adults. MZB express a similar phenotype o f IgMhl IgD10 CD21hl CD2310, in the spleen and 
peripheral blood of humans and mice (253, 315). It has been suggested that MZB are involved in 
the early response to TI-2 antigens and produce AFC secreting large amounts of IgM antibody 
followed by rapid class-switching to IgG (267, 301, 323) and provide long lasting immunity (415, 
426). MZB accumulate with age and have high frequencies of somatic gene mutations (144, 250, 
252, 307, 320, 427). Some authors have suggested that, following the development of a 
functional splenic marginal zone in the second year of life, the improved efficacy of  
glycoconjugates over plain polysaccharide vaccines is reduced because polysaccharides are 
sequestered in the marginal zone even when conjugated to proteins, still inducing marginal zone 
like responses that are T-cell and CD40L independent (267, 315). These data from adults 
following immunisation with Pnc7 are consistent with this view.
The importance of the splenic marginal zone and germinal center for the formation of  
polysaccharide reactive plasma cells may explain the high risk of invasive pneumococcal disease 
in infants, who have immature germinal center structure (428) and lack MZB (253).
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4.7.5 The magnitude of the immune response to Pnc7 is 
serotype dependent
There was considerable variability in the magnitude of the response against each antigen in a 
given individual and between subjects. This was true for the ex vivo plasma cell response, the in 
vitro stimulated, memory B cell response and the serum antibody response.
Individuals making good carrier specific responses (diphtheria,) did not necessarily make good 
polysaccharide specific responses and vice versa (188). The immunogenicity o f serotype 23F, as 
measured by ex-vivo AFC frequency, was greater than that of serotype 4. This observation is 
supported by previous studies that measured IgG in serum (157, 165, 187). Previous studies 
investigating the effect o f conjugation on polysaccharide specific responses have proposed that 
the individual polysaccharides conjugated to CRMi97 provoke differing cytokine profiles within 
the germinal centres. This in turn affects the isotype and quality o f antibody produced (189). 
Variations in immune responses to the same polysaccharide between individuals will likely 
depend on both host genetic factors and prior exposure to the organism through nasopharyngeal 
colonisation. However, differences in the polysaccharides themselves, particularly in relation to 
charge may direct significant differences in responses (429). The observation that T cell 
responses may after all be important in determining polysaccharide-specific B cell activation 
provides further possibilities to explain the variation in isotype response (131-134).
4.7.6 No difference in the B cell response was found following 
either a primary or booster dose of Pnc7
The benefits of administering a single or booster dose o f Pnc7 was investigated in this study. 
Comparison was made between the groups based on plasma cell and plasmablast/memory B cell 
frequency and kinetics.
This revealed that there were no differences in plasmablast/memory B cell frequency following 
either a primary or booster dose o f Pnc7. There were two exceptions to this observation however.
164
One was a trend for lower frequencies o f anti-diphtheria IgG-AFC following the booster Pnc7 
dose (p=0.06 at day 15 post immunisation). The second was for slightly higher IgG-AFC 
frequencies for serotype 23F at day 6 following a booster dose than after a primary dose 
(p=0.008). The general outcome of no difference is a result of great interest since there have been 
mixed views on the benefits of the use of conjugated pneumococcal vaccines in adults and more 
so in the elderly. This result follows that seen following re-immunisation with pneumococcal 
polysaccharide vaccines in the studies by Kehrl et al (108). In studies comparing the benefit of 
conjugate versus polysaccharide vaccine in adults, (101, 172) there appeared to be no real 
immunological benfit of re-immunisation with pneumococcal conjugate vaccines over 
polysaccharide vaccines. One study found a slight benefit of administering conjugate over 
polysaccharide, but that it was serotype dependent (410). While another found the benefits o f  
conjugate vaccination were also age dependent and that conjugated and plain pneumococcal 
polysaccharide vaccines induced IgG2 preferentially over IgGl in adults (172). Another study 
found that re-immunisation of adults with a pneumococcal conjugate, 6 months after the first 
dose, had no significant effect on the level of antibody generated (101). The poorer response to 
the CRM 197 carrier protein (quantified here using diphtheria toxoid), may be explained following 
the study by Ralph Nanan et al (372), who showed that the frequency of IgG-AFC derived from 
in vitro culture of memory B cells was inversely proportional to the number o f doses of diphtheria 
vaccine.
4.8 Conclusions
In conclusion it appears that in adults, the response to a booster dose of Pnc7 is marked by the 
generation of a population of rapidly responding plasma cells (IgG, IgA and to a lesser extent 
IgM,) that peaks at days 6-7 after immunisation. Memory cells generated following the response 
to the primary dose of Pnc7 rapidly differentiate upon re-encountering specific antigen, and 
spontaneously secret antibody in the ELISpot assay (106-108, 259, 264).
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Culture with SAC+IL-2 allowed detection of IgG, IgA and IgM ASC, even after the ex vivo 
response had declined back to baseline.
The secreting cells were CD20+/'CD27+CD38+ and expressed low levels of immunoglobulins. The 
CD20+ plasmablasts resembled MZB with IgD and IgM expression and MZB are now considered 
to play a critical role in protective immunity against polysaccharide-encapsulated pathogens such 
as S. pneumoniae. The predominance o f an IgM-ASC response in the cultured PBMC system 
may result from the activation o f MZB-like CD27+CD20+IgD+IgM+ B-cells (124, 144, 252, 301, 
415, 426, 430).
It is the aim of futher work to try and phenotype the cells that proliferate and differentiate into 
IgG-AFC following in vitro stimulation.
The speed of this immune response following encounter with pathogenic pneumococci may not 
be quick enough to prevent invasion of the organism in the first 6-7 days after acquisition in an 
individual with sub-protective levels of specific serum antibody. Generation of memory cells and 
long-lived plasma cells as detected in this study provides at least one mechanism to sustain serum 
antibody above protective thresholds and provide long-term protection against EPD.
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Chapter 5: Identifying the B cell subsets 
involved in the humoral response to Pnc7
5.1 Abstract
The B cell response detected following in vitro stimulation of PBMCs with SAC+CpG+PWM 
(SCP) was compared with that seen following SAC+IL-2 (SI) stimulation. PBMCs were isolated 
on days 0, 6, 7,15 and 28 after a primary dose o f pnc7 in young adults.
This comparison revealed differences in the kinetics of the IgG-AFC response between the two 
culture systems. With SCP there was a peak in AFC frequency at day 15 post immunisation, 
while with SI the peak occurred on day 7 for vaccine related antigens. Non vaccine antigen 
(tetanus toxoid or total-IgG) specific IgG-AFC were detected at a constant frequency throughout 
the time course but were o f much higher frequency in the SCP culture system.
Proliferation of B cell subsets was limited with SAC and PWM, but was enhanced by CpG in 
both the naive and memory B cell populations. SCP induced the greatest proliferation and 
resulted in higher AFC frequencies than any individual stimulant. CD27+IgM+ B cells 
proliferated more strongly than CD27'IgM+ B cells. There was a rise in IgD+ B cell proliferation 
following immunisation, peaking at day 15 (IgDhi) for SCP and day 28 (IgDhl) for SI. These are 
classically naive B cells while IgD10 is more associated with memory B cells and this population 
peaked at day 6 following m vitro stimulation with SI.
The kinetics of proliferating B cells was not affected by the post immunisation time point chosen 
for analysis. The marker o f a good proliferative response is >4 cell divisions as measured by 
CFSE dye dilution. Using SCP there was an accumulation of IgG+, IgD10 (memory) and IgDhl
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(naive) B cells undergoing > 4 divisions after 5 days of culture. With SI only a small population 
of memory B cells proliferated past the >4 cell division cut off and no IgDhl cells achieved this. 
Depletion of IgD+ B cells appeared to remove the proliferation of nai've B cells (IgD111) but had no 
effect on the IgM+CD27+ B cell proliferation which included IgD10 B cells. The IgD+ fractions 
from the sorted B cells were enriched for proliferating naive IgDhl and IgD10 IgM* memory B cells 
in comparison to that seen in the unsorted PBMC culture.
Conclusion
The difference in the IgG-AFC response seen following the in vitro stimulation of B cells with 
SAC+CpG+PWM and SAC+IL-2 rests with the B cell subsets differentiating during culture and 
is affected by the cells present in the peripheral blood at different time points after immunisation. 
SCP stimulated CD27+, CD27', IgG+, IgM+IgD+, IgM only, IgD10 and IgDhi B cells to differentiate 
into plasma cells. SI only stimulated IgG+, IgD10, CD27+ B cells to proliferate. AFC derived 
from naive and memory B cells in the SCP system leads to increased IgG-AFC frequency in the 
ELISpot compared to SI.
The size o f the proliferating population in the SI system is much smaller than seen for the same 
subsets in the SCP system. This is because SI only stimulates recently in vivo activated B cells 
and possibly plasmablasts to fully differentiate and they require fewer in vitro cell divisions to 
become mature plasma cells. SCP it truly polyclonal and will activate the entire subset of B cells 
and not just the antigen specific ones.
These studies have not clarified whether there is any effect of age on the generation of memory B 
cells and plasma cells or whether the type o f antigen (conjugate or polysaccharide) might affect 
the response in each of the culture systems.
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5.2 Introduction
To facilitate the detection of antigen specific AFC at time points that are distant from the time of 
antigen challenge requires the in vitro stimulation of B cells. The studies described so far have 
involved stimulation of PBMCs with a combination of Staphylococcus aureus Cowan Strain 
(SAC) and IL-2. This combination of B cell mitogen and cytokine has been used in many 
previously published studies (183, 213, 372, 376, 377, 414). These in vitro stimulatory 
conditions, plus or minus T cell factors such as IL-10 and anti-CD40-Mab, efficiently induce B 
cell proliferation and immunoglobulin secretion (mainly IgM and IgG), in cultures of PBMCs or 
purified B cells. However, the interest of the study described in this chapter was to see whether it 
would be possible to increase the sensitivity o f the polysaccharide specific IgG-AFC ELISpot 
assay by using a combination of antigens reported by Crotty et al (370, 378, 431). They reported 
that a combination of SAC plus pokeweed mitogen (PWM) and CpG oligodeoxynucleotide 
(ODN) enabled the detection of smallpox specific memory B cells at more than 50 years after 
immunisation and that the frequency of the virus specific B cells increased following 
immunisation.
One substantial problem with trying to identify antigen specific memory B cells is that the 
majority of antigen specific memory B cells or long lived plasma cells are sequestered in 
physiological locations such as the bone marrow and secondary lymphoid organs which are not 
readily accessible. It has been shown that during immunological challenge with antigen that AFC 
and resting memory B-cells are induced to circulate through the peripheral blood and peak in 
frequency during the first two weeks following challenge. In some studies it has been suggested 
that the majority of circulating AFC are not related to the antigen of interest but are forced into 
the circulation by the arrival o f newly generated memory and long lived plasma cells (254, 257, 
400). As discussed in the preceding chapter it is possible to distinguish at least two subsets of 
circulating B cells following immunisation and to show the kinetics o f arrival and disappearance
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of these subsets in the circulation. There are at least two phenotypes of spontaneously secreting 
AFC. One of the subsets has a more mature plasma cell like appearance while the other has a 
more germinal centre like appearance (432).
Therefore it was of interest in this study to try and identify the B cell subsets that were involved 
in the response to glycoconjugate immunisation and whether it would be possible to detect 
different properties among these populations.
Resting naive and memory B cells can be driven to proliferate and differentiate into plasma cells 
that secrete antibody by in vitro stimulation with polyclonal stimulants such as mitogens and also 
molecules that do not act via the BCR. By this process it is possible to detect small populations 
of re-circulating, antigen specific cells (by ELISpot), following their differentiation into AFC. 
The ability to detect such rare populations o f B cells is particularly important in the absence o f  
recent natural exposure to or immunisation with the antigen of interest. For example, the 
longevity of B cell memory to small pox immunisation, which may have occurred up to 50 years 
prior to the attempted detection of memory B cells, and for which there is no exposure to 
environmental antigen(370, 431, 433). In the case of the pneumococcus, there is a high rate of 
natural exposure to the organism via nasopharyngeal carriage, but any memory B cells that are 
specific for the capsular polysaccharides may be rare given the T cell independent nature o f the 
antigen.
Traditional polyclonal B cell stimulants include poke weed mitogen (PWM), Staphylococcus 
aureus Cowan Strain (SAC) and T-cells/T-cell supernatants/ factors such as interleukin (IL-)2. 
Individually these mitogens appear to stimulate distinct subsets of B cells.
5.2.1 Polyclonal stimulants of lymphocyte proliferation
PWM is a T-cell dependant (TD) mitogen that acts on T-cells, in co-culture with B cells, leading 
to provision of T cell help to the resting B cells. This T cell help may be through direct cell-cell
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contact of in the guise o f secreted cytokines. Removal o f T cells from the system removes the 
activity of PWM on B cells (418, 434-436).
SAC has been described as a T cell Independent (TI) mitogen that is able to activate B cells by 
cross-linking surface bound immunoglobulin to generate an activation signal. In particular, the 
protein A component of the SAC cell wall (SpA) provides two separate mechanisms of B cell 
activation. One mechanism involves direct interaction of SpA with the surface immunoglobulin 
Fab fragments, cross-linking 2 or more B cell receptors (BCRs) to provide adequate signal 
strength for activation of B cells without T-cell help. The second mechanism involves SpA 
interation with the Fc portion of the surface bound Ig molecules (437-444).
T-cell factors, such as IL-2, act directly on activated B cells. IL-2 receptor (CD25) is up- 
regulated in activated B cell and increases the sensitivity of these cells to secreted IL-2 from 
activated T-cells(212, 213, 445). SAC in combination with IL-2 is a potent system for activation 
of B cells and their differentiation into antibody secreting plasma cells. SAC alone, while driving 
proliferation does not lead to differentiation of the B cells. Therefore, while proliferation is T- 
independent, differentiation is T-dependent. The combination of SAC+IL-2 has been used in a 
number o f studies investigating human B cell activity (183, 213, 372, 376, 377, 414).
Other T cell factors involved in B cell activation and proliferation include direct interaction with 
antigen activated T cells via CD40-CD40L. In experiments using plasma membranes from 
activated helper T cell clones investigators have shown that murine B cells required CD40- 
CD40L interaction to induce B cell activation in vitro (419, 446-448). B cell receptor (BCR) 
ligation by T cell dependent antigens was enough to signal the B cell to up-regulate stimulatory 
molecules, such as CD40, CD80 and MHC class II (449, 450), but T cell help was needed for B 
cell differentiation and antibody class switching to occur (448). The resulting up-regulation of 
CD80 allowed the B cell to interact with CD28 on the T cell which in turn led to the up-regulation 
of CD40L on the T cell, which then interacted with CD40 on the B cell. This cognate interaction 
between B and T cell induced B cell proliferation. Proliferation is essential for B cell
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differentiation into plasma cells. Blocking of this interaction in mouse experiments inhibited T 
cell dependent B cell activation (447). The strength of the interaction between CD40-CD40L and 
also concurrent exposure of activated B cells to various cytokines affected the isotype switching 
of antibody and survival o f the B cells (448). Anti-CD40 Mab plus Th2 cytokines (such as IL-4 
or IL-5) induced class switching from IgM to IgGl (after 3 divisions), and IgE (after 5 divisions), 
shown in figure 5.1, while Thl cytokines (such as IFNy) induced switching to IgG2a. The 
isotype of antibody was also determined by the number of cell divisions undergone by the B cell 
(416, 451), and IFNy was able to inhibit IL-4 mediated proliferation, decreasing the number of B 
cells undergoing cell divisions and thus altering the antibody isotype produced in culture (207, 
452,453).
CpG-ODN have recently been identified as good stimulators of lymphocyte stimulation. They 
are bacterial DNA fragments (or oligodeoxynucleotides,) containing unmethylated, cytosine- 
guanine (CpG) sequences that have been used as mitogens for human lymphocytes. CpG-ODN 
occur in two main types CpG-A and CpG-B that is determined by the nature o f the link (p) 
between the C and G base (454). In CpG-A ODN the p-link is a phosphate bond and these 
sequences are efficient activators of natural killer (NK) cells and IFNy producing dendritic cells. 
In the CpG-B ODN sequence, the p-link is a phosphorothioate bond and these sequences are 
potent stimulators of human B cells (455). CpG-B ODN motifs are surrounded by specific base 
sequences and it was found that optimal activity required the presence of TpC base pair 5’ o f  
three CpG (5’-GTCGTT-3’) motifs that were separated by TpT. Alone or in combination with 
SAC and or PWM and IL-2, CpG is able to activate B cells via the toll like receptor (TLR-)9 
(456, 457). TLR-9 is up-regulated on activated and memory B cells and provides a mechanism 
for provision of a second signal for B cells activated via the antigen receptor. The most potent 
ODN sequence for activating human B cells was identified as (5’- 
TCGTCGTTTTGTCGTTTTGTCGTT-3 ’) and given the name ODN 2006 (231, 232, 458).
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Combinations of these mitogens act synergistically to drive the maximal B cell proliferation in 
vitro, allowing expansion and identification of antigen specific memory B cells many years after 
immunisation (228, 351, 359, 370, 371,459).
In the initial pilot vaccine studies in chapters 3 and 4 B cells were stimulated with a combination 
of SAC+IL-2 and while finding memory B cell responses in adults the sensitivity of detection in 
infants appeared far lower. Therefore, to enhance the sensitivity of detection in the Elispot assay 
the effects of two culture systems on the peripheral blood of adults were compared. The first was 
the original culture system of SAC+IL-2 (SI) and the second was one published by Crotty et al 
(378), using a combination of SAC+CpG+PWM (SCP).
The comparison involved labelling adult PBMCs with CFSE and then culturing the cells with 
either SCP or SI for 5 days. CFSE labelling allowed the number of cell divisions undergone by 
the PBMCs (and individual B cell subsets), in each of the culture conditions to be determined as 
cell division sequentially dilutes the fluorescent dye (fig.5.1). As discussed above it has 
previously been shown that B cells need to undergo at least 4 cell divisions before 
immunoglobulin secretion occurs (387, 416, 417, 451) and it is thought that T-cell help, either 
through cognate interaction or via T-cell factors, is required for the differentiation of B cells into 
antibody forming cells (AFC)(207,450,451,460).
Therefore, the aim of this study was to determine whether the in vitro stimulation of PBMCs with 
SAC+CpG+PWM compared to SAC+IL-2 would increase the frequency o f IgG-AFC detected by 
ELISpot. It was also the aim of this study to determine whether distinctions could be made 
between the proliferating B cell subsets within each of the in vitro stimulation systems and 
whether this related to the ELISpot outcome.
5.3 Subjects and clinical procedures
A group of 10 adults with no previous pneumococcal vaccination history were recruited with 
informed consent and after ethical approval (OxRec C02.005), to receive a single dose o f Pnc7.
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Blood was drawn on days 0, 6, 7, 15 and 28 following immunisation with a single dose o f Pnc7 
vaccine (Chapter 2, section 2.4). Serum was stored at -80°C and PBMCs were isolated from 18ml 
of heparinised whole blood.
Two unimmunised, adult volunteers were recruited from the laboratory with informed consent to 
isolated PBMCs to evaluate the cell culture conditions for the memory B cell ELISpot assay 
described in figures 5.6 -  5.8.
5.4 Methods
PBMCs were isolated as described in Chapter 2, section 2.4 at each of the time points (day 0, 6, 7, 
15 and 28).
In order to increase sensitivity of the memory B cell ELISpot assay the original stimulatory 
antigen combination of SAC+IL-2 (SI) was compared with a new combination, 
SAC+CpG+PWM (SCP), suggested by Crotty et al (378).
Equal numbers of PBMCs from each sample (a total of 9.6x106 cells at 2xl05cells/well), were 
stimulated with either SI or SCP for five days at 37°C in 5%C02 and 95% humidity (as in 
Chapter 2, section 2.6).
Prior to in vitro stimulation with SI or SCP the PBMCs were labelled with 2pM CFSE (as in 
Chapter 2, section 2.14), to assess cellular proliferation by dye dilution on a flow cytometer. By 
using CFSE dye dilution analysis it was possible to look for differences in proliferative capacity 
of different B-cell subsets following in vitro stimulation (figure 5.1).
After 5 days the cells were harvested and labelled with combinations of CD19-PerCP, IgD-PE, 
IgG-PE, IgM-Cychrome and CD27-PE, for analysis o f proliferating B cell subsets by flow 
cytometry (as in figure 5.1). The remaining harvested cells were seeded in antigen coated plates 
for enumeration of diphtheria, tetanus, serotype 4, 14 and 23F specific IgG-AFC by ELISpot
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(Chapter 2, sections 2.5, 2.7, and 2.8). The phenotypes of the proliferation B cell populations and 
all the Ig-secreting activity were compared between the two culture conditions.
Fresh PBMCs isolated on day 7 or 28 following immunisation were separated using 
AutoMACs™ magnetic cell separation, on the basis o f the surface expression o f IgD or IgG as in 
(Chapter 2, section 2.9).
N jTfr-t' c l *»SW !S
cFse-----------
F ig u r r  2 .  T a c k in g  H ce ll d iv r.io ru  rw ty p e  tw itch in g , an d  A f f f te a t i i a o n  u sin g  C FS F - C F S E -U b cU d  tm a2 , d « n te  B  t r i l l  w e re  tn m u li tc d  w ith  T l i  
rcw m bfanc a n d  in  fo r  v arious n m n  b r f b f r  b e in g  harvested  an d  tu r n e d  (d )  (Tejp) C F S E  fluo rescence h m o g r tm i  foe ac tiva ted  B  cell* tak e n  a t  d m  2  5 . 3 .  
3 ,5 . an d  4 i f t e t  th e  s u n  o f  c u ltu re . T h e  p co g re tu o n  o f  ce ll d iv isio n  w ith  t im e  tt in d ic ite d  b y  teqoencsa! tw o fo ld  re d u c tio n s  in  C F S E  in ten sity , D ash ed  
gutdeSinw  c n  ea ch  g ra p h  in d ica te  th e  p o s itio n  o f  each  divrnors cycle n u m b e r, U n d e rn e a th  ea ch  h isto g ram  a re  tw o  -d im en sio n al c o n to u r  p lo ts  o f  C F S E  
vrnrn tuifke labe ling  with CD44. IgD. IgM. and IgG I. (fl) Dm from A were gxted to o J c u l i a  the proportion of tool vuhle «IK it; culture found in 
each  dsvB ion cyc le  at each  htrse p o in t (Mp>. T h e  p ro p o r tio n  of cells  in  each  d iv jtio n  cy c le  th a t  w e re  Ig G  I*  a t  ea ch  tim e  p o in t .  A d jac en t gates
w e re  vet u s in g  C eB quew  to ftw a te  t o  acco«nm odat*% equential d iv ision  fo u n d s  c e n te re d  o n  th e  m ea n  fo r ea ch  d iv isio n
R eference: B-cell differentiation an d  iso type switching is related to  division cycle num ber. Hodgkin PD , L ee JH , Lyons AB. J. Exp M ed. 1996 Ju l 1;184(1):277-81
F igure 5.1 D ivision cycle num ber and B  cell surface phenotype fo llow ing in vitro stim ulation  w ith  Th  
plasm a m em branes.
The example in this figure is from a study by Hodgkin et al, and show s how  the number o f  dividing cells  
can be established for each o f  the B cell subsets and how  proliferation affects the expression o f  surface 
immunoglobulin.
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5.5 Results
5.5.1 Kinetics and frequency of IgG-AFC derived from adult 
memory B-cells following 5 days of stimulation with SCP (blue) 
versus SI (red).
Using SCP to stimulate PBMCs induced a significantly higher frequency of total IgG-AFC than 
that generated following PBMC stimulation with SI and this remained so throughout the time 
course (Fig. 5.2a, p=<0.01 at days 0, 6 and 7; p=<0.05 at days 15 and 28). The frequency of 
tetanus toxoid specific IgG-AFC was a significantly higher following PBMC stimulation with 
SCP than with SI at all o f the time points except at day 0 (Fig 5.2b. p=<0.01.) The frequencies of 
both the total-IgG-AFC and the tetanus toxoid specific IgG-AFC remained constant throughout 
the time course irrespective of the type of stimulus used in vitro (fig. 5.2a-b.)
Stimulation of PBMCs with either SI or SCP generated similar frequencies of diphtheria specific 
IgG-AFC at all time points throughout the time course (Fig.5.2c). There was a difference in the 
kinetics between the two in vitro systems however. In the SI system the frequency of inducible 
diphtheria toxoid specific IgG-AFC peaked above baseline levels on day 7 following 
immunisation (p=<0.01, red asterix.) Numbers remained elevated above baseline at day 15 but 
had returned to baseline by day 28 (fig 5.2c.) The median frequency of diphtheria specific IgG- 
AFC induced by SCP stimulation peaked at day 15 following immunisation (p=<0.01, blue 
asterix), but had returned to baseline by day 28 (fig.5.2c).
Prior to immunisation the in vitro stimulation of PBMCs with SCP induced significantly higher 
frequencies of IgG-AFC specific for the polysaccharide capsules o f serotype 4 and 23F than was 
seen following stimulation with SI (p=<0.01, black asterix, fig.5.2d+f). No difference was seen 
in the baseline frequency of serotype 14 polysaccharide specific IgG-AFC between the two 
systems (fig.5.2e).
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Following immunisation there was a rise in frequency of polysaccharide specific IgG-AFC 
induced by both the SCP and SI in vitro stimulation systems. The elevation in frequency was first 
apparent at day 7 and tailed away again by day 28 (fig.5.2d-f).
The post immunisation frequencies of polysaccharide specific IgG-AFC induced by in vitro 
stimulation of PBMCs with SCP were equal to or greater than those seen following stimulation 
with SI at day 7 and were significantly higher than those induced by SI at days 15 and 28 in 
response to serotypes 4 , 14F (p=<0.01) and 23F (p=<0.05) (fig.5.2d-f, black asterix).
The median frequency of IgG-AFC induced by in vitro stimulation of PBMCs with SCP peaked 
significantly at day 15 for serotypes 4, 23F (p=<0.01), and 14 (p=<0.05) (fig.5.2d-f, blue asterix). 
By day 28 post immunisation only serotype 4 specific IgG-AFC remained significantly elevated 
above baseline in the SCP system (p=<0.05, fig.5.2d, blue asterix).
The median frequency of IgG-AFC induced by in vitro stimulation of PBMCs by SI peaked 
significantly above baseline at day 7 for serotype 4 (p=<0.01), and 23F (p=<0.05) and remained 
elevated above baseline for serotype 23F at day 15 (p=<0.05) (fig.5.2d-f, red asterix).
Thus these data show that SCP induces higher frequencies o f IgG-AFC from B cells than does SI 
if  B cells have not recently been stimulated by the immunising antigen (e.g. tetanus toxoid 
specific IgG-AFC). IgG-AFC specific for recent vaccine antigens (diphtheria toxoid and the 
pneumococcal polysaccharides), were detected at similar frequencies in both the SCP and SI 
systems from PBMCs isolated in the first week after immunisation. Higher frequencies of 
polysaccharide specific IgG-AFC were seen at baseline and day 15 to 28 following in vitro 
culture with SCP then with SI. This suggested that there were differences in the B cells present at 
these time points.
177
n  <m »-
00
m
T3■o
oXo+■> T3
V)
3
C
JS CD
O
O
3 )
5 CD
O
-o
CD
00
C\J
in
LL
CO
CM
CD
-aa>in
CM
in
o
a>
a
oL-
•—0
CD
T3a></>
CD
00
CM
HUH
a
H E
CO
TJ
SQIAiad PSJmino q(H*l-/OdV-0 6 |
c/>
>*
CO
co
‘■p
CO
.eg
'c
3
E
E
•<->
u>oa .
a>
E
£Cl-+
uCL
u+
u
<
o
NN
W
CM■
- JH-+
u
<CZ5
03
Oh
•5
onc
Io
> .
u
e
CD
s
c
U
Urn
<Ia
DJD
00
fc*o
E
«
C L
E
o
U
<s
it]
35>u
2  CD ^2 o o
■S CD J 3
O  C/3u o „
S3 § 2
=  c  J
(D Cl -O
•S ’o 'g  2 §
3 to £
3  3o o
oo
r -
CD
<D
c/3 t :  3
3  <D 
T 3  +-> -C  
_  o  
m  t o  cD 
. C  CD
<2 *  C  X-2 S
T 3
CD
CD
£  Ua. c  oo £*;- 
. "O  <d
^  r N> CO
<D 0 0H H 0)
>-D  C  O
^  cci X )
0L- E U 3 00 -E
D
CD
(D
J 3
x :
'%
o 'v
>
s
.13  £
£ ° ^  sz
T 3  w  
CD o  3 ^ 
O  T 3  
O  (D
-O  £  
CD
13 +-> _cD o"3 Oh2 C/1
I  3■ w
o  o  
C  o
o  CD
- oc
CD
oo
<N
- ac
CD
i n  id—i >
bl)
'O - ’g
d ig
c/3 C>> «S
CD3 - x c“*T3 CD * C
CD
CD
r T * C/3
on cn 
<N
u TD .2 12
« Ib .2
^  CD
U  C  ^ 3
OQ 33 
P h
<DT3 fa 
C  B
^  3CD
* c
• CD 
■'D- <D
C/3 ^
CD ' ■
~a <D X )Ui03 ?? -C CD O CD 
CD c  
j _ . e n  CD ?D 
33 ID c/3 fa
-2 £
^  <  J Z  CLT3
5.5.2 CFSE dye dilution analysis of B-cell subset proliferation
PBMCs were isolated from an un-immunised adult donor to determine the effect of the different 
polyclonal stimulants either individually or in combination and which induced the best 
proliferation of lymphocytes. The stimulants used were 10%-NBBS only, SAC (1/5000), PWM 
(83ng/ml), CpG (2.5pg/ml), SAC+CpG, SAC+PWM, PWM+CpG and SAC+CpG+PWM. 
Following 5 days of culture the cells were harvested and labelled for surface expression of IgM- 
PerCP and CD27-PE with CFSE providing the third colour for analysis by three colour flow 
cytometry. The cells were first gated on the live lymphocyte population (fig 5.3a).
R1 = live lymphocyte gate
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Figure 5.3 An exam ple o f  the lym phocyte gating used prior to C FSE  proliferation  analysis o f  P B M C  
sam ples that had undergone 5 days o f  in vitro stim ulation.
(a) Live lymphocyte gate, R1 and (b) shows the subgates for CD27' (R2) and CD27+ (R3) lymphocytes 
within R1 population.
Within the R1 population the overall lymphocyte proliferation was analysed (fig.5.4a-h) for each 
of the in vitro stimulants alone and in combination. The PBMCs were labelled with CFSE and 
cultured for 5 days in the presence of CpG, SAC, PWM or combinations of these as shown in 
figure 5.4.
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Figure 5.4 T otal C FSE  proliferation o f PB M C s in R1 (fig 5.3a) follow ing 5 days o f  in vitro stim ulation  
w ith individual and com binations o f  polyclonal B cell activators (day 28 post im m unisation).
Isolated PBMCs were labelled with 2pM CFSE and then cultured for 5 days with a) 10%NBBS alone 
(unstimulated control, M l), b) CpG 2.5pg/ml, c) PWM (83ng/ml), d) SAC (1:5000) or combinations of 
these; e)SAC+CpG, f) PWM+CpG, g) SAC+PWM and f) SAC+CpG+PWM. After 5 days of stimulation 
the cells were harvested and the total lymphocyte population was analysed for the amount of proliferation 
by CFSE dye dilution (dark blue line). The negative cut off for CFSE fluorescence was made using the 
unlabelled cell controls (pale blue line). The markers (M1-M5) represent 0, 1, 2, 3 or >4 cell divisions 
based on reduction in CFSE fluorescence (x-axis) and cell numbers (y-axis).
Of the three individual stimulants it can be seen that CpG (5.4b) and PWM (5.4c) induced more 
lymphocytes to divide >4 times than did SAC alone (5.4d). When the stimulants were combined 
there appeared to be a synergistic effect, with all combinations inducing more cell division than 
any of the individual stimulants alone. Combining SAC with either CpG (fig.5.4e), or PWM
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(fig.5.4g) increased the number of cells undergoing >4 cell divisions after 5 days o f culture when 
compared to SAC alone (fig.5.4e and g).
The combinations that included CpG (SAC+CpG, PWM+CpG, fig 5.4e-f) appeared to induce 
more cell division than was seen in response to stimulation with SAC+PWM (5.4g.) The best 
combination was SAC+CpG+PWM (fig.5.4h), as had been suggested by Crotty et al (378).
The percentage o f CFSE positive lymphocytes within each marker (M1-M5) was then plotted for 
each of the culture conditions and is shown in figure 5.5. The 10%-NBBS control induced 
minimal background proliferation of lymphocytes with 99% of lymphocytes remaining 
undivided. In response to SAC stimulation 85% of lymphocytes remained undivided, followed 
by CpG (78%), and PWM (68%). With the combined stimulants the percentage o f undivided 
lymphocytes was greatest in response to SAC+PWM (72%), followed by SAC+CpG (65%), then 
PWM+CpG (58%) and finally SAC+CpG+PWM where only 43% of lymphocytes remained non­
proliferating.
The percentage of CFSE positive lymphocytes achieving 4 or more divisions was greater in 
response to SAC-tCpG+PWM (35%) followed by PWM+CpG (21%), SAC+CpG (18%), 
SAC+PWM (14%), PWM (12%), CpG (10%) and SAC (8%).
For a more detailed analysis of the B cell subsets proliferating during the 5 day stimulation 
culture a further sub analysis was carried out on the memory B cell (CD27+), and naive B cell 
(CD27') populations, focusing on the surface expression IgM. For this analysis the lymphocytes 
(fig.5.3a), were sub-gated on the absence (R2) and presence (R3) o f surface CD27 expression 
(Fig 5.3b). Within the CD27+ and CD27' lymphocyte populations the B cells were selected for 
the surface expression of IgM and dot plots were created showing the CD27+/' IgM+ populations 
versus CFSE dilution (fig.5.6a-p).
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Figure 5.5 C om parison o f  proliferative capicity o f  B cells follow ing 5 days in vitro stim ualtion  w ith  
different com binations o f  polyclonal activators.
PBMCs isolated 28 days after a primary dose of Pnc7 were labelled with 2pM CFSE and then cultured for 
5 days with 10%NBBS alone (purple, unstimulated control,) CpG 2.5pg/ml (green), PWM 83ng/ml 
(yellow), SAC 1:5000 (red), SAC+CpG (orange), PWM+CpG (blue), SAC+PWM (dark purple) and 
SAC+CpG+PWM (lilac). After 5 days of stimulation the cells were harvested and the total lymphocyte 
population (figure 5.2a) was analysed for the amount of proliferation by CFSE dye dilution. The data in 
this figure is a graphical representation of the data in figure 5.4. The percentage of lymphocytes (y-axis) 
within each of the marker bounds (M1-M5) shown in figure 5.4 plotted against the number of cell divisions 
(0, 1, 2, 3, >4) for each of the culture conditions.
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In the un-stimulated controls (10%-NBBS only, fig.5.6a+e), there remained a surviving 
population of non-dividing, naive (CD27‘) IgM* cells (fig.5.6a), while no non-dividing memory 
(CD27+) IgM* lymphocyte population remained (fig.5.6e).
Stimulation of B cells with SAC or PWM appeared only to induce proliferation of CD27*IgM* 
memory B cells (fig.5.6.f-g), but had no effect on the naive CD27+IgM+ B cell population 
(fig.5.6b-c).
CpG stimulation, however, induced proliferation of both naive (fig.5.6d), and memory (fig.5.6h), 
B cells although the number of cell divisions undergone by the naive B cell population was lower 
than in the memory B cell population.
An x-axis (log10 CFSE fluorescence), value o f 8x101 marked the >4 cell division marker as 
denoted in figure 5.4. While CpG induced the majority of CD27+IgM+ memory B cells to 
proliferate past this point, the majority of the naive CD27'IgM* B cell population also proliferated 
but did divide as quickly as the memory B cells within the same time frame. Therefore CpG was 
able to induce proliferation of both naive and memory B cells.
Combining SAC+PWM had an additive effect on the rate of proliferation of memory B cells 
(fig.5.6m), when compared to either mitogen alone but did not alter the naive B cell response 
(fig.5.6i). The combination of CpG with either SAC (fig.5.6j+n), or PWM (fig.5.6k+o), enhanced 
the proliferative response of both the nai've and memory B cell subsets when compared to any o f  
the three stimuli alone. Combining SAC+CpG+PWM induced the majority o f both naive 
(fig.5.61), and memory (fig.5.6p), B cells to undergo >4 cell divisions.
Thus SAC+CpG+PWM appeared to be the ideal combination o f mitogens for the stimulation o f B 
cells for the memory B cell ELISpot.
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5.5.3 Immunoglobulin secretion by in vitro stimulated, 
peripheral blood B cells
PBMCs isolated on day 28 after a single dose of Pnc7 vaccine and cultured for 5 days with SAC, 
PWM, CpG, IL-2 (50U/ml) and SAC+CpG+PWM were harvested and seeded into antigen 
specific ELISpot plates for the detection of IgG-AFC or IgM-AFC as shown in figures 5.7 and 
5.8.
There was some residual total IgG-AFC activity from the un-stimulated cells (fig.5.7 10%- 
NBBS) but no antigen specific activity.
Stimulation with SAC or PWM alone (fig.5.7), induced more o f both total IgG-AFC and also 
antigen specific IgG-AFC with very similar numbers o f pneumococcal capsular polysaccharide 
specific AFC for serotypes 4, 14 and 23F. There were no tetanus or diphtheria specific AFC 
however. Stimulation with IL-2 induced some total-IgG-AFC secretion but no antigen specific 
AFC were seen. CpG alone also appeared as equally effective at inducing the formation of IgG- 
AFC as SAC and PWM alone (fig.5.8, rows g and h). CpG also appeared to induce tetanus 
toxoid specific IgG-AFC formation, while no tetanus or diphtheria specific AFC were seen in 
response to SAC or PWM.
The combination of SAC+CpG+PWM strongly induced IgG-AFC formation to all three capsular 
polysaccharides, tetanus and diphtheria toxoid (fig.5.8, rows a-c), and also an overwhelming IgM- 
AFC response (fig.5.8, rows d-f). In fact, when paired with the CFSE proliferation data from 
figure 5.6 it seems that the SAC+CpG+PWM stimulation system preferentially induces IgM 
production in comparison to IgG.
These experiments were only carried out on individual donors, but provided valuable information 
about the effects o f the individual and combined polyclonal stimulants.
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Figure 5.7 The E LlSpot (IgG ) output o f  from  PBM C s stim ulated  w ith 10% N BB S, SA C , PW M  or IL - 
2 (50U/m I).
PBMCs were isolated from a healthy adult donor and stimulated for 5 days. The cells were then harvested, 
re-suspended to the cell concentrations shown in the left hand columns of the template shown above and 
seeded into well of an ELlSpot plate coated with PBS, anti-Ig (columns 2-4), tet, dip, serotype 4, 14 and 
23F. The cells for the Ig-control wells were diluted 1:10 and 1:100 from the initial cell suspension. The 
secreting cells were detected with anti-IgG-alkaline phosphatase conjugate. The black crosses show wells 
that received no cells due to sample volume constraint.
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1x105cells/well
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CpG2.5pg/ml G PBS 1:10 1:10 1:10 TET DIP 4 14 23F
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F igure 5.8 The E L lSp ot output and tem plate for PB M C s isolated from  the sam e donor as in figure  
5.7.
The PBMCs were stimulated in vitro with SAC+CpG+PWM, or CpG alone for 5 days. The cells were then 
harvested, re-suspended to the cell concentrations shown in the left hand column of the template shown 
above and seeded into well of an ELlSpot plate coated with PBS, anti-Ig (columns 2-4), tet, dip, serotype 4, 
14 and 23F. The cells for the Ig-control wells were diluted 1:10 and 1:100 from the initial cell suspension 
(and 1:1000 for SAC+CpG+PWM). The secreting cells were detected with either anti-IgG-alkaline 
phosphatase conjugate (rows a-c and g-h) or anti-IgM-alkaline phosphatase conjugate (rows d-f). The 
black crosses show wells that received no cells due to sample volume constraint.
187
5.5.4 The total lgD+, IgM* and lgG+ B cell subset in vitro 
proliferation after Pnc7 immunisation. (SAC+IL-2 vs 
SAC+CpG+PWM)
The aim of this study was to determine the ideal conditions with which to generate IgG-AFC 
from memory B cells. CFSE dye dilution analysis enabled the identification of the B cell subsets 
involved in the response to Pnc7 immunisation.
Adult donors received a single dose of Pnc7 and PBMCs were obtained on days 0, 6 ,1 ,15  and 28 
after immunisation. The PBMCs were labelled with CFSE and cultured with SAC+IL-2 (SI) or 
SAC+CpG+PWM (SCP) for 5 days. Following in vitro stimulation the cells were harvested and 
labelled for expression of surface immunoglobulin. The ability of B cells from the immunised 
donors to proliferate in response to polyclonal stimulation at various time points after vaccination 
was quantified (fig 5.9).
The proliferation of IgD+ B cells (fig.5.9a), peaked above baseline by 7 to 15 days after 
immunisation This was significant in the SCP system (p=0.031), but in the SI system the 
increased proliferative response was delayed until days 15 to 28 (p=0.011, p=0.018 respectively). 
IgD+ B cell proliferation at day 6 post immunisation was significantly lower than at day 0 in the 
SCP system (p=0.009), while no such effect was seen in the SI system. There was no appreciable 
alteration in the ability o f IgM+ B cells (fig.5.9b), to proliferate in response to either set of stimuli 
at any of the time points studied. There was no change in the in vitro proliferation of IgG+ B 
cells isolated after immunisation (fig 5.9c).
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Figure 5.9 T he total am ount o f proliferation (>1 cell d ivision in 5 days), w ith in  the IgD +, IgM + or  
IgG + B cell subsets.
PBMCs were isolated from adult volunteers on days 0, 6, 7, 15 and 28 after a single dose of Pnc7 and 
labelled with 2pM CFSE. The labelled PBMCs were the cultured for 5 days in the presence of 
SAC+CpG+PWM (blue) or SAC+IL-2 (red). On day 5 of stimulation the cells were harvested and labelled 
for expression of surface immunoglobulins. The data represent the percentage of a) IgD+, b) IgM+ and c) 
IgG+ B cells undergoing at least one CFSE dye dilution, (or cell division), at the end of 5 days. The 
columns represent the mean of 10 individuals, with 95% Cl, */*p=<0.05.
5.5.5 The effect Pnc7 immunisation on the frequency of lgD+ B- 
cells following in vitro stimulation
Since Pnc7 immunisation appeared only to affect the proliferation of IgD+ B cells the overall 
frequency of IgD expressing B cells was assessed following in vitro stimulation of the isolated 
PBMCs (fig.5.10a-d).
In the SCP system IgDhl expressing B cells reached a peak in frequency by day 15 (p=0.045, 
fig.5.9a), after immunisation while the percentage of the IgD10 subset remained constant 
throughout the time course (fig.5.10b).
Following stimulation of PBMCs with SI the IgDhl B cells remained at a constant level until day 
28, by which time the frequency of proliferating IgDhl B cells was elevated significantly above 
baseline (p=0.042, fig.5.10c). The IgD10 B cells peaked above baseline on day 6 (p=0.017, 
fig.5.10d), and then returned to baseline levels.
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Figure 5.10 The percentage o f  IgD + (Io/hi) B cells present a fter in vitro stim ulation  o f  P B M C s prior  
to and follow ing a single dose o f  Pnc7 vaccine.
PBMCs were isolated from healthy adults on days 0, 6, 7, 15 and 28 after immunisation. The cells were 
then stimulated for 5 days in the presence of SAC+CpG+PWM (SCP, a+b) or SAC+IL-2 (SI, c+d). On day 
5 the cells were harvested and labelled for expression of surface IgD expression which was then analysed 
by flow cytometry. The data represent the percentage of IgD10 or IgDhl B cells (hi or lo fluorescence 
intensity) in each individual and the bar shows the mean expression in ten individuals. (*) p=<0.05 by 
student paired T-Test.
5.5.6 Adult B cell proliferation following immunisation Pnc7: A 
comparison of SCP and SI for in vitro stimulation.
By plotting the number of cell divisions, obtained from the CFSE dye dilution assay, against the 
percentage of selected B cells subsets it was possible to see the rate of proliferation following 5 
day of in vitro stimulation. This method allowed the direct comparison between SI and SCP
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stimulation. The desired outcome was to drive as many B cells as possible through at least 4 cell 
divisions. Figure 5.11a-p shows the kinetics of B cell proliferation after PBMCs were isolated 
and cultured for 5 days.
In all cases it can be seen that there were more B cells undergoing >4 cell divisions in the SCP 
system than in the SI system. However, there were no significant differences in proliferation 
rates between days in either system when looked at in this way.
The data were also plotted to show only the cells that had undergone >4 divisions (fig.5.12a-g). 
Slight differences between days become more apparent when the data was analysed in this way. 
There was a significant increase above baseline in the proliferation of CD19+CD27+ B cells in the 
SI system by days 7 to 15 (p=<0.05, fig.5.12a), while the proliferation of memoiy B cells in the 
SCP system remained constant at all time points. There was a similar trend in the naive 
(CD19+CD27‘) population (fig.5.12b). There were also some significant changes in the 
percentage of IgG+ B cells proliferating in the SCP system with a decrease in numbers at day 6 
(p=<0.05, fig.5.12c), and a rise in the SI system at day 7 (p=<0.05). The proliferation of naive 
IgDhl B cells appeared to peak at day 15 in the SCP system (p=<0.01, fig.5.12g) while no such 
change was observed in the SI system.
In figure 5.11, the differences between the two culture systems can be observed. In the SCP 
system, naive (CD19+CD27‘) and memory (CD19+CD27+) B cells proliferated well, although the 
rate appeared slower in the naive population (fig.5.11a) with a peak in the number of cells 
proliferating at 4 cell divisions while memory B cells peaked at >4 cell divisions (fig.5.1 lc). The 
SI system induced no significant proliferation of naive B cells, with a cell division number 
peaking at <4 divisions (fig.5.1 Id). Memory cells proliferated in the SI system but the percentage 
of these cells was much lower than in the SCP system.
There was no real difference in the proliferation of the double positive IgD+IgM+, IgM+ only or 
IgDhl B cells in the SI system (fig.5. l lh,  j+n), while there were more IgG+ and IgD10 B cells 
proliferating (fig.5.1 lf+1).
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In the SCP system all B cell subsets proliferated but those with a more memory like phenotype, 
i.e. IgG+ or IgD10 (fig.5.11e+k) responded more rapidly than did the B cells with a more naive 
phenotype IgD+IgM+, IgDhl (fig.5.1 lh+m).
5.5.7 The predominant B cell subset proliferating prior to and 
following Pnc7 immunisation (SCP versus SI).
A comparison of particular B cell subsets proliferating in each culture system at each time point, 
prior to and following immunisation was made based on >4 cell divisions.
Firstly naive and memory B cell proliferation was compared at each time point (fig.5.13). At day 
0 there were significantly more memory than naive B cells proliferating in the SI system 
(p=0.011), while there was no such difference in the SCP system. The increased proliferation of 
memory B cells only appeared in the SCP system at days 7 to 15 (p=0.013 and 0.0051 
respectively), and then was lost by day 28. In the SI system, the difference between memory and 
naive cells was lost following immunisation until day 15 (p=<0.05).
There was a slight difference in the proliferation of IgG+ (bright green) B cell and IgM+IgD+ B 
cells (blue) in the SCP system with more IgG+ cells making >4 divisions than IgD+IgM+ B cells 
(p=0.045). There was no difference between these two populations in the SI system at any time 
point.
There were significantly fewer IgDhi B cells (orange) proliferating than IgD10 B cells (yellow) at 
all time points except day 6 in the SCP system although this was most noticeable at day 0 
(p=0.0007) and day 28 (p=0.0001.) The same result was seen in the SI system also.
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Figure 5.12 A com parison o f  the B cell proliferation induced by in vitro stim ulation  o f  P B M C s w ith  
SCP or SI.
PBMCs were harvested on days 0, 6, 7, 15 and 28 following immunisation and labelled with CFSE. The 
cells were then stimulated with SCP (blue) or SI (red) for 5 days. At the end of 5 days the cells were 
harvested and labelled for the expression of a)CD19+CD27+(memory B cells), b) CD19 CD27" (nai've B 
cells), c) IgG+ B cells, d) IgM+IgD+ B cells, e) IgM+ only B cells, f) IgD10 B cells and g) IgDh' B cells. The 
percentage of these populations that had achieved >4 cell divisions (as measured by CFSE analysis) were 
then quantified and compared between the two culture systems. The columns represent the mean of ten 
individuals and the bars show the 95% Cl. *p=<0.05, **p=<0.01.
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Figure 5.13 P roliferation B cell subsets follow ing im m unisation  o f  adults w ith a single dose o f  Pnc7. 
PBM C s w ere harvested on days 0, 6, 7, 15 and 28 follow ing im m unisation , and then labelled  w ith  
C FSE.
The cells were then stimulated in vitro with a) SCP or b) SI for 5 days. The cells were then harvested and 
labelled for the expression of CD19+CD27+ memory B cells (purple), CD19+CD27'nai've B cells (dark 
blue), IgM+IgDT B cells (light blue), IgM+ only B cells (pale green), IgG+ B cells (bright green), IgD10 B 
cells (yellow) and IgDhl B cells (orange). The percentage of these populations that had achieved >4 cell 
divisions (as measured by CFSE analysis), were then quantified by flow cytometry and compared between 
the two culture systems. The columns represent the mean of ten individuals with 95%CI. *p=<0.05,
**p=<0.01, ***p=<0.0008.
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5.5.8 Depletion or enrichment of peripheral blood B cells 
expressing lgD+ or lgG+ and the subsequent proliferation of 
these B cells in vitro.
PBMCs were isolated from two adult donors (donor 1 and donor 2, fig.5.15) immunised with 
Pnc7, more than 6 months previously, were labelled with CFSE to allow determination of the 
proliferation of B cell subsets. The proliferation of the cells within these fractions was analysed 
by CFSE dye dilution, an example analysis of which is shown in figure 5.14. The percentage of 
cells undergoing art least 1 cell division was quantified (marker M2 fig. 5.14).
From the donor 1 experiment (fig.5.15) it can be seen that depletion of either IgG or IgD led to 
decreased proliferation of the IgG+ and IgD+ B cells when compared to the un separated fraction. 
The same effect was seen within the total CD19+ populations. The proliferation of IgM only 
memory cells (CD27+IgM+) was unaffected by the depletion of IgG or IgD B cells and compared 
well to the un separated fraction. The proliferation of the naive B cells (CD27'IgM+) was affected 
more by the depletion of IgD than IgG, but both depletions dramatically reduced the amount of 
proliferation seen in comparison to the unseparated cells.
In the donor 2 experiment (fig.5.15), where the depleted and enriched fractions were compared 
directly the following observations were made. Firstly there was an equivalent percentage o f  
surface IgG+ B cells proliferating in the IgG+(dark green) and IgD+(purple) enriched fractions and 
in both cases the enriched fractions proliferated more than the depleted (IgD', IgG' fractions). 
There was a higher percentage of IgD+ B cells proliferating in the IgD enriched fraction than in 
the IgG depleted fraction while no IgD+ B cells were seen proliferating in the IgG+ enriched or 
IgD depleted fraction. There was a higher percentage of total CD19+ B cells proliferating in the 
IgD enriched fraction than in either the IgG enriched or depleted fraction. There was no 
proliferation in the IgD depleted fraction. Proliferation of CD27+IgM+ B cells was considerably 
higher in the IgD enriched fraction. Enrichment or depletion of IgG+ B cells had no effect on the 
proliferation of CD27+IgM+ cells. Naive B cell proliferation was enriched in the IgD+ enriched
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fraction and there was also some proliferation of naive cells in the IgG depleted fraction but this 
was lower than the IgD enriched fraction.
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Figure 5.14 B cell subset proliferation as measured by CFSE dye dilution.
PBMCs from a healthy adult donor were labelled with CFSE, a fraction were kept unlabelled as the 
negative cut off for cell division numbers, shown by marker (M) 3, (green). The PBMCs were then 
separated by AutoM ACs™ on the basis of IgD or IgG expression. The separated cells were then cultured 
for 5 days in the presence of SAC+CpG+PWM. Following this the cells were harvested the percentage of 
B cells proliferating (blue) in the IgD+/- and IgG+/- fractions was quantified by flow cytometery on the 
basis of CFSE dye dilution (x-axis). Ml shows the non-proliferating cells and M2 the percentage of B cells 
that proliferated in each fraction.
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Figure 5.15 Proliferation of PBMCs depleted or enriched for IgD+ or IgG+ B cells.
PBMCs were isolated from two adult donors (donor 1 and donor 2), who had previously been immunised 
with Pnc7. The PBMCs were labelled with CFSE as described previously and were then separated on the 
basis of either IgG or IgD expression. Each of the fractions, along with an unseparated PBMC control, 
were stimulated for 5 days in the presence of SAC+CpG+PWM. At the end of the 5 day stimulation culture 
the cells were harvested and labelled for IgG, IgD, CD 19, CD27+IgM+ and CD27'IgM+ expression which 
was anaylsed by flow cytometry. The proliferation of each of these subpopulations was expressed as the 
percentage of cells that had undergone at least 1 cell division as determined by CFSE dye dilution as shown 
in figure 5.14.
5.5.9 The purity of the depleted and enriched PBMC fractions 
following IgD based cell sorting
In order to determine the purity and phenotype of the cells within each of the fractions obtained 
by AutoMACs™ cell sorting, the percentage of lymphocyte populations was determined (figure 
5.16). Data was collected from five individuals and the percentage surface expression of CD27, 
CD 19, CD3, IgM, IgD (5.16a) and subpopulations based on the percentage of IgD and IgM
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expressed within the CD27+ or CD27' populations (5.16b) within each of the sorted fractions 
were analysed.
The overall B cell population (CD19+) was enriched by sorting on IgD expression. The 
percentage o f CD19+ B cells in the un-separated PBMCs was 12% and this was enriched to 64% 
in the IgD+ sorted fraction (fig.5.16a). The percentage o f  IgD+ B cells was enriched by the 
sorting process so that in the un-separated PBMCs there was 11% IgD+ B cells while in the sorted 
IgD+ fraction the proportion of IgD+ B cells increased to 62%. There was a concurrent 
enrichment of IgM+ B cells going from 9% in the un-separated fraction to 59% in the IgD+ sorted 
fraction. There was less than 1% IgD+ or IgM+ B cell in the IgD' sorted fraction, yet there 
remained 2.85% CD19+ B cells that may have been the IgG+ B cells.
The nai've (CD27') lymphocyte population was enriched in the IgD+ fraction compared to the IgD' 
fraction (62% vs 23%), while the reverse was true for the CD27+ population (37.9% vs 77%), 
although this would include CD27+ T cells as well as B cells.
The B cell subsets were also different between the IgD+ and IgD' fractions (fig.5.15b). There was 
less than 0.5% IgM only B cells in either the CD27+ or CD27' populations in any of the fractions. 
The CD27'IgM+IgD+ population was enriched in the IgD+ fraction with 72% versus 18% and 
0.1% in the un-separated and IgD' fractions respectively. The CD27+IgM+IgD+ population was 
similarly enriched although was much lower than the CD27' population (21%, 1.7% and 0.2% in 
the IgD+, un-separated and IgD' fractions respectively). There was similar enrichment o f the 
IgD+only B cell population in the sorted versus un-separated fractions.
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Figure 5.16 The purity of the magnetic cell sorting based on IgD expression.
PBMCs were sorted on the basis of IgD expression and then the total lymphocyte subsets within each 
fraction were determined, a) CD27', CD27+, CD19+, IgD+, IgM+ and CD3+ populations and b) show the 
nai've (CD27 ) B cell populations in the top row CD27' IgM+, CD27' IgM+IgD+ and CD27' IgD+ and the 
memory (CD27+) B cell populations on the bottom row CD27+IgM+, CD27+IgM+IgD+ and CD27+IgD+. 
The data represent the median, 25th and 75th percentiles with outliers for five individuals.
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5.6 Discussion
The data presented in this chapter show that the nature of the polyclonal stimulation given to 
peripheral blood B cells affects the type of polysaccharide specific IgG-AFC detected by ELISpot 
following recent immunisation with a glycoconjugate vaccine. No such effect was observed in 
relation to the carrier protein specific IgG-AFC (diphtheria toxoid). The frequency of total IgG- 
AFC was significantly higher following B cell stimulation with SCP compared to SI and this was 
also true o f IgG-AFC specific for the non-vaccine related protein, tetanus toxoid.
5.6.1 SAC+CpG+PWM stimulation of PBMCs generates higher 
frequencies of IgG-AFC than is seen with SAC+IL-2.
The frequency of total IgG-AFC harvested from SCP cultures compared to SI cultures was 
always higher, but remained at a constant frequency during the time course. This was also the 
case for tetanus toxoid specific IgG-AFC. Although the frequency of diphtheria toxoid specific 
IgG-AFC increased following immunisation there was no significant difference between the SCP 
and SI systems, except that the peak days were different. Therefore, detection of IgG-AFC 
specific for a recently administered protein antigen did not appear to be influenced by the system 
of polyclonal, in vitro B cell stimulation used.
There did appear to be differences in the activation requirements o f polysaccharide specific B 
cells that became apparent following polyclonal stimulation with either SCP or SI. At baseline 
and also on days 15 and 28 following immunisation the in vitro stimulation of PBMCs with SCP 
induced higher IgG-AFC frequencies specific for pneumococcal capsular polysaccharides. This 
result suggests that the polysaccharide specific B cells, present in the peripheral blood prior to 
and 2-4 weeks after immunisation have different activation requirements than those seen 6/7 days 
after immunisation.
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In a previous study, PWM stimulation of PBMCs generated increased frequencies of anti- 
pneumococcal polysaccharide specific AFC from two weeks after immunisation (434), which 
supports the findings in this study with SAC+CpG+PWM, where the peak in antigen specific 
AFC was seen at day 15 verses day 7 with SAC+IL-2. Thus, T cell dependent polyclonal 
activation of B cells is more efficient from 15 days post immunisation, while T cell independent 
B cell stimulation works more efficiently during the first two weeks after immunisation. This 
suggests an intrinsic difference in the co-stimulatoiy requirements of the B cells present in 
peripheral blood during these two time periods. To further support this hypothesis, a study from 
1983 of in vitro antibody formation following pneumococcal polysaccharide vaccine in humans 
(109), demonstrated a suppressive effect of PWM (T cell dependent, polyclonal stimulation), on 
early antibody responses while the in vitro response of B cells to specific polysaccharide antigens 
remained intact during the first week after immunisation. In contrast at two weeks after 
immunisation the reverse was true with in vitro responses to specific polysaccharide antigens 
disappearing and polyclonal stimulation by PWM leading to polysaccharide specific antibody 
secretion in vitro.
The data in this chapter study, therefore, supports the role o f SAC+IL-2 as a T cell independent 
antigen, behaving in a manner similar to specific polysaccharide antigen. In vitro stimulation o f  
PBMCs with SAC+IL-2, promotes the differentiation of activated B cells into AFC during the 
first week after immunisation. This effect returns to baseline by day 15-28 when such B cells 
have migrated to bone marrow or returned to lymphoid tissues. The similar frequencies of IgG- 
AFC seen following SAC+CpG+PWM stimulation at this stage in the vaccine response suggests 
that PWM may be antagonising the combined effects of SAC and CpG. Thus only the same 
subset of B cells will differentiate into AFC. By day 15 this effect disappears and much higher 
AFC frequencies are induced by SAC+CpG+PWM than by SAC+IL-2. A similar suggestion was 
made following studies of human anti-sheep red blood cell (SRBC)-AFC induced by either SAC
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or PWM (461). Here it was shown that specific antigen (SRBC) was required to stimulate human 
B cells before a SAC or PWM induced response was observed.
The data from this study combined with these previous observations suggests a role for PWM 
activated T cells in the generation of AFC and that they may have a suppressive effect during the 
first week to 14 days after immunisation.
5.6.2 Stimulation of PBMCs with SAC+IL-2 induces memory B 
cell differentiation.
The literature suggests that the use o f SAC alone induces polyclonal activation of B cells in a T 
cell independent manner, and seems to exert its effect on B cells that have recently been exposed 
to their specific antigen (437, 438). There is conflicting evidence about whether SAC alone is 
able to induce full differentiation of B cells into IgG-AFC (437, 444, 462), or not and whether the 
addition of IL-2 provides an extra stimulus (438, 444,463, 464).
A two signal hypothesis was suggested where, signal 1 was provided via surface Ig cross-linking 
(437, 440, 444), and signal 2 was provided by concurrent exposure to T cell factors such as IL-2 
(438, 465). B cell receptor cross-linking by antigens such as SAC leads to up-regulation for the 
IL-2 receptor alpha (IL-2R-a) chain (or CD25), on the B cell surface enhancing proliferation of 
the activated B cell. It was later shown that IL-2 enhanced the expression of Bcl-XL (a survival 
signal related to Bel), in B cells activated by SAC mediated BCR cross-linking that enhanced the 
survival of these cells in culture (439, 443). However, the combination of SAC with IL-2 still 
only activated memory B cells to differentiate into IgG secreting cells (376, 377, 444).
The ELIspot data presented in this chapter suggests that SAC+IL-2 exerts an effect on different B 
cell subset to that seen with SAC+CpG+PWM because there is a peak in AFC formation at day 7 
verses day 15. In a study be Suzuki et al (444), it was observed that high density human B cells 
stimulated with SAC alone (in the absence of T cell factors) proliferated but did not differentiate 
in to antibody secreting cells, while low density B cells did differentiate into antibody secreting
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cells without the need for further in vitro proliferation. This may be what is occurring in the first 
week after immunisation.
5.6.3 In vitro co-stimulatory signals provided in vitro directly 
affect the AFC frequency detected in the ELISpot assay
In the week following immunisation antigen specific B cells were proliferating in vivo. They 
were then placed into the in vitro culture system using SAC+IL-2, which induced antigen 
activated B cells to differentiate into antibody secreting cells, the frequency of which peaked at 
days 6/7 after immunisation but had returned to baseline 1 month later.
In the case of SAC+CpG+PWM the scope o f B cell activation is enhanced by the provision of 
three separate signals for B cell activation. SAC provides the BCR signalling while PWM 
provides direct B cell stimulation but requires T cell help to do so (442, 466). Rapid build up of 
T cell factors in PWM stimulated cultures, which can then be used to provide help to the B cells 
was demonstrated in work by Dosch et al-1980 (437). It has also been shown that PWM activates 
the early growth response gene (EGR)-l in B cells, but that the effect of PWM is concentration 
dependent (467). Saiki et al (464), then showed that low concentrations o f PWM worked in 
synergy with SAC to provide optimal B cell activation and differentiation into antibody secreting 
cells.
There is only a small subset (<1%) of peripheral blood B cells that respond to PWM and it has 
previously been shown in humans that they are surface IgG positive but produce IgM antibody 
(468, 469). So the combination of SAC+PWM satisfies similar signalling requirements to those 
provided by SAC+IL-2. It would still appear that this system might only enhance the 
proliferation and differentiation of memory B cells however. So for the difference in the ELISpot 
data obtained from the two systems attention must turn to the effects of CpG-ODN-2006 on B 
cell activation.
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CpG-ODN-2006 activates both nai've and memory B cells in a polyclonal manner but the 
requirements for the activation of memory versus naive B cells differ (228, 470, 471). CpG-DNA 
activates B cells via interaction with TLR-9 which is expressed in intracellular vesicles (455). 
CpG-DNA may be taken up by pinocytosis or endocytosis and then co-localises with TLR-9 in 
endosomal vesicles (472), as TLR-9 is not expressed at the surface unlike TLR-4 and 10 (457). 
Cross-linking of the BCR leads to up-regulated expression of TLR-9 in naive B cells (228, 351, 
471). The interaction of CpG with TLR-9 leads to up-regulation of co-stimulatory molecules 
such as CD80, MHC class II and CD40 on the B cell surface and enhanced antigen presenting 
capabilities of the naive B cell (449), so that it is then able to recruit antigen specific T cell help 
which provides the signals for B cell differentiation into antibody secreting cells. What this 
means for the ELISpot outcome is that peripheral blood B cells isolated prior to and following 
immunisation will be activated by this combination of polyclonal stimulants irrespective o f how 
recently they were exposed to their specific antigen. The total IgG-AFC frequency was much 
higher because SCP is able to induce proliferation and differentiation of nai've, resting memory 
and activated memory B cells while SAC+IL-2 only induces differentiation of antigen activated 
memory B cells. During the week after immunisation SCP and SI induce equivalent numbers of 
IgG-AFC. This suggests that the ability of the B cells present in the circulation at this time to 
proliferate and differentiate into plasma cells is independent of in vitro T cell help or TLR-9 
signalling. Diphtheria specific B cells appear to proliferate and differentiate independently o f T 
cell and TLR-9 signalling throughout the study time course while it is restricted to days 6/7 for 
the polysaccharide specific B cells.
By day 15 to 28 the B cells present in the circulation appear to be a mixture o f cells that require 
signalling via TLR-9, BCR and T cell help for differentiation and those that require only 
SAC+IL-2.
Therefore the data in this chapter show that there does appear to be a distinct difference in the 
activation requirements of polysaccharide specific B cells depending on the time at which they
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are isolated following immunisation. In order to determine the effect o f the different polyclonal 
stimuli on PBMCs CFSE labelling was used to look for differences in proliferation lymphocytes 
stimulated with the individual or combined mitogens.
5.6.4 CFSE analysis of lymphocytes reveals differences in the 
effects of SAC, PWM, CpG on B cell proliferation.
Using PBMCs isolated from an un-immunised individual it was possible to look at the 
proliferation of the B cells in response to the polyclonal stimuli. Combining CpG with either 
PWM or SAC appeared to synergistically enhance lymphocyte proliferation compared to either 
PWM or SAC alone. Rush et al-2002 showed that B cells could be stimulated with CpG and T 
cell-B cell interaction via CD40-CD40L and Jiang et al-2001 showed that CpG could stimulate 
the up-regulation of CD40 on the B cell surface in the absence of BCR cross-linking. SAC and 
CpG augment each other since SAC interaction with the BCR leads to TLR-9 up-regulation and 
CpG-TLR-9 interaction lowers the activation threshold o f the B cells (455, 473). Thus, 
combining SAC+CpG+PWM resulted in the maximal proliferation of both CD27‘ and CD27+ B 
cells. This is important for the outcome of the ELISpot since differentiation, immunoglobulin 
secretion and class switching all rely on B cell division number (387, 416, 417, 451, 474). 
Secretion of antibody requires proliferating B cells to have undergone at least 4 divisions (the M5 
marker in figure 5.4), (387, 416, 417, 474).
The level o f proliferation correlated with the outcome of the ELISpot shown in figures 5.8 and 
5.9, in that cultures with the highest degree of proliferation resulted in more IgG-AFC detected in 
the ELISpot.
Individually SAC, PWM and CpG all induced lymphocyte proliferation in the CFSE analysis and 
IgG secretion in the ELISpot assay. However, combining all three dramatically increased the 
amount of proliferation and also antibody secretion (IgG and IgM, figure 5.8), both to the 
polysaccharide antigens and protein antigens compared to the individual stimulants. There was
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also a much higher frequency of IgM-AFC produced than IgG-AFC and this appeared to be fairly 
non-antigen specific.
Individually SAC (418, 462), CpG (470, 475) and PWM (468, 469) induce IgM production as 
well as IgG and the CFSE proliferation data in figure 5.6 shows this clearly. CpG elicited an 
IgM* B cell response from both naive and memory B cells, and a previous study (470), showed 
that the IgM antibody was secreted from nai've B cells while the IgG was from memory B cells in 
response to CpG. The difference in isotype may be related to rapidity of proliferation of CD27+ 
versus CD27' B cells since a higher divison number is required for IgG secretion then IgM (387, 
416,417, 474).
SAC and PWM only induced proliferation of memory B cells as already discussed. Combining 
CpG with SAC or PWM or both lead to progressive down regulation of IgM which suggests that 
class switching was occurring with this combination of antigens while CpG alone appeared to 
maintain IgMhl B cells.
Having established from these data that there were obvious differences in the types o f B cell 
being maintained in cultures using these different mitogens the next step was to determine 
whether it was possible to detect gross differences in B cell subset proliferation at different time 
points after immunisation.
5.6.5 Proliferation of lgD+ B cells is induced by in vitro 
stimulation with SCP and SI.
Only proliferation of IgD expressing B cells appeared to be altered following immunisation, with 
a rise in the percentage of proliferating IgD+ cells by day 7 in response to SCP stimulation 
peaking at day 15. This effect was delayed in the SAC+IL-2 system. Saiki et al-1982 showed 
that removal o f IgD+ B cells led to decreased IgM-AFC responses following SAC and PWM 
stimulation while the removal of IgM* B cells lead to a complete loss of the IgM-AFC response. 
The IgG-AFC response to SAC and PWM was unaffected by depletion of these cells.
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The limited cell sorting data shown in this chapter suggests that magnetic cell sorting to deplete 
IgD+ cells preferentially removes the IgDhl B cell population because, a) there were still some 
IgD* B cells in the IgD negative fraction and b) there was a reduction in the naive (CD27'IgM*) B 
cell proliferation in the IgD depleted fraction compared to the unseparated PBMCs. Also there 
was no difference in the proliferation of un-switched CD27*IgM* memory B cells (mostly IgD10), 
compared to the un-separated PBMCs or IgG depleted fractions (fig.5.15). This preferential 
removal of IgDhl nai’ve cells could explain why the SAC and PWM induced IgM response was 
reduced while the IgG response remained. Another murine study by Defrance et al-1992 showed 
that IgD* cells mediated the IgM response while IgG* B cells secreted IgG, IgM and IgA. Since 
the proliferation of IgD expressing cells was altered following immunisation, the overall 
percentage of IgD expressing B cells remaining in culture after 5 days stimulation was 
determined (figure 5.9).
IgDhl B cells are classically nai've (CD27'IgM*IgDhl) while IgD10 B cells are memory 
(CD27*IgM*IgD*) B cells (124, 320, 321). It is the CD27*IgM*IgDl0 B cells that are implicated 
in polysaccharide responses (252, 267, 321) and the data in this chapter show a relationship in the 
timing between IgD expressing B cell frequency and IgG-AFC frequency (fig.5.2. and 5.9 and 
5.10).
There is a peak in IgDhl B cells that coincides with the peak in IgG-AFC seen in the ELISpot 
assay following stimulation of PBMC with SAC+CpG+PWM, while the frequency o f IgD10 
(memory) B cells remained constant through out the time course. As has been discussed already, 
this combination of antigens stimulates memory and nai’ve B cells. There was a peak in IgD10 
(memory) B cell frequency in the SAC+IL-2 system that peaked on day 6 after immunisation. 
The peak in IgG-AFC was at day 7 in this system so frequency of memory B cells did not directly 
tie with IgG-AFC frequency in this system. However, one suggestion might be down regulation 
of IgD as the B cells class switched. This is hard to confirm without looking at the kinetics o f B 
cell subset proliferation. (See figure 5.11 and fig. 5.12).
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5.6.6 In vitro stimulation, but not immunisation, affected B cell 
subset proliferation kinetics
The memory B cell subsets (CD27*CD19*, IgG+, and IgD10,) all underwent more rapid 
proliferation than the nai've B cells, with the majority achieving >4 cell divisions. This was more 
apparent in the SCP system than in the SI system. Also apparent was the difference in the effects 
of the two systems on the proliferation of nai've B cells. Very few achieved the target >4 cell 
divisions in the SI system which is of no great surprise since we now know that this combination 
of antigens only induced proliferation of in vivo activated B cells. There was an accumulation of 
B cells from all subsets in the SCP system after 5 days of culture and all achieved a high 
percentage of B cells undergoing >4 cell divisions. The high percentage of B cells achieving >4 
cell divisions in the SCP system may be the reason for the higher frequencies of IgG-AFC 
detected in the ELISpot compared to that seen with SI stimulation. Experiments carried out in 
mice to look at in vitro induced class switching revealed results that are similar to those shown in 
figure 5.11. Hodgkin-1996 and Hasbold-1998 stimulated small, dense, resting murine B cells 
with plasma membranes from Th cells plus T cell supernatants. In both of these studies there was 
an observed increase in the expression of IgG after cultured B cells had undergone at least 2 cells 
divisions. The data reported here show that the SCP system, which is the T cell dependent system 
showed similar kinetics for the up-regulation of IgG while in the SI system this was delayed until 
5 cell divisions. This suggests a delay in class switching in the absence of direct T cell help in the 
SI system. The murine studies reported loss of IgD expression in cultured B cells after 2 cell 
divisions with complete loss by 4 cell divisions. In this study the SCP system maintained IgD 
expressing B cells while the SI system induced a loss o f IgDhi B cell expression by 4 cell 
divisions. Thus it seems that nai've B cells did not survive in culture with SAC+IL-2 alone. The 
kinetics o f IgM down regulation or class switching was similar in the murine studies and in the 
SCP system in this study with IgM loss following 6-7 cell divisions. In the SI system, IgM only 
B cell expression was negligible. There was no effect o f bleed day on the kinetics of proliferation
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in either system although individuals varied. Other murine studies (446, 476) have shown a 
relationship between division number and Ig germ line gene mRNA transcript expression and 
class switch recombination that is regulated by cytokines such as IL-4 (IgGl, IgE), IFNy (IgG2a), 
and TGFp (IgA), in conjuction with CD40L co-stimulation of the B cells.
In conclusion, these experiments show that PBMC stimulation with SAC+CpG+PWM versus 
SAC+IL-2 enables distinction to be made between recently activated B cells and resting B cells. 
There were also differing in vitro effects on the anti-polysaccharide response compared to the 
protein (anti-diphtheria) response.
SAC+CpG+PWM enables the detection o f polysaccharide specific IgG-AFC within the 
peripheral blood at anytime, while SAC+IL-2 is useful for defining the actual peak in frequency 
of vaccine induced IgG-AFC (fig.5.17).
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Figure 5.17 The kinetics of IgG-AFC frequency following immunisation with Pnc7.
During the first week after immunisation, there was no difference in the signalling requirements of B cells 
detected in either polyclonal stimulation system. At baseline (**)or from two weeks post vaccination 
onwards (**) there was a very low frequency of B cells that did not require T cell help or TLR-9 co­
stimulation for proliferation and differentiation during in vitro culture. Therefore the sensitivity o f the 
SAC+IL-2 system was reduced in un-immunised volunteers or at time points beyond seven days post 
immunisation. The CFSE proliferation studies show clear differences in the B cell subsets maintained 
during in vitro stimulation with SCP vs SI, with the predominant difference being maintenance of naive B 
cell responses in the SCP system and bystander stimulation of IgD+IgM+CD27+ B cells implicated in anti­
polysaccharide responses.
Since the SAC+CpG+PWM system enabled the detection of pre-existing polysaccharide specific B cells in 
the ELISpot prior to immunisation this system was chosen for to look at the effect of age on the response to 
pneumococcal conjugate vaccine to avoid biases that may be introduced by an ageing or immature immune 
system.
2 1 1
Chapter 6: The effect of age on the 
development of immune memory in 
response to Pnc7 immunisation.
6.1 Abstract
The effects of age on the B cell response to a primary dose of Pnc7 were compared between 
toddlers and young adults, and elderly versus young adults. Toddlers received two doses, 2 
months apart. Elderly adults were also grouped to receive a primary dose o f Pnc7 or 23PsV to 
compare the B cell response to a TD- versus TI-2 vaccine.
The primary Pnc7 dose in toddlers induced a rise in plasma cell frequency by day 7 and this was 
also seen following secondary immunisation, though there was no difference in magnitude. There 
was also a steady rise in memory B cell frequency seen following the primary and secondary 
immunisation (using SAC+CpG+PWM in vitro stimulation).
When compared to the response in young adults the plasma cell frequency was significantly 
lower in the toddlers than the adults and the difference was maintained after the second dose.
The total-IgG memory B cell frequency was significantly lower in the PBMCs from the toddlers 
at all time points than in the adult’s PBMCs. The memory response to the polysaccharide 
components of the vaccine was significantly lower in toddlers than in adults after primary 
immunisation. However, 7 days after a second dose of Pnc7 toddler memory cell frequencies 
equalled that of adults after a single Pnc7 dose.
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When young adults were compared to elderly adults following a primary dose o f conjugate 
vaccine there was no difference in the memory B cell response between the groups, even though 
at baseline, the frequencies of polysaccharide specific memory B cells were lower in the elderly. 
Comparison of toddlers, young adults and elderly adults at baseline revealed no difference in 
tetanus or diphtheria specific memory but highly significant differences in polysaccharide specific 
memory cell frequency (adults>elderly>toddlers).
The serum antibody response in toddlers was slower to mature than in young adults. After the 
primary dose of Pnc7 IgM still predominated in response to serotype 14 and 23F while serotype 4 
induced a similar response in both age groups (IgG, IgA and IgM). After the second toddler dose 
IgG was equivalent between the age groups for serotype 14 and 23F and higher for type 4 in the 
toddler group.
Characterising the response of elderly adult B cells to in vitro stimulation with SAC+CpG+PWM 
and SAC+IL-2 revealed a significantly lower rate of proliferation of IgM+IgD+ B cells in both 
culture systems at day 0 when compared to that seen for young adults. This was also evident at 
day 28 in the SCP system. The elderly adults also had decreased proliferation of CD27+ B cells at 
day 0 and day 28 than was observed for young adults.
When the SCP and SI systems where used to compare the response of elderly adults to a single 
dose of Pnc7 versus 23PsV the outcome of the response to immunisation was significantly 
different. In vitro stimulation with SCP revealed a significant increase in memory B cell 
frequency following conjugate immunisation but this was lost when SI was used to stimulate the 
B cells. In response to the polysaccharide vaccine, neither SCP nor SI showed a significant rise 
in memory cell frequency.
Conclusion
Toddlers require at least 2 doses of Pnc7 to generate memory responses equivalent to adults. 
Young and elderly adults are able to mount equivalent memory responses to Pnc7 immunisation 
even though there appears to be some difference in the quality o f the B cell subsets induced by in
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vitro stimulation of PBMCs. Immunisation of elderly adults with a conjugate vaccine did not 
induce significantly more memory B cell IgG-AFC when compared with the polysaccharide 
vaccine.
6.2 Introduction
The pneumococcal-CRM197 conjugate vaccine was introduced into the UK infant immunisation 
schedule in 2006 and involves three immunisations while un-immunized children who were in 
their second year of life were offered a single dose of the vaccine in a catch up campaign. 
However, at 12 months of age, a single dose of heptavalent conjugate vaccine may not be 
sufficient to induce protective antibody levels (a protective level has been variously described as 
>0.2mcg/ml, or 0.35pg/ml or l.Opg/ml) (174, 362) to all seven serotypes included in the current 
vaccine (477).
There is little information about the persistence of antibody after this single dose priming regime 
and subsequent memory responses. Infants immunized at 2, 4, and 6 months o f age generate IgG 
antibody responses to the Pnc7 vaccine (187), but the serum antibody wanes rapidly, with some 
serotype specific antibody levels falling below the protective threshold within a matter o f months 
(157, 477). Similarly, antibody wanes rapidly after immunisation with other glycoconjugate 
vaccines in early infancy such as Haemophilus influenzae type b (Hib) (478) and serogroup C 
Neisseria meningitidis glycoconjugate vaccine (MenC) (479), and there is a corresponding loss o f  
vaccine effectiveness (480, 481). This failure of persistence of IgG to capsular polysaccharides 
after immunisation in infancy may be overcome by the subsequent administration of a booster 
dose of a conjugate vaccine at 12-15 months of age, a marked rise in IgG antibody levels 
demonstrating that immunological memory had been induced by priming (179, 482, 483). 
Therefore, despite the below adequate levels of circulating antibody, most infants have developed 
immune memory in response to primary immunisations with glycoconjugate vaccines.
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By contrast, in young adults a single dose of Pnc7 vaccine is sufficient to induce protective levels 
of IgG to all seven serotypes included in the heptavalent vaccine, although the levels also wane 
somewhat (101, 159, 181, 410) and no further increase in response is demonstrated following re­
immunisation (267) possibly because polysaccharide antigens (conjugated as well as purified), 
appear to stimulate predominantly marginal zone B cell responses in this age group (123, 252, 
267,411).
The role of the different B cell subsets involved in response to the vaccine components becomes 
more of an issue when comparing different age groups. B I B  cells are present early in foetal 
development and are known to mediate innate immune responses rather than participate in 
vaccine specific responses. It is the roles of the FO and MZB cells that are more likely to differ 
between age groups. MZB cells accumulate with age and require a mature splenic marginal zone 
to function and can undergo rapid isotype switching to IgG+ during the first week after 
immunisation (307). It is the appearance of mature MZB that coincides with the ability o f  
individuals to respond to polysaccharide antigens. MZB have little or no role in infant immune 
responses before 12 months o f age since there are few and they are immature. This feature o f the 
infant immune system may be a contributing factor in the lack of long term maintenance o f serum 
IgG levels in infants (317). Responses to polysaccharides in this age group are mediated by FO B 
cells that require T cell help to respond to primary exposure to polysaccharide antigens. This is 
the reason for the lack of immune memory in infants immunised with plain polysaccharide. In 
young adults the role of FO B cells in the response to polysaccharide antigens is mitigated by the 
preferential localisation of complement opsonised polysaccharide to the splenic marginal zone. 
Fully mature marginal zone B cells bind the opsonised polysaccharide via surface bound 
complement receptor-BCR complex. This co-ligation of receptors leads to enhanced signalling to 
the B cell, negating the need for T cell co-stimulation to instigate B cell proliferation and 
differentiation. Infant MZB cells lack the expression of the complement receptor CD21, a surface
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receptor for C3d component that is known to mediate binding of opsonised pneumococcal 
polysaccharides by B cells and fully mature MZB cells have not been detected until two years of 
age. While increasingly mature MZB cells allow immune responses to polysaccharides to 
develop, conjugation o f the polysaccharide would not alter this response.
Immunisation against pneumcoccal disease in the elderly is recommended above the age of 65 
years in the UK and involves a single dose o f 23 valent purified polysaccharide vaccine (23PsV). 
While the conjugate vaccine is efficacious in infants, there is little evidence that it would be of  
benfit to replace the existing polysaccharide vaccine with the conjugate. At this extreme of the 
age range, MZB cells are present, but after the age of forty years old the frequency steadily 
declines (figure 1.4 of introduction from Y. Shi et al figure 6 (250) and S. Weller et al (252, 
253)).
The efficacy o f 23PsV is not good though and several studies have shown that in the long term 
the benfits of immunisation are poor (90, 484-486). However, in young healthy adults the 
efficacy of 23PsV is better, inducing protection against invasive disease and pneumonia (90, 
487). The benefit of pneumococcal conjugate vaccines over 23PsV in the elderly is unclear and 
had been little studied since 23PsV was thought to be efficacious (488). Also, Pnc7 only covers 
around 56%-66% of disease causing serotypes in the >65’s (64, 488). Responses in the infants 
and young adults are boosted by prior exposure to pneumococci through nasopharyngeal carriage, 
but carriage decreased with increasing age (489), so the potential augmentation of the response to 
the conjugate vaccine may be reduced in the elderly. Also it has been shown that natural anti- 
pneumococcal immunity in the elderly is mediated through antibody against the cell wall 
polysaccharide (CwPS), and Sankilampi et al (487) showed that 99% of >65’s had anti-CwPS 
IgG antibody in their serum, while capsule specific antibody decreased with age. The benfits o f a 
single dose of conjugate are un-certain and comparison with a single dose of 23PsV revealed 
similar responses in serum IgG (90), but multiple doses did improve the response. Powers et al
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(172) had previously shown that a single dose of a pentavalent-CRM conjugate had no benefit 
over the polysaccharide and that boosting a single dose of conjugate with a dose of 23PsV had no 
effect.
One reason for the poor efficacy of the new conjugates in the elderly may lie in impaired T cell 
immunity. Studies in mice have revealed that TD-responses are impaired in the elderly compared 
to young adults. The IgG response to the Tl-antigen (purified polysaccharide from serotype 14), 
was equivalent in the young and elderly adults while the IgG response to serotype- 14-PspA 
conjugate was impaired in the elderly (409). Before this study, Hwang et al (490), showed that 
blockade of CD40L by a monoclonal antibody reduced the murine IgG response to both the 
capsular polysaccharide and PspA components of the conjugate but the response to the CwPS 
remained intact. Both of these studies suggested that elderly T cell responses where impaired, 
affecting the B cell response to the polysaccharide conjugate but not the innate immune response 
to CwPS, and thus possibly accounting for high levels of antibody against CwPS in this age group 
while there remained concurrent low levels of capsule specific antibody (491). T cell responses 
in the elderly may be impaired through increased clonality of the memory population through 
chronic latent infections by viruses such as cytomegalovirus (CMV) and Epstein Barr virus 
(EBV) (492). A study of responses to influenza vaccine in the elderly revealed that CD4+T cell 
responses were similar in the elderly and young adults, but that the elderly failed to maintain a 
population of effector memory T cells (TEM) (140). The CD4+ TEM population is replenished from 
the central memory population (493), so increasing clonality of the central memory population 
with age would impair antigen specific T cell responses in the elderly. Lack of T cell responses 
to immunisation would account for the poor quality o f antibody produced in this age group with 
conjugates as a result of poor affinity (105) and germinal centre formation, decreased somatic 
mutation rates and defective generation of long lived plasma cells (409).
The age groups chosen in this study should reflect these differences in the frequencies o f B cell 
populations involved in the immune response to pneumococcal polysaccharides. There may also
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be differences in the in vitro B cell response between the age groups and between polysaccharide 
verses conjugate vaccines.
6.3 Aims
The aim of this study was to investigate the capsular polysaccharide specific B-cell response 
following immunisation of different age groups with Pnc7 conjugate vaccine. The groups chosen 
were 12-month old toddlers, young adults and elderly adults.
The second aim of this study was to determine the differences in the serum antibody response to 
the polysaccharide component of the Pnc7 immunisation in adults and toddlers. The final aim 
was to see whether the responding B cell subsets differed between the young and elderly adults 
and whether administration of a conjugate vaccine had any benefit over the polysaccharide 
vaccine in inducing B cell subset responses in the elderly.
6.4 Subjects and clinical procedures
Details of the subjects, vaccine and blood draw schedules for each of the groups are summarised 
in table 6.1. The number of samples obtained for each part of the three age group studies is 
shown in table 6.2 .
6.4.1 Toddler Study
Forty healthy toddlers, aged 12-months (see table 6.1), received 2 doses of heptavalent 
pneumococcal-CRMig? conjugate vaccine at a 2 month interval. A 5ml venous blood sample was 
collected (1ml into a clotted tube for serum and 4ml into a heparin tube for isolation o f PBMCs), 
prior to vaccination, on days 6 or 7 following the primary dose, on day 56 (prior to the second 
dose), and finally 6 or 7 days following the second immunisation.
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6.4.2 Young adult study
Twenty healthy adult volunteers with a mean age of 32 years, (see table 6.1), with no previous 
history of pneumococcal vaccination, received a primary dose of the heptavalent pneumococcal- 
CRM197 conjugate vaccine (Pnc7, Wyeth Vaccines, Pearl River, MA) by intra-muscular injection 
in the left deltoid. The 0.5ml dose of the vaccine contained a concentration of polysaccharides of  
2.0jig/ml for each of serotypes-4, 9V, 4 , 18C, 19F, 23F and 4pg/ml of 6B. Each polysaccharide is 
conjugated to CRMi97 (mutant diphtheria toxoid) and adsorbed on aluminium phosphate. A 20ml 
venous blood sample was collected (2ml into a clotted tube for serum and 18ml into a heparin 
tube for isolation of peripheral blood mononuclear cells (PBMCs), prior to vaccination and again 
on days 6, 7, 15 and 28 following immunisation.
Informed consent for both the young adult and toddler studies was obtained from the volunteers 
and the protocol was approved by the Oxfordshire Research Ethics Committee (OxREC number 
C02.005).
6.4.3 Elderly adult study
A group of 27 elderly adults with a mean age of 59 years (see table 6.1), were recruited as a 
subgroup of part of a larger study, and were randomised to receive a single dose o f Pnc7 
conjugate vaccine (n=T8) or 23PnV polysaccharide vaccine (n=9) with a 20ml heparinised blood 
sample obtained prior to and 28 days after immunisation. The samples were blinded with coded 
laboratory numbers so that the vaccine group was unknown until statistical analysis.
Informed consent was obtained from the volunteers and the study was approved by the 
Oxfordshire Research Ethics Committee (OxREC number OVG2006/01).
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6.5 Materials and methods
Serum IgG, IgA and IgM ELISAs, ex vivo and memory ELISpots were performed in the study 
samples from the young adults and toddlers and memory ELISpots alone were undertaken in the 
study of the elderly adults. B cell proliferation studies were carried out using CFSE analysis on 
PBMCs from both the elderly and young adults. The serum antibody levels for the elderly adult 
group were sent to the Health Protection Agency in Manchester for analysis by multiplex 
serotype analysis by Luminex™. Data for these serum samples was not available for this thesis 
and the method was different from the ELISA used to analyse the samples from the young adult 
and toddler groups.
The antibodies used in the ELISA and ELISpot assays are listed in chapter 2, section 2.1. The 
buffers used are listed in chapter 2, section 2.2. PBMCs were separated as described in chapter 2, 
section 2.4. Following the studies discussed in chapter 5 the stimulation of the PBMCs for the 
inter age comparison of IgG-AFC frequencies was carried out using SAC+CpG+PWM as 
described in chapter 2, section 2.6 and the cells harvested as in section 2.7.
The ELISPot assays for all age groups was undertaken as described in chapter 2, section 2.5 and 
the serum antibodies were measured as described in chapter 2, section 2 .10.
For the B cell proliferation studies in the young and elderly adults the PBMCs were labelled with 
CFSE as described in chapter 2, section 2.14. In vitro stimulation of the labelled PBMCs was 
carried out using SAC+IL-2 and SAC+CpG+PWM as described in chapter 2, section 2.6 and 
phenotyping of the cell surface markers as in section 2.8.
6.6 Statistics
Comparisons o f  cell frequencies, obtained by ELISpot, between individuals o f  the same 
age group at each time point were carried out using the Wilcoxon Signed Rank test.
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Comparisons o f  cell frequencies between the age groups were analysed using the Mann 
Whitney Test in SPSS v l2  and Graph pad Prism V4.0. Log transformation o f  ELISA 
data and calculation o f  geometric mean concentrations (GMC) was carried out using 
Microsoft Excel statistical functions. The comparisons within and between age groups 
were carried out using the paired and unpaired TTEST function respectively.
6.7 Results
6.7.1 The ex vivo IgG-AFC response in 12 month old toddlers 
given a primary (day 0) and secondary dose (day 56) of Pnc7.
For all of the antigens tested except diphtheria toxoid there was at least one individual who had 
some ex vivo AFC on day 0, prior to immunisation (Figure 6.1a-e). However, at days 6/7 
following immunisation there was a significant rise in frequency of AFC in response to diphtheria 
toxoid (dip) and serotypes-4, 14 and 23F (p=0.001, p=0.002, p=0.007, p=0.013 respectively), 
fig.6.1b-e. The overall AFC response 1 week after immunisation was high with between 74% 
(serotype 23F) and 97% (dip) of toddlers demonstrating an increased frequency of IgG-AFC 
specific for the vaccine antigens, and only 6.5% for tetanus toxoid. The strongest responses 
following the primary dose of Pnc7 were to diphtheria toxoid and serotype-4 (median spot 
number of 40 and 30 spots/106 PBMCs respectively, fig.lb-c), with >90% responding. Serotype- 
14 and 23F induced a lower response with a median number of 10 spots/106 PBMC (fig.6.1d-e). 
Following re-immunisation of the toddlers with a second dose of Pnc7 on day 56 after the first 
dose, there was no significant difference in the overall magnitude o f the secondary response over 
the primary response 1 week after immunisation (fig 6.1b-e). The number of responders to the 
polysaccharide component of the vaccine dropped by 24%, 14% and 7% for serotypes-4, 14 and 
23F respectively, following the second dose of vaccine. The ex vivo response to diphtheria toxoid
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was also lower than after the first dose, (p=0.002), with the number of responders decreasing 
from 93.5% to 80%.
6.7.2 The in vitro induced IgG-AFC response in 12 month old 
toddlers given a primary (day 0) and secondary dose (day 56) of 
Pnc7,
In vitro stimulation of B cells isolated from the peripheral blood allowed the detection of IgG- 
AFC derived from memory B cells. The memory B cell derived AFC frequency to tetanus toxoid 
(a non-vaccine related antigen), remained unaltered throughout the study time course (flg.6. If). 
Also 86% of the toddlers already had diphtheria specific memory cells while only 2.5-5.6% had 
any polysaccharide specific memory prior to immunisation. Seven days after the primary Pnc7 
immunisation of toddlers, there was a significant increase in the frequency of in vitro inducible, 
antigen specific AFC, derived from peripheral blood memory B-cells (fig. 6.1 g-j). The median 
number of spots at days 6/7 was 70, 10, 5 and 10 per 106 cultured PBMCs for diphtheria, 
serotype-4, 14 and 23F respectively. The percentage of toddlers with detectable serotype-14 and 
23F specific memory B-cells increased to almost 70%, and >90% for serotype-4 and diphtheria 
toxoid. By day 56 the frequency remained significantly elevated or even increased further above 
baseline levels (63-91% showing polysaccharide memory) (Fig 6.1g-j). On day 56, 
administration of the second Pnc7 dose, generated a further increase in inducible, polysaccharide 
specific AFC one week following immunisation (d62/63), with 86.9 to 95.6% being responders. 
However, the response to diphtheria toxoid appeared to reach a plateau following the primary 
dose and was not improved by re-immunisation (fig 6.1g). The resulting memory response 1 
week post secondary immunisation appeared to be most prominent to serotype-4, followed by 
23F and 14 (also represented by the percentage o f individuals responding to immunisation).
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6.7.3 The effect of age on the ex vivo IgG-AFC response to 
immunisation with Pnc7 vaccine
The frequency of spontaneously secreting, antigen specific AFC was significantly greater in 
adults than in the 12-month old infants as measured seven days after administration of a primary 
dose of Pnc7-CRM conjugate vaccine (fig 6.2a, p=<0.0001).
Administration of a second dose of conjugate vaccine did not alter this difference in frequency 
which remained highly significant for all antigens (diphtheria, serotype-4, 14 and 23F, fig 6.2b).
6.7.4 The effect of age on the memory B cell derived IgG-AFC 
response to immunisation with Pnc7 vaccine.
Total IgG secreting cells (fig. 6.3a), were enumerated as a control for the in vitro differentiation 
of AFC from peripheral blood memory B-cells. At all time points studied the median frequency 
of total IgG-secreting cells was significantly lower in infants than in young adults, although the 
median frequency was constant within each of these two groups (fig. 6.3a). The infants were re­
immunized 56 days after the first dose o f Pnc7 (black arrow,fig 6.3a). The frequency of total IgG 
secreting cells was unaltered one week after the second dose (d63 in fig 6.3a), compared to that at 
day 56 or day 0.
There remained a significant difference, between the age groups, in antigen specific memory B 
cell frequency specific for serotype-4, 14 and 23F (p=0.002, <0.001, 0.009 respectively, fig.6.3b), 
on day 7 after the primary dose of Pnc7. Adult responses were higher with the exception of  
diphtheria toxoid, in response to which the toddlers and young adults mounted equivalent 
responses (p=>0.05).
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Figure 6.1 The frequency of spontaneously secreting IgG-AFC and memory B-cell derived IgG-AFC.
PBMCs were isolated from the peripheral blood of 12 month old toddlers prior to a first dose (dO) and 
second dose (d56) of Pnc7 (shown by the red arrows). PBMCs were also obtained one week after each 
dose on days 6/7 or 62/63. At each time point the frequency of plasma cells were quantified in the ex vivo 
ELISpot (a-e). PBMCs from the same samples were also stimulated for 5 days with SAC+CpG+PWM to 
detect memory B cell derived IgG-AFC (f-j) after which they were harvested and allowed to secrete IgG 
onto well of an ELISPot plate. The ELISpot wells were coated with tet, dip, and serotypes 4, 14 and 23F 
polysaccharides. Data are expressed per 106 PBMCs or cultured PBMCs and the red line shows the median 
frequency.
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Figure 6.2 The frequency of spontaneously secreting IgG-AFC, isolated from the peripheral blood of 
adults (red triangles) and 12 month old toddlers (black circles) were compared.
PBMCs were isolated seven days after a primary or secondary dose of Pnc7 and seeded into antigen coated 
ELISPot wells for the detection of IgG-AFC specific for tet, dip, serotype 4, 14 and 23F. (a) Compares the 
IgG-AFC frequency after a primary dose in both adults and toddlers, (b) Compares the primary dose 
response in adults with that o f toddlers seven days after their second dose of Pnc7. The data are expressed 
as the IgG-AFC/106 PBMCs for each individual and the black bar shows the median frequency for each 
group. The inter age group comparison was analysed using the Mann Whitney U test for un-paired, non 
parametric data.
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PBMCs were isolated prior to (dO) and seven days after (d7) administration o f  a single dose o f  Pnc7 for 
adults and toddlers. Two months later (d56 post primary) the toddlers received a second dose o f  Pnc7. 
PBMCs were isolated before (d56) and seven days after the second dose (d63 post primary dose). The 
PBMCs at all time points were stimulated for 5 days in the presence o f  SAC+CpG+PW M , and then 
harvested and seeded on to antigen coated ELISpot w ells were they were left to secrete IgG overnight, a) 
ELISpot w ells coated with anti-human immunoglobulin were used as the control for IgG-AFC formation, 
b) Antigen specific IgG-AFC were detected in antigen coated w ells. The data are expressed per 106 
cultured PBMCs and the bars show the median frequency for each antigen.
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6.7.5 The time elapsed since immunisation and its effect on 
detection of memory B cell derived, antigen specific IgG-AFC in 
young adults and toddlers.
There was no significant difference in IgG-AFC frequency for serotype 4 and diphtheria or 
tetanus toxoid, between adults on day 28 and toddlers on day 56 (fig 6.4a). However, IgG-AFC 
specific for serotype-14 and 23F remained significantly lower in frequency in the toddlers than in 
adults at these time points.
Toddlers received a second dose of Pnc7 two months (d56,14 months of age) after the first dose. 
One week following the second dose of conjugate (day 63 of enrolement), blood was drawn and 
the memory B cell derived AFC frequency quantified (fig.6.4b). Toddlers attained levels o f  
memory B cells equivalent to those achieved by adults one week after a primary dose. This was 
the case for all antigens except serotype-14 (fig 6.4b), to which the response remained 
significantly lower in the toddlers (p=0.004). When the toddler response one week after the 
secondary response was compared with the young adult response on day 28 after the primary 
dose, no significant difference in memory B cell derived IgG-AFC frequency was found in 
response to any of the antigens tested (fig 6.4c).
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Figure 6.4 A comparison of memory B cell derived IgG-AFC from adults (red triangles) and 12- 
month old toddler (black circles) peripheral blood.
PBMCs were isolated and cultured for 5 days in the presence of SAC+CpG+PWM before enumeration of 
IgG-AFC by ELISpot specific for tet, dip, serotype 4, 14 and 23F polysaccharides. The frequency of 
memory B cell derived IgG-AFC were compared between adults (d28) and toddlers (d56) to see the longer 
term effect o f a single dose of Pnc7 on frequency (a). The frequency of IgG-AFC 7 days after a single 
Pnc7 dose in adults was compared with that from toddlers seven days after a second dose (b). The adult 
memory B cell derived IgG-AFC frequency at d28 post primary was compared to that seen in toddlers 
seven days after the second dose of Pnc7 (d63) (c). Data are expressed as the IgG-AFC/10(> cultured 
PBMCs and the bars show the median frequencies in adults and infants.
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6.7.6 The effect of increasing age on response of peripheral 
blood memory B cells to Pnc7 immunisation of young and 
elderly adults.
Prior to immunisation there was a significant difference in the frequency of the total IgG-AFC 
between the age groups (fig.6.5a). The pre-existing memory B cell derived IgG-AFC frequency in 
the elderly adults was significantly lower with a median spot number of 25,938/106 cultured 
PBMCs, (0.026%), versus 105,000/106 cultured PBMCs, (0.105%), in the younger age group. 
Following immunisation the difference in frequency remained but was not significant (p=0.303) 
with a median spot count of 54,165/106 cultured PBMCs, (0.054%), in the elderly and 
121,675/106 cultured PBMCs, (0.12%), in the younger age group.
Twenty-eight days after immunisation with a single dose of the pneumococcal conjugate vaccine, 
both young and elderly adults achieved equivalent frequencies o f antigen specific IgG-AFC 
(fig.6.5b-c). The median frequencies of spots/106 cultured PBMCs in the elderly vs young adults 
were as follows: Tetanus (47 vs 53, p=0.848) and diphtheria (21 vs 106, p=180); Serotype-4 (20 
vs 40.8, p=0.108), serotype-14 (21.5 vs 25.3, p=0.980), serotype-23F (20 vs 33, p=0.533).
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Figure 6.5 A comparison of the frequency of memory B cell derived IgG-AFC isolated from the 
peripheral of young adults (red, n=10) and elderly adults (blue, n=18) prior to (dO) and 28 days (d28) 
after immunisation with a single dose of Pnc7 vaccine.
The PBMCs were cultured for 5 days with SAC+CpG+PWM. After 5 days the cells were harvested and 
seeded onto antigen coated ELISpot plates specific for total-IgG (fig.6.5a), tetanus (tet) and diphtheria (dip) 
toxoid (fig.6.5b), and pneumococcal capsular polysaccharides from serotypes 4, 14 and 23F (fig.6.5c). The 
data represent the number of IgG-AFC/106 cultured PBMCs with the median frequency represented by the 
black bar.
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6.7.7 The effect of age on the baseline frequency of memory B 
cell derived IgG-AFC in toddlers, young and elderly adults.
There was a slight difference in the frequency of tetanus specific memory IgG-AFC between the 
elderly adults and infants (Fig.6.6a, p=0.022) but no difference in diphtheria toxoid specific IgG- 
AFC frequency (21 vs. 5 vs 14 spots/106 cultured PBMCs respectively), as is seen in fig. 6.6b).
In the case of pneumococcal serotype specific baseline memory cell frequency (fig.6.6c-d), young 
adults demonstrated the highest frequencies o f polysaccharide specific memory IgG-AFC. The 
median IgG-AFC frequency was significantly higher in the young adult group than in the elderly 
or toddler group (fig.6.6 c-d). The elderly group demonstrated significantly higher baseline B cell 
memory to the polysaccharide antigens than that found in the toddlers (fig 6.6.c-d).
For the capsular polysaccharides o f serotypes-4, 14 and 23F the median spot counts for the young 
adults vs elderly adults vs infants were (26 vs. 2 vs 0), (23 vs. 4 vs. 0) and (27 vs. 2 vs. 0 IgG- 
AFC/106 cultured PBMCs respectively).
6.7.8 The toddler anti-polysaccharide antibody responses 
following primary and secondary doses of Pnc7.
A single dose of Pnc7 in 12-month old toddlers led to a significant increase in IgG, IgA and IgM 
anti-polysaccharide antibodies to each of the three serotypes tested at one week after 
immunisation (table 6.3).
By day 56 (2 months post immunisation), IgG levels had increased significantly above the d6/7 
levels for serotypes-4 and 14 (GMC 2.16pg/ml and 2.78pg/ml respectively). A single dose o f  
Pnc7 did not appear to generate such a good response to 23F during the same time period, 
although the IgG level o f 0.33pg/ml was above one postulated threshold for protection 
(>0.2pg/ml). IgA and IgM levels over the same 2 month period declined from day 6/7 levels, 
though remained above baseline.
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A second dose o f Pnc7 induced a significant increase in IgG, IgA and IgM to all three serotypes, 
with serotype-14 generating the greatest IgG response and 23F the least. The serotype 14 and 
23F response consisted almost equally of IgG and IgM.
The primary dose induced more polysaccharide specific IgM than IgG to all three serotypes. By 
day 56 this was still the case for serotype-14 and 23F, while the serotype-4 response appeared to 
have switched to a more IgG mediated response. Following the second dose of Pnc7 IgG 
appeared to be the main mediator o f the response to serotypes 4, 14 and 23F.
6.7.9 Serum anti-pneumococcal antibody in adults and toddlers.
Prior to immunisation the adults had significantly more serum IgG antibody to serotypes-4, 14 
and 23F than that detected in the 12-month old toddlers (fig 6.7a). This was also the case for 
serum IgA (fig 6.7b). However, serum IgM was only significantly different for serotypes-4 and 
14 (fig.6.7c). Similar levels of IgM against serotype 23F were present in both age groups 
(p=0.590, fig. 6.7c). The percentage contributions of IgG, IgA and IgM were noticeably different 
between adults and toddlers prior to immunisation (dO, fig.6.9). IgM dominated the serum 
antibody response to all three serotypes in toddlers, while IgG contributed 43%-66% of the total 
antibody response in adults to each serotype.
At seven days following the primary dose o f Pnc7 the GMC of serotype 4 specific IgG was the 
same in both age groups (p=0.544, fig.6.8a), while there was still significantly higher 
concentrations of IgG to serotype-14 and 23F in adults (p=<0.0001 in both cases fig.6.8a). There 
were no significant differences in the levels of IgA generated by the first dose o f Pnc7 in the two 
age groups to any of the serotypes (fig.6.8b, p=0.149, 0.124 and 0.056 respectively for serotypes 
4, 14 and 23F). This was also true for IgM induced by serotype-4 (fig.6.8c, p=0.199). There was
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a trend for higher IgM to serotype-14 in toddlers and a significantly higher level of 23F IgM 
compared to adults (p=0.088 and p=0.026 respectively, see figure 6.8c).
The percentage contribution of each isotype to the overall response 1 week after a single dose was 
similar for serotype-4 in both adults and infants (fig 6.9). IgM still dominated the infant antibody 
response to serotypes-14 and 23F.
The adults B cell and antibody response at d28 was compared with the toddler response on day 56 
after a primary dose of Pnc7 to look at the development of the IgG response. Ethical constraints 
did not allow for an extra toddler sample at day 28. By day 56 in toddlers verses day 28 in adults 
the contribution of IgG in the response to all three serotypes had increased further in toddlers (fig 
6.9). The response to serotype 4 was now the same as that in adults while the responses to 
serotypes 14 and 23F were still mediated more by IgM than in adults (fig 6.9).
Following the second dose of Pnc7 in toddlers there were no significant differences in the GMC 
of serum IgG when compared with adults one week after their first dose (fig.6.8d). This was also 
true for serum IgA levels to each of the capsular polysaccharides (fig.6.8e).
The IgM response to the second dose in infants induced significantly higher levels of IgM for 
serotypes 14 and 23F in the infants (fig 6.8f), while for serotype 4 the levels were equivalent. 
Comparing the contributions o f IgG, IgM and IgA to the serum antibody response in toddlers at 1 
week after a secondary dose o f conjugate with adults 1 week after a primary dose revealed the 
following. The response to serotype 4 in infants was now 79% IgG vs 37% in adults (fig.6.9). 
The percentages of the isotypes induced by serotype 14 were now the same in adults and infants. 
Serotype 23F was still inducing a split IgG/IgM response in infants (49%/45% respectively), 
while in adults after one dose the response of IgG/IgM was 68%/24% respectively (fig 6.9).
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Figure 6.6 The effect of age on the baseline (dO) frequency of protein and polysaccharide specific 
memory B cell derived IgG-AFC.
PBMCs were isolated from the peripheral blood of young adults (red, n=10), elderly adults (blue, n=18) 
and toddlers (black, n=36). The PBMCs were then cultured for 5 days in the presence of 
SAC+CpG+PWM. Following stimulation the cells were harvested and the frequency o f antigen specific 
IgG-AFC determined by ELISPOT specific for tetanus (a), diphtheria (b) serotype 4 (c), 14 (d), and 23F 
(e). The data are expressed as the number of IgG-AFC/106 cultured PBMCs and the bar shows the median 
value for each of the studies.
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quantified by ELISA. The data represent the antibody concentration in pg/ml and the bar shows the GMC.
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6.7.10 The effect of age on peripheral blood B cell subset 
proliferation following immunisation with a single dose of Pnc7
The percentage of CD19+CD27+ (memory), CD19+CD27‘ (naive), IgM+IgD+, IgM+only and 
IgG+only B cells undergoing >4 cell divisions was quantified, as previously described. This 
proliferative capacity was then compared between the young and elderly adults for each of the in 
vitro culture conditions (SAC+CpG+PWM versus SAC+IL-2 (figure 6.10). In all cases the 
percentage of B cells undergoing >4 cell divisions in the SAC+IL-2 system was lower than in the 
SAC+CpG+PWM system.
Immunisation with a single dose of Pnc7 vaccine affected the percentage o f B cells undergoing 
>4 cell divisons if  the B cells expressed an IgM+IgD+ or IgG+ phenotype. Prior to immunisation 
the percentage of IgM+IgD+ B cells that had undergone >4 cell divisions was lower in the elderly 
than in the young adult population following stimulation with SCP or SI. After immunisation this 
difference in proliferation remained for IgM+IgD+ B cells stimulated with SCP but there was no 
difference in the age groups when SI was used. Also following immunisation there were fewer 
IgG+ B cell that had achieved >4 cell divisions in the elderly group following SI stimulation of 
PBMCs.
There were significantly fewer memory B cells (CD19+CD27+) proliferating in response to in 
vitro stimulation with SAC+CpG+PWM (blue) at day 0 and at day 28 in the elderly (hatched 
blue), compared to the young adults (plain blue) in fig.6.10a. However there was no effect o f age 
on memory B cell proliferation when PBMCs were stimulated with SAC+IL-2 (red). There was 
no effect of age or in vitro stimulant on the proliferation of the naive (CD19+CD27') B cell subset 
at day 0 or day 28 (fig.6.10b).
The IgM+IgD+ B cell subset (fig.6.10c), showed poorer proliferative capacity in the elderly than 
in the young adults. This was seen in response to both SCP and SI at day 0 but following 
immunisation the poorer proliferative response was only observed in response to in vitro 
stimulation with SCP. IgM+only B cells proliferated equally as well in both age groups and in
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both culture systems while IgG+ B cells proliferated less well in the SI system in the elderly than 
in the young adults.
Therefore there appears to be an age related deficiency in the capacity o f CD19+CD27+ and 
IgM+IgD+ B cells to proliferate in response to in vitro stimulation with SCP.
6.7.11 The effect of age and the type of vaccine on polyclonal, 
in vitro stimulation of peripheral blood B cell subsets.
The data in figure 6.11 shows the B cell proliferation of PBMCs obtained on day 0 and day 28 
following immunisation with the heptavalent conjugate vaccine (Pnc7) or 23-valent 
polysaccharide vaccine (23PsV). As already seen in figure 6.10, the percentage of proliferating B 
cells was significantly reduced in the SI culture system compared to the SCP system. Aside from 
this difference there was no effect of vaccine or age on the in vitro proliferative response o f the B 
cell subsets.
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Figure 6.10 The effect of age on the in vitro stimulation of peripheral blood B cells from young and 
elderly adults.
PBMCs were isolated prior to and 28 days after a single dose of Pnc7 was given to a group of young adults 
(n=10, plain columns) and elderly adults (n=18, hatched columns). The PBMCs were then labelled with 
CFSE and stimulated for 5 days with SAC+CpG+PWM (SCP, blue) or SAC+IL-2 (SI, red). After 5 days 
the cells were harvested and labelled for the surface expression of: a) CD19+CD27+, b) CD19fCD27\ c) 
IgM*IgD+, d) IgM+ only and e) IgG+ only. The data represent the mean percentage of cells within the 
specified populations that had achieved >4 cell divisions during the 5 day culture. The bars are the 
standard error. (*p=<0.05, ***p=<0.01).
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Figure 6.11 The effect of in vitro stimulation on the proliferation of B cells isolated from the 
peripheral blood of elderly adults.
PBMCs were isolated on day 0 (dO, plain columns) and 28 days after (d28, hatched columns) 
immunisation. The elderly adults were given either a single dose of Pnc7 (n=l 8, dark blue, red) or 23PnV 
(n=9, pale blue, pink). The PBMCs were labelled with CFSE and cultured for 5 days with SCP (dark and 
pale blue) or SI (red and pink). After 5 days the cells were harvested and labelled for the surface 
expression of: a) CD19+CD27+, b) CD19+CD27\ c) IgM+IgD+, d) IgM+ only and e) IgG+ only. The data 
represent the mean percentage of cells within the specified populations that had achieved >4 cell divisions 
during the 5 day culture. The bars are the standard error.
244
6.7.12 In vitro stimulation of PBMCs with SCP or SI and the 
detection of IgG-AFC at baseline.
Prior to immunisation (dO), there was no significant difference in the frequency of total-IgG-AFC 
in the conjugate vaccine group (fig.6.12a), while in the polysaccharide vaccine group stimulation 
with SCP induce a significantly higher number of total-IgG-AFC. There was a slightly higher 
frequency of tetanus toxoid specific IgG-AFC following in vitro culture with SCP than with SI in 
the conjugate group while no difference was seen in the polysaccharide group (fig.6.12b). In 
vitro stimulation with SCP and SI made no significant difference to the detection of diphtheria 
toxoid specific IgG-AFC at dO in either vaccine group (fig.6.12c).
The frequency of serotype 4, 14 and 23F specific IgG-AFC at dO was slightly higher following in 
vitro stimulation of PBMCs with SCP (p=<0.05) in the conjugate group (fig.6.12d). The only 
such difference seen in the polysaccharide vaccine group was in IgG-AFC specific for serotype 
23F which were of higher frequency following in vitro stimulation with SCP, p=<0.05 (fig.6.12e).
6.7.13 In vitro stimulation of PBMCs with SCP or SI and the 
detection of IgG-AFC 28 days after immunisation.
Twenty-eight days after immunisation with the pneumcoccal conjugate vaccine (Pnc7) the 
frequency of IgG-AFC specific for total-IgG (fig.6.12a), tetanus toxoid (fig.6.12b), diphtheria 
toxoid (fig.6.12c) and serotypes 4, 14 and 23F (fig.6.12d. p=<0.001) was significantly higher 
following in vitro stimulation o f PBMCs with SCP than with SI.
There was no difference to the frequency of diphtheria toxoid specific IgG-AFC (fig.6.12c) 
between SCP and SI stimulation following immunisation with the polysaccharide vaccine. 
However, the frequency of IgG-AFC specific for total-IgG and tetanus toxoid (fig.6.12a-b) was 
significantly higher following stimulation of PBMCs with SCP than with SI and this was also true 
for serotype 14 polysaccharide (fig.6.12e).
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Immunisation with the pneumococcal conjugate vaccine followed by in vitro stimulation o f day 
28 PBMCs with SAC+CpG+PWM was the only combination that revealed a significant rise in 
the frequency of memory B cell derived IgG-AFC specific for diphtheria toxoid and serotypes 4, 
14 and 23F (fig. 6.12c-d). SAC+IL-2 stimulation did not reveal any increase in memory cell 
frequency from dO to d28. Following immunisation with the polysaccharide vaccine in vitro 
stimulation with SCP or SI failed to show any rise in memory B Cell derived IgG-AFC frequency. 
PBMC stimulation with SAC+CpG+PWM revealed a significant higher frequency of IgG-AFC 
induced by the conjugate vaccine rather than the polysaccharide vaccine, except for serotype 14. 
With SAC+IL-2 the only difference between the vaccines was a higher diphtheria response in the 
conjugate group (fig.6.12c).
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Figure 6.12 The effect of in vitro stimulation on the IgG-AFC response to a pneumococcal conjugate 
or plain polysaccharide vaccine in the elderly.
PBMCs were isolated from elderly adults prior to (dO) and again 28 after (d28) a single dose o f conjugate 
vaccine (n=18), or polysaccharide vaccine (n=9). The PBMCs were cultured for 5 days with 
SAC+CpG+PWM (blue) or SAC+IL-2 (red). After 5 days the cells were harvested and seeded into antigen 
specific ELISpot plates coated with; (a) anti-Ig, (b) tetanus toxoid, (c) diphtheria toxoid, (d+e) serotype 4, 
14 and 23F polysaccharides. The boxes represent the 25th and 75th percentile, the whiskers show the 
outliers and the black dots are the extreme outliers. The central bar is the median IgG-AFC/106 cultured 
PBMCs. Wilcoxon paired, non-parametric test was used to compare IgG-AFC frequencies between the 
SCP and SI cultures within the conjugate vaccine group and the polysaccharide group (*). The same 
analysis was used to compare dO with d28 within each vaccine group (*). Comparison of IgG-AFC 
frequency between vaccine groups was made using the Mann Whitney U test for un-paired, non-parametric 
data(*). (*p=<0.05. **p=<0.01, ***p=<0.001).
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6.8 Discussion
This comparative study of the immune response to a pneumococcal conjugate vaccine in young 
and elderly adults and 12 month old toddlers and has shown that individuals o f all ages responded 
well to a single dose of the conjugate vaccine. Young and elderly adults responded equally well 
while the response in the toddlers was significantly lower. This observation was true with respect 
to spontaneously secreting IgG-AFC and in vitro stimulated IgG-AFC as well as with serum IgG, 
IgA and IgM antibody levels in young adults compared to toddlers. The difference in the 
magnitude of the B cell response may explain the short duration of antibody production and 
vaccine effectiveness at a population level following conjugate vaccine immunisation, in early 
childhood.
The second dose of vaccine in infants, 2 months after the primary dose, brought their memory B 
cell derived AFC and antibody responses to a similar level as seen in the young adults after one 
dose, suggesting that more doses of glycoconjugate vaccines may be needed in the 12 month old 
age group to generate the same size B cell memory pool as seen in young adults.
The responding B cells may be important both for sustained antibody responses and the rapid rise 
in antibody following re-exposure to the antigen during invasive disease. Indeed, booster doses of  
conjugate vaccines are now widely used at 12-15 months of age and induce memory responses 
with rapid elevations in antibody concentration. These rises in antibody concentration are seen 
even when pre-booster antibody levels are negligible.
However, despite generating similar levels of memory B cell derived AFC, a second dose o f Pnc7 
did not alter the difference in magnitude of the ex vivo plasma cell response in the infants which 
remained significantly lower than that seen in the adults one week after a single dose. Although 
not proven, it is likely that protection against rapidly invasive micro-organisms is provided by 
maintenance of protective serum antibody levels and by the rapidity o f antibody rise following 
infection or booster dose of vaccine, (provided by the ex vivo plasma cell response). Also it is
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possible that the ex vivo plasma cell response is generated from a different B-cell subset, such as 
the marginal zone B cells that are fewer in number in infants compared to older age groups(253). 
In order to better understand the mechanism involved in maintaining protective immunity further 
studies of the B cell phenotypes induced by immunisation and differences, between the B-cells 
isolated from infants and from young adults needs to be undertaken (252, 318, 494).
6.8.1 Baseline immunity prior to a single dose of Pnc7
Prior to immunisation, all of the young adults in the study had IgG-producing memory B-cells 
specific for the capsular polysaccharides o f serotypes 4, 14 and 23F, while in the elderly and the 
12 month old toddlers there was little if  any detectable memory B cell derived IgG-AFC 
following in vitro stimulation of the B cells with SAC+CpG+PWM. Similarly, the young adults 
had pre-existing serum IgG above protective levels for all three serotypes tested while IgG was 
almost undetectable in the toddlers. On the other hand the levels of IgM were quite similar in the 
toddlers and young adults (table 6.2 and figure 6.7c).
The absence of naturally acquired, polysaccharide specific B-cell memory in infants prior to 
immunisation with Pnc7 may relate to differences in nasopharyngeal carriage of pneumococci or 
immaturity of the immune system when compared with adults. However, most infants at 12 
months of age are known to have experienced some nasopharyngeal carriage of pneumococci 
(59). In one Oxford study vaccine type pneumococci were isolated from 38% of infants and 
vaccine related types (6A, 19A, 23A), were isolated from 13% of infants at 12 months o f age 
(397), and other studies have shown that more than 80% of children will have carried 
pneumococci by 1 year of age, with even higher rates in resource poor settings (79, 495, 496). 
These observations suggest that exposure of infants to pneumococcal carriage in the first year of 
life may fail to induce IgG memory in these infants.
It may be that repeated exposure to the capsular antigens is the necessary requirement to maintain 
detectable levels of IgG memory and that this immunological experience is only possible over
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some years (497). Interestingly, in this study adults had higher levels of naturally acquired IgG to 
the more commonly carried serotype-14 and 23F than to the rarely detected serotype-4 (58, 59, 
92).
The elderly adults may also have lower rates of pneumococcal carriage than the younger adults 
since carriage decreases with age (489). There is also a decrease in serotype specific IgG with 
age, although 99% of >65’s had antibody against the cross-reactive cell wall polysaccharide (Cw- 
PS) despite lacking capsule specific antibody (491).
Infants had higher levels of IgM to these serotypes, but no IgG. It is known that MZB are 
involved in the response to polysaccharide antigens and that MZB predominantly secrete IgM 
with some IgG (144, 252, 266, 267, 315, 323). Therefore it is possible that natural anti­
polysaccharide immunity in young infants may be mediated entirely by this B-cell subset while 
there may be a greater role for follicular B cells in adults, and that other factors are required to 
induce a switch from IgM to IgG/A as is seen in the adults, such as cytokines secreted by by­
stander activated T cells (452).
Several other factors must be considered that may contribute to the apparent immaturity o f the 
infant immune response and the inability to maintain an IgG-memory response. Infants may lack 
appropriate bone marrow niches for long-lived plasma cell survival (142, 350, 356), and their 
splenic structure lacks some adult functional features such as CD27+ B-cells(317) and CD21 
expression(494, 498, 499). The low frequency of CD27+ memory B-cells may just be a result of  
fewer antigen exposures than in adults. Low expression of CD21 (complement receptor CR2) 
reduces the strength of signaling via BCR-co-receptor complex(316, 499, 500), therefore antigen 
presentation in toddlers is less efficient than in adults. IgM is a potent activator o f complement, 
but a lack of surface CD21 on infant MZB might reduce the strength of the signal received by the 
B-cell.
There was no significant difference between the age groups in frequency of baseline diphtheria 
specific IgG-AFC. More than 80% of 1 year old toddlers had pre-existing memory to the protein
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antigens, presumably induced by 3 dose priming with routine immunisations during the first 6 
months o f life but we do not have data to provide a comparison with a conjugate vaccine vaccine 
given in the same schedule.
6.8.2 Response to the first dose of Pnc7 conjugate
It was proposed that the cells detected ex vivo, in the first week following immunisation (figure 
6.2) are likely to be short-lived mature plasma cells generated from extra-follicular differentiation 
of B-cell subsets such as MZB and B1 B-cells (127, 263, 398). These mature, antigen specific 
plasma cells disappear from peripheral blood by day 9 (432, 501), but non-secreting plasmablasts 
may still be circulating (385).
In vitro stimulation of the PBMCs taken at these same time points drives proliferation and 
differentiation of plasmablasts and memory B cells in vitro to AFC which can be detected in the 
Elispot assay (350). It is presumed that the memory response, which involves germinal centre 
formation, consists of newly generated memory cells and precursors of long-lived plasma cells 
(263, 354). By day 15, the cells present in the in vitro stimulation Elispot may include; i) mature 
plasma cells that probably do not survive the culture system after 5 days and so are unlikely to 
contribute to the frequency of AFC detected in the Elispot, ii) memory B-cells mobilized, 
following immunisation, to re-circulate via the peripheral blood and back to the lymphoid tissues 
and, iii) long-lived plasma cell pre-cursors migrating to the bone marrow where they take up 
residence for long-term antibody production (145, 338, 350, 357). Either o f these latter two 
subsets may contribute to the measured Elispot response. Migration to the bone marrow or re­
circulation back to the lymphoid tissues could explain the subsequent waning of the memory 
response by day 28 back to baseline levels. Long-lived plasma cells are thought to be the 
dominant cell type in circulation following antigen challenge at day 14-15 following 
immunisation, but are not necessarily mature enough to secrete antibody without stimulation until
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they reach bone marrow niches (263). This could explain why, if present, such cells disappear 
from the ex vivo assay and remain elevated in the in vitro assay.
6.8.3 B cell subset proliferation following a single dose of Pnc7
Because of the uncertainty of the B cell type being detected in the in vitro stimulated ELISpot a 
comparison was made of the B cell proliferation in the young with that in elderly adults. PBMCs 
were cultured with SAC+CpG+PWM or SAC+IL-2 for 5 days. The in vitro proliferation of the 
different B cell subsets, before and after immunisation, was then compared. The elderly adults 
demonstrated less proliferation of memory (CD27+CD19+) B cells when PBMCs were cultured 
with SCP. This was the same before and after immunisation. There was no such difference when 
PBMCs were stimulated with SAC+IL-2. There were also fewer IgM+IgD+ B cells at the same 
time point under the same conditions. However there was also reduced proliferation of this 
subset in the SI group prior to immunisation. There were no differences in the the proliferation of 
IgM only B cells , while IgG only B cells differed at day 28 after stimulation with SAC+IL-2. 
This difference in IgG only B cells suggests that there were fewer recently activated memory B 
cells in the circulation in the elderly than in the young adults (fig.6.10e). There was no difference 
following stimulation with SCP which shows that T cell help and CpG-TLR-9 were required in 
both age groups for maximum IgG+ B cell proliferation. Together, these results suggest that there 
is a deficit in the CD27+IgM+IgD+ B cell population in the elderly population. This is the 
phenotype of MZB that are implicated as having a role in anti-polysaccharide responses and also 
decrease in frequency with age (figure 1.4 in the introduction) (123,251, 252, 273, 301, 502). 
Another reason for age related differences in response to the conjugate may result from 
nasopharyngeal carriage of pneumococci, as demonstrated in mouse models (240, 497). 
Continuing exposure to pneumococcus over many years may enhance the adult immune response 
to Pnc7(497) while in 12-month old infants this effect is minimal in comparison, resulting in the 
lower AFC frequencies observed and an antibody response dominated by IgM production. This is
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also the case in the elderly who had higher baseline memory cell frequency than the toddlers but 
less than the young adults. This link between the effectiveness of conjugate immunisation and 
carriage was recently suggested in the UK where lack of exposure to Hib carriage led to increased 
disease among children given a priming course of immunisations but no booster (478).
The difference in magnitude of the response to the polysaccharide antigens between adults and 
toddlers does not correspond to differences in the response to the carrier protein. Indeed there 
was no significant difference in the frequency of diphtheria IgG-AFC (diphtheria toxoid contains 
B cell epitopes included in the CRM197 carrier protein of Pnc7) between the age groups, prior to 
or following immunisation.
The anti-polysaccharide antibody response to a single dose of conjugate vaccine was dominated 
by IgM, despite the recruitment of T-cell help by the carrier protein in the toddler group. It has 
previously been shown that antibody to carrier proteins can inhibit anti-capsular responses 
following glycoconjugate immunisation where there is a high anti-carrier protein antibody 
concentration present(149, 190, 503, 504). This is either because serum antibody mops up 
antigen, targeting it for macrophage engulfment before a B-cell is activated or that epitope 
specific antibody blocks B-cell binding. The diphtheria memory-AFC response in the infants 
appeared to reach a plateau, and the ex vivo plasma cell response showed a slight decrease on re­
immunisation. These results may imply that antibody concentration was involved in regulation of 
the magnitude of the response.
6.8.4 Response to the second Pnc7 dose in infants
Re-immunisation of the infants at 14-months of age failed to generate increased frequencies of ex 
vivo AFC, when compared with the response 2 months earlier. It has previously been shown that 
re-immunisation of adults with polysaccharide does not boost the frequency of spontaneously
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secreting plasma cells (108), but the effect of a second immunisation with a conjugate vaccine is 
not certain and is age and serotype dependent in adults, working less well in the elderly than in 
young adults(410). It has also been suggested that the secondary response comprises mainly 
plasmablasts, leaving the lymphoid tissues and migrating to the bone marrow. These cells are not 
necessarily secreting antibody until they receive further stimulation. Therefore they may also be 
detected in the in vitro system rather than the ex vivo system. In contrast the memory response 
generated by the first dose of conjugate was boosted following the second immunisation in the 
infants.
All of these data suggest that the short-lived plasma cell response is highly regulated and is 
probably involved in controlling infection before the memory response (which includes long- 
lived plasma cells secreting high affinity IgG antibody), can develop. It also suggests that the ex 
vivo and memory responses to immunisation may be independent (505). In relation to this, it has 
previously been shown that infants immunised with a MenC conjugate at 4 years of age, who 
generated no serum bactericidal response were still capable of generating a high magnitude 
response when boosted 2 years later. These data suggest that memory was laid down even in the 
absence of an ex vivo (in this case serum antibody), response, providing further evidence of 
separate mechanisms for memory versus short-term antibody responses (506).
The frequency of diphtheria specific memory IgG-AFC appeared to reach a plateau following the 
first dose of conjugate, declining slightly during the two month period before re-immunisation 
and was not boosted following re-immunisation. An inverse relationship has been described 
between AFC frequency and number of does of diphtheria vaccine in adults (372). The 
frequencies of diphtheria specific memory cells in toddlers in the study reported in this chapter 
were equivalent to those seen in adults after a single dose of Pnc7. Obunkhanych et al 2006 (507) 
have recently demonstrated that serum IgG levels can regulate the responsiveness of B-cells to 
antigen stimulation. Infants already have immunity to diphtheria and it may be that pre-existing,
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high affinity antibody limits the magnitude of the diphtheria response following Pnc7 re­
immunisation (508, 509).
6.8.5 The antibody response following the first and second dose 
of Pnc7
The antibody concentration following the first dose of Pnc7 was similar to that seen in 2-5 year 
old children primed by 23PsV (178). Therefore, any pre-existing carrier specific memory or pre­
exposure to nasopharyngeal carriage did not seem to affect the response to the first dose given at 
12 months of age. Even so the data for infants (table 6.2), did show evidence of class switching 
in the week following the second dose of conjugate. This was particularly evident for serotype-4 
that was predominantly IgG mediated by day 63, while the responses to serotypes-14 and 23F 
were still a mixture of IgG and IgM. This suggests that even though the first dose of vaccine 
induced antibody that was mainly of IgM, memory was being generated to enable a more rapid 
appearance of IgG following the second dose. The changing antibody isotypes are more clearly 
visualised in figure 6.11.
The mixed IgG/IgM response may be of benefit in protection against IPD. IgM protects against 
blood borne infections and the higher IgM levels induced following immunisation with serotypes- 
14 and 23F may reflect their reduced invasiveness compared to serotype-4 that induced little IgM 
in response to immunisation.
In this study differences were found in the IgA concentration generated in response to the 
different serotypes. IgA is transported to mucosal surfaces where it can block adhesion of bacteria 
to epithelial cells. It also functions as an opsonin, leading to uptake and killing of bacteria by 
macrophages and neutrophils via the FcaR and Fca/pR(41). Serotype-23F induced the lowest IgA 
response. This might mean it is more able to adhere to mucosal surfaces and be less rapidly 
cleared from the nasopharynx than serotypes-14 and 4. In previous studies on carriage and 
disease, serotype-23 F has been the most frequently detected nasopharyngeal isolate (58, 59, 92).
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Of the three serotypes investigated serotype-4 induced the best IgA response following the 
primary immunisation. This serotype is almost never detected in carriage studies, a characteristic 
that may be related to its propensity to stimulate IgA production (58, 59, 92). The infrequency of 
serotype-4 carriage may explain the similarity in response to this serotype between adults and 
infants.
6.8.6 The difference in B cell subsets recruited following 
immunisation with Pnc7 or 23PnV in the elderly.
Since there was such difference in the baseline memory responses between the age groups, but 
only for the capsular polysaccharides, it became important to determine whether there were age 
related differences in B cell subset proliferation and differentiation into IgG-AFC. The data in 
figure 6.6 show that prior to immunisation there was a significantly lower frequency of IgG-AFC 
in elderly adult peripheral blood than was seen in the peripheral blood of young adults. 
Following immunisation with a single dose of Pnc7 similar frequencies of polysaccharide and 
protein specific IgG-AFC were induced in both young and elderly adults (figure 6.5b+c). These 
data were obtained using in vitro stimulation of peripheral blood with SAC+CpG+PWM. By 
using this system of stimulation it has also been possible to show that the elderly volunteers 
responded more robustly to the conjugate vaccine in comparison to the polysaccharide vaccine 
but this was not as apparent from the B cell proliferation studies.
This study has shown is that SAC+CpG+PWM stimulation of PBMCs significantly enhanced the 
IgG-AFC frequency detected in response to the conjugate and polysaccharide vaccine and it was 
significantly higher than after SAC+IL-2 stimulation. The IgG-AFC response following Pnc7 
immunisation increased significantly above baseline to the polysaccharide and carrier protein 
antigens when PBMCs were pre stimulated with SAC+CpG+PWM. Pre-stimulation of PBMCs 
with SAC+IL-2 showed no difference in IgG-AFC following immunisation with the conjugate or
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polysaccharide vaccine, infact the responses were identical, to both vaccines in the SAC+IL-2 
group, except for the diphtheria response.
Thus the difference between these two systems has now been shown to result in different 
outcomes of response to immunisation with Pnc7 versus 23PsV, with above baseline IgG-AFC 
frequencies detectable at day 28 in the SCP system but not in the SI system (fig.6.12c-d).
As discussed in chapter 5, SAC+IL-2 stimulates B cell proliferation by a similar mechanism to 
specific antigen. It therefore only induces AFC formation from in vivo activated B cells. These 
cells have returned to pre-immunisation frequencies by day 28 so it looks as though no response 
was made when this combination of stimulants is used. SAC+CpG+PWM is able to activate 
resting B cells and also long-lived plasma cells that are not mature enough to secrete antibody 
without stimulation until they reach bone marrow niches (263). These cells are present for up to 
6 weeks post immunisation and so the response remains elevated above baseline by day 28. 
Diphtheria specific B cells are able to recruit antigen specific T cell help and therefore there is 
still an elevated response in the SAC+IL-2 group. The polysaccharide vaccine only induces short 
term B cell activation in vivo with no germinal centre formation, and therefore neither culture 
system is able to induce AFC formation as the cells required are not in circulation at day 28. It 
might be expected that the conjugate and polysaccharide vaccine responses would be similar at 
day 7 with either culture system and would be elevated above baseline since the B cells at that 
time point would be antigen activated and it was shown in chapter 5 that SCP and SI induced 
identical responses on days 6-7 post immunisation.
6.9 Conclusion
This study of the immune response to immunisation with pneumococcal vaccines has shown that 
the human toddlers require at least two priming doses of Pnc7 to achieve memory B cell and IgG 
antibody levels of similar magnitude as those found in young adults. Despite improved memory
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B cell and serum IgG concentrations following a second dose of Pnc7, the generation of ex vivo 
plasma cell remained significantly reduced in toddlers compared to young adults. The peak in 
spontaneously secreting AFC may well be derived from MZB responses that occur early in the 
immune response and explains why they are lower in infants. It would be interesting to make the 
comparison in the elderly if the frequency of MZB is falling with old age. It would be expected 
that young adults would have the highest ex vivo response, followed by the elderly and then the 
toddlers depending on the extremes of the age differences.
Lower frequencies of polysaccharide-responsive B-cell subpopulations, absence of the splenic 
marginal zone, impaired maintenance of long-lived plasma cells, and age-dependent differences 
in polysaccharide immune responsiveness may all contribute to poor maintenance of immune 
responses to glycoconjugate vaccines in infants and explain the higher risk from invasive disease 
in this age group.
It is important to choose the time point and in vitro antigen stimulation carefully otherwise it may 
appear that individuals are not responding to immunisation or that there was no memory response. 
Continued exposure through nasopharyngeal carriage may help maintain adult memory B cell 
levels and booster doses of vaccine might overcome the lack of sustained immunity in young 
children by increasing the size of the memory B cell pool to young adult levels.
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Chapter 7: Discussion.
7.1 Summary
Invasive pneumococcal disease remains one of the most significant global causes of childhood 
mortality, particularly in children under 2 years of age(37, 62-65). The heptavalent 
pneumococcal polysaccharide-CRM197 conjugate vaccine (Pnc7) has been introduced to target 
the major disease causing serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) in childhood in many 
countries.
The effectiveness of this vaccine has been clearly demonstrated in the United States, where there 
has been a 93% reduction in IPD in the <5 year olds and also a reduction in carriage(152, 157, 
158, 510-512). Herd immunity resulting from a decrease in nasopharyngeal carriage in young 
children (who are the reservoir for transmission) impacted on the rates of adult disease, reducing 
the rates of vaccine type disease cases(152,157, 158, 510-512).
All age groups immunised so far in various studies (table 1.2) have demonstrated good serum IgG 
antibody responses as well as effective boosting with plain polysaccharide after priming with 
Pnc7. The purpose of this thesis was to determine whether it was possible to detect pre-existing 
immune memory B cells in the peripheral blood of toddlers and adults and whether the magnitude 
of the B cell response to Pnc7 immunisation reflected the subsequent antibody response.
The major findings of this thesis have been to define the kinetics of the plasma cell and memory 
B cell responses in adults following immunisation with Pnc7 (Chapter 4). This enabled inter age 
group comparisons of the B cell responses to be made between 12 month old toddlers, young 
adults and the elderly (Chapter 6). The phenotypes of B cell populations in peripheral blood,
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following immunisation, were identified. The effect of depleting some of the B cell subsets on 
IgG-AFC frequency was also determined. The effect of in vitro stimulation of peripheral blood B 
cells was also investigated along with how this altered the perceived memory B cell response 
following immunisation (Chapter 5).
7.2 Antigen specific plasma cells and memory B cells 
were detected in toddler peripheral blood.
The first aim of this thesis was to determine whether it was possible to detect polysaccharide 
specific B cells in peripheral blood of toddlers.
A single dose of Pnc7 induced a significant rise in dip specific IgG plasma cell frequency by days 
9-11 post immunisation with a similar, but none significant trend in response to the 
polysaccharides of serotype 4 and 14 but not serotype 23F. Isolation of cells at day 7 (Chapter 6, 
fig 6.1) showed that the toddlers made a robust plasma cell response to all antigens tested. 
Previous toddler studies (age <24 months), have quantified the ex vivo plasma cell response 7 
days after immunisation, finding elevated frequencies of polysaccharide specific IgG-AFC 
specific for the vaccine given, a quadravalent-mixed carrier protein glycoconjugate (113). 
However, the IgG plasma cell frequency resembled that seen in adults after polysaccharide 
immunisation rather than after a dose of conjugate vaccine (113, 383). A second dose of Pnc7 
(Chapter 6, fig 6.1), did not alter the magnitude of the plasma cell response.
There is no previous data about memory B cell responses in toddlers. However, it has been 
possible to show elevation of memory B cell frequency in toddlers in the studies included in this 
thesis. In this thesis the toddlers immunised with a single dose of Pnc7 demonstrated serotype 
specific IgG antibody responses similar to those obtained from another UK study in toddlers 
following a single dose of a 9-valent pneumococcal conjugate vaccine (Pnc9) (175). Our study
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found serum IgG specific for serotype 4 and 14 and 23F rose significantly after a single dose 
when measured on day 7 and day 56 of the response. In a Finish study the serum IgG data 
obtained from 3 month old infants after a single dose of Pnc7 also showed elevated levels of IgG 
in response to serotypes 4 and 14 but not to 23F (187).
The generation of memory B cells in our toddler studies appeared to mirror the antibody response 
although the rise in memory cell frequency was serotype dependent and might be evidence of 
serotype specific priming (513). Priming by immunisation with conjugate vaccine in the toddler 
age group has been demonstrated for meningococcal group C (MenC) vaccines. Toddlers 
receiving a booster immunisation of MenC polysaccharide vaccine mounted rapid rises in serum 
bactericidal (SBA) activity if previously primed with MenC conjugate vaccine at 12-15 months of 
age (514). Priming of toddlers with one or two doses of Pnc9 at 12 months of age also primed for 
enhanced responses to the polysaccharide vaccine one year later (175). This is also seen in the 
response to the second dose of conjugate in toddlers in this thesis. Antibody responses switched 
from IgM to IgG and memory B cell frequencies continued to increase. Despite the similarity 
between the memory B cell and antibody responses to Pnc7 however, there were no significant 
correlations between cell frequency and IgG concentration. A recent review by Amanna et al 
(515) described a similar lack of correlation between serum IgG and circulating memory B cell 
frequency in response to tetanus and diphtheria toxoid immunisation and Epstein Bar virus and 
varicella-zoster virus infection (515).
7.3 Adult peripheral blood B cell responses peaked on 
days 6-7 after a single or booster dose of Pnc7.
Immunisation of adults with a booster dose of Pnc7 induced a peak in frequency of antigen 
specific plasma cells on days 6-7, as reported in other studies (Chapter 4 fig.4.1)(107, 108, 111, 
516, 517). The response varied in magnitude between individuals and for the different antigens
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(Chapter 4 fig.4.2). In vitro stimulation of PBMCs with SAC+IL-2 allowed detection of memory 
B cells which also peaked in frequency at day 7 following immunisation (Chapter 4. fig.4.4). The 
magnitude and timing of the polysaccharide specific B cell response in adults was the same 
following a single or booster dose of Pnc7 (Chapter 4 fig. 10 and 4.11). A similar observation was 
seen following repeat immunisation with 23 valent polysaccharide vaccine in adults (108). 
Carrier protein (diphtheria) specific plasma cell and memory B cell frequency was higher after a 
single dose than after the booster dose. A previous study of diphtheria toxoid specific memory B 
cell responses in adult humans, using SAC+IL-2 for in vitro stimulation, showed an inverse 
relationship between number of doses and memory cell frequency (372), thus supporting the 
results from these studies.
7.4 Phenotype of the plasma cells responding to Pnc7 
immunisation of adults.
It is known that MZB and FO B cells fulfil distinct roles in response to infection or immunisation. 
The phenotype of these cells is well documented but the effect of glycoconjugate immunisation 
on these B cell subsets is not thoroughly understood. Part of this thesis involved identification of 
vaccine specific plasma and memory B cells in the peripheral blood.
Initially PBMCs depleted of or enriched for B cells expressing CD27, CD38 or CD20 were used 
to identify the plasma cells in the peripheral blood following immunisation, and positive ELISpot 
results were obtained from the CD27+, CD38+ and CD20+/' fractions. This data suggested the 
presence of two populations of spontaneously secreting plasma cells in peripheral blood on day 7 
after immunisation. They were CD20+CD27+CD38+ and CD20'CD27+CD38+ with low level 
surface immunoglobulin expression compared to the cell fractions with no AFC as determined by 
ELISpot (432). A previous report noted that parenteral immunisation induced a heterogeneous 
population of circulating plasma cells containing both terminally differentiated B cells (CD 19/20'
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) and intermediate plasmablasts (CD19/20+) (518). However, it has also been reported in humans 
that plasma cells can survive in secondary lymphoid tissues as well as the bone marrow and that 
in the secondary tissues the plasma cells maintain CD20 expression (519). This was also shown 
in a previous study of human plasma cells by Medina et al (262) where CD20 expression was 
highest in the secondary lymphoid tissues (tonsil) reduced in the blood and absent in the bone 
marrow. Therefore the CD20- and CD20+ populations maybe plasma cell populations with 
homing potential for either the bone marrow (CD20-) or secondary lymphoid tissues (CD20+).
Furthermore, when PBMCs were sorted on the basis of CD5 expression (following depletion of T 
cells), immunoglobulin secretion occurred in both the CD5+ and CD5' populations. CD5 is the 
surface marker used to identify the B la cell population. The frequency of these B cells declines 
with increasing age dropping from 54% of B cells at 12 months of age to 25% at 24-48 years of 
age (520). CD5 is also lost during the transition from plasmablast to plasmocyte, further 
establishing the heterogeneity of the circulating AFC population on day 7 after Pnc7 
immunisation in adults (518).
CD5 based sorting also revealed that different phenotypes of plasma cell were involved in 
responses to protein versus polysaccharide antigens. Most of the diphtheria toxoid specific AFC 
were in the CD5' population while the B cell response to serotype 4 polysaccharide was mediated 
mainly by the CD5+ population. Earlier studies have looked at responses to tetanus and cholera 
toxin B-subunit vaccines, where CD5 expression was detected on a small proportion of the IgG 
and IgA secreting cells, for example; 28% of tetanus toxoid specific IgG AFC express CD5 (518). 
Together these data suggest that protein specific plasma cells arise from a different B cell subset 
compared to the polysaccharide specific cells.
In order to re-circulate to the lymph node or bone marrow, plasma cells need to be responsive to 
locally secreted chemokines. Sorting based on the expression of the chemokine receptors
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CXCR4 and CXCR5 revealed that vaccine antigen specific antibody secretion occurred in both 
the CXCR4+/‘ and CXCR5+/' fractions. The literature suggests that the expression of chemokine 
receptors controls the migration of plasmablasts from the medullary cords or B cell follicles to 
maturation and survival niches in the bone marrow, secondary lymphoid tissues, the mucosa and 
locations of inflammatory response for the sole purpose of maintaining antibody production (257, 
262, 348, 521, 522). The expression of CXCR5 mediates homing to the secondary lymphoid 
tissues in response to CXCL13 (338, 521) while CXCR4 is upregulated on activated CD27+ B 
cells and is highly expressed on extrafollicular plasmablasts (348, 522). In murine CXCR4 k/o 
models there was build up of plasma cells in the secondary lymphoid tissues and blood with no 
migration to the bone marrow. Therefore it was suggested CXCR4 mediates plasmablast homing 
to the bone marrow in response to bone marrow stromal cell production of CXCL12 (262, 348, 
521). Medina et al (262) demonstrated increased CXCR4 expression on human plasmablasts in 
the bone marrow compared to the blood with even lower expression in the tonsils, suggesting a 
migration pattern from lymph node, through blood to the bone marrow. Thus the data from the 
study described in this thesis suggests that Pnc7 immunisation induced a plasmablast population 
that is split between homing to the bone marrow and returning the secondary lymphoid tissues. It 
is also possible that the phenotypic differences in these plasma cells at day 7 post booster 
immunisation represent newly generated, vaccine specific plasmablasts versus mature, non 
antigen specific plasma cells dislodged from bone marrow niches (257, 347). Such that CD20+, 
CD5+ and CXCR5+, CXCR4+ may indicate newly formed plasmablasts migrating to secondary 
lymphoid tissues or bone marrow to mature into CD20‘, CD5‘, CXCR5', CXCR4' mature plasma 
cells.
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7.5 In vitro stimulation of peripheral blood B cells 
affected the frequency of memory B cell derived IgG- 
AFC.
Enumeration of antigen specific, peripheral blood memory B cells requires in vitro stimulation of 
PBMCs to induce differentiation in to AFC that are then detected by ELISpot. In this thesis 
PBMCs were stimulated for 5 days using SAC+IL-2 (SI) or SAC+CpG+PWM (SCP). The 
outcome of the culture systems was quantified by antigen specific ELISpot for the detection of 
IgG-AFC and B cell proliferation by CFSE dye dilution, at each time point after immunisation 
(day 0, 6, 7, 15 and 28).
The frequency of total-IgG-AFC detected by ELISpot was significantly higher using SCP than 
with SI. This is expected as all B cell subsets are stimulated by SCP, while SI only stimulates 
memory B cells. This difference between the two systems was also true for tetanus toxoid 
specific IgG-AFC frequency. The proliferation of B cells in vitro supported the ELISpot findings 
in that SI induced proliferation of memory B cells with CD27+IgG+ or CD27+IgD1° phenotypes 
but not with IgDhl or CD27+IgM+. While SCP induced proliferation of both memory (CD27+IgD1° 
and CD27+IgG+) and naive (CD27'IgDhi) B cell populations (Chapter 5, figures 5.9-5.12). 
Therefore it seems that SI induced proliferation and differentiation of switched memory B cells 
(CD27+IgG+ or CD27+IgD1°) and SCP induce proliferation and differentiation of switched 
memory B cells and also IgM memory B cells (CD27+IgM+) and naive B cells accounting for the 
higher IgG-AFC frequency in the ELISpot.
SCP stimulation induced more polysaccharide specific IgG-AFC formation in bloods taken at 
baseline, but in the first seven days after immunisation there was no difference in polysaccharide 
specific IgG-AFC frequency between SCP and SI stimulation.
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From day 15 onwards SCP induced differentiation of more B cells into IgG-AFC than SI did. So 
it may be that different signals are required for B cell activation depending on the timing after 
immunisation. The difference in signals required by B cells in the first week compared to the 
third and fourth weeks after immunisation may reflect differentiation status of the B cells.
Previous studies have shown that in vitro stimulation of B cells with SAC only induces 
proliferation and differentiation of B cells recently activated by specific antigen in vivo (437, 
438), while IL-2 enhances SAC stimulation of memory B cells (212, 213, 438, 444, 463, 464). 
The addition of CpG-ODN to the polyclonal stimuli provided appropriate signals for the 
proliferation of both memory and naive B cells, although proliferation rate of the naive B cells 
was slower (fig.5.12).
Memory B cells constitutively express the intracellular TLR9 (the CpG receptor), while it is low 
or absent in naive B cells (228, 351). BCR ligation is needed to signal the upregulation of TLR9 
expression by naive B cells, therefore the proliferative response is delayed compared to memory 
B cells (228, 470-472).
A recent murine study of TLR9 ligation saw induced differentiation of B1 and MZB cells, but not 
FO B cells, into mature plasma cells, promoting high amounts of IgM and IgG secretion (299). 
This might account for the accumulation of marginal zone like (IgMlgD10) B cells in the SCP 
culture while mainly IgG+ memory cells accumulated in the SI culture.
Following in vitro stimulation of PBMCs in this study with SCP there was a greater accumulation 
of CD27+ B cells than with SI, particularly IgG+ and IgM+IgD+ with most of the IgD+ cells being 
IgD10.
The secretion of immunoglobulin in culture or as quantified by AFC activity in ELISpots is 
linked to the cell division number in vitro and >4 cell divisions is required following in vitro 
stimulation of PBMCs (387, 416, 417,446, 451).
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The number of memory B cells undergoing >4 cell divisions in the SI system was lower than in 
the SCP system. However, when the two in vitro systems were compared the observed difference 
in proliferation did not affect the IgG-AFC frequency detected in the ELISpot of cells isolated in 
the first 2 weeks after immunisation (Chapter 5, fig.5.2). This suggests that antigen specific B 
cells isolated in the first week after immunisation are already partially differentiated when they 
enter the in vitro systems, thus requiring minimum stimulation to differentiate into plasma cells. 
It has been suggested that resting FO B cells require BCR cross-linking plus cognate T cell help 
(299, 315) for full activation and differentiation, but cells recently activated in vivo may only 
require SAC+IL-2 for continued differentiation (437, 438).
From day 15 onwards the SCP system induced greater proliferation and differentiation of B cells 
into IgG-AFC. Thus the combination of SAC (BCR cross-linking) plus CpG (TLR9) along with 
PWM (B cell and T cell stimulation) was thought to be optimal to induce proliferation and 
differentiation of all B cells into IgG secreting cells.
7.6 The responsiveness of B cells to in vitro 
stimulation was altered by increasing age.
The proliferation of memory B cells following in vitro stimulation was lower in PBMCs obtained 
from elderly adults than young adults. In the SCP system the difference between the age groups 
was significant but not for SI. There was no difference in the proliferation of naive B cells 
between the age groups.
The age associated difference in memory B cell proliferation may be accounted for by increased 
sensitivity of CD27+ B cells to apoptosis in elderly adults compared to young adults while CD27' 
B cells do not alter as dramatically (523). However this report was conducted in adults older than 
70 years of age. The age difference between the groups in this thesis (mean age of 33 years vs 59 
years old) might not be extreme enough to see such a difference in susceptibility of peripheral B
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cells to death. As well as increased susceptibility to apoptosis, the percentage of CD27+ B cells 
declines in the elderly (524). There is also a decline in the numbers of B1 cells with age (520).
In the elderly there were significantly fewer IgM+IgD+ B cells proliferating to SI stimulation at 
baseline (day 0) than was observed for the young adults, but this difference disappeared following 
a single dose of Pnc7. Since there was no observed age effect on naive B cell proliferation these 
data suggest that it is the CD27+IgM+IgD+ B cells that are affected in the elderly population. 
Previous investigators have shown that CD27+IgM+IgD+ B cells decrease with age (250, 251, 
253) and that in vivo proliferation of peripheral B cells (525) and in vitro differentiation into 
plasma cells declines with age (250).
These studies support the proliferation data obtained in this thesis where proliferation of 
IgM+IgD+ B cells in response to SCP stimulation was impaired in the elderly adults compared to 
the young adults with fewer IgM+IgD+ B cells achieving >4 cell divisions in the elderly group. 
However, age did not affect the proliferation of IgM+IgD+ B cells in response to SI stimulation of 
PBMCs 28 days after Pnc7 immunisation. This result implies that the B cells stimulated by SI are 
not affected by increasing age.
This result is also supported by the ELISpot data from this thesis comparing the pneumococcal 
polysaccharide vaccine with Pnc7. Only the conjugated polysaccharides induced a significant 
rise in memory B cell frequency as detected by cultured ELISpot. A similar rise in frequency was 
not seen in response to plain polysaccharides. MZB and B1 cells mediate natural immunity to 
pneumococcal polysaccharides, so a reduced capacity of these cells to proliferate in vitro may 
explain the lower frequencies of polysaccharide specific memory B cell derived IgG-AFC at 
baseline in the elderly compared to young adults.
Since IgM+IgD+ B cells decrease in frequency with age (123, 250, 251, 253, 520) elderly adult 
humoral responses may be preferentially mediated by follicular B cells that require T cell help 
(526). The tetanus and diphtheria IgG-AFC responses obtained in this thesis where similar in
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both young and elderly adults and these responses are mediated by FO B cells (123, 305, 502). 
So this data confirms that the FO B cell pathway is functional in both age groups while the B1 
and MZB cells providing natural immunity and extrafollicular responses are reduced or impaired 
in the elderly group. The increasing susceptibility of the elderly to disease may result from 
impaired B1 and MZB cells mediated immunity that ordinarily provides rapid production of short 
lived plasma cells secreting IgM and IgG (123, 315, 527).
7.7 Age affects the frequency and generation of 
memory B cells in the peripheral blood
Age affects the response to immunisation, but the factors which contribute to the responses are 
complex. This thesis examined the effect of age on pre-existing memory B cell frequency with 
specificity for the vaccine polysaccharide and carrier protein antigens. Also determined were the 
differences in generation of IgG memory following immunisation with Pnc7 in the different age 
groups.
First, there was no significant difference in the frequency of carrier protein (diphtheria toxoid) 
specific memory B cells prior to immunisation, but a slightly lower frequency in tetanus toxoid 
specific memory B cells in the toddler group compared to the young adults on day 7 after 
immunisation. Therefore age did not affect the thymus dependent response to the protein 
antigens such as diphtheria toxoid.
Pre-immunisation frequencies of polysaccharide specific memory B cells were lowest in toddlers 
followed by the elderly adults and young adults had the highest frequencies. Interestingly this 
age related frequency of polysaccharide specific memory B cells follows what is known about the 
frequencies of MZB with age (see figure 1.12) (251). MZB are low in frequency and are not fully 
mature in the <2 year olds, they peak in young adults and wane again after 35yrs of age. B1 cells 
also wane with age and but are present in the <2 year olds. B1 cells secrete IgM and the ELISA
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data for the toddler group show strong IgM responses to all three serotypes tested and there is also 
evidence of class switching to IgG 56 days after immunisation. The young adults also make good 
IgM responses to the Pnc7 vaccine pneumococcal serotypes but proportionately more IgG as is 
seen in secondary responses.
B la cells secrete natural IgM antibody specific for phosphorylcholine (PCh) residues of 
pneumococcal CwPS without the need for prior exposure (268). This natural antibody is essential 
in controlling early infection by blood borne pathogens (268, 286, 426). B la cells are absent in 
CD 19 knock-out mice and xid mice leaving them vulnerable to overwhelming infection by 
pneumococci (268, 286, 426). However, B ib cells secrete IgM and some IgG3 in response to the 
capsular polysaccharides of pneumococci, but require previous exposure to the organism in order 
to respond. Therefore toddlers may be more susceptible to invasive pneumococcal disease as a 
result of immature MZB and lack of prior nasopharyngeal carriage to prime the immune system 
for more rapid IgM and IgG responses by the B ib cells (56, 397, 497, 528). Murine colonisation 
models have shown that previous colonisation with pneumococcal serotypes enhances IgG 
responses to subsequent immunisation with pneumococcal conjugate vaccines (497, 528).
Elderly adults lose both the MZB and B1 cells as they age and this may account for increased IPD 
susceptibility (520). The data reported here have shown that pre-existing memory to 
pneumococci is low in the elderly but they still make good responses to immunisation possible 
via the FO B cells pathway.
7.8 Conclusions and future work
The generation of IgG memory in response to immunisation with Pnc7 vaccine is affected by age, 
and previous priming through either nasopharyngeal carriage or previous immunisation. The rate 
of IgG memory induction is also dependent on the serotype of the pneumococcus (513).
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Prior to immunisation elderly adults and toddlers had low frequencies of IgG memory B cells 
specific for the capsular polysaccharides. This may be related to the reduced frequencies of MZB 
in both age groups and also immature status in toddlers. Natural IgG antibody produced by MZB 
and Bib cells requires previous exposure to polysaccharide antigens and toddlers have 
experienced fewer episodes of nasopharyngeal carriage than adults. Thus the immune response is 
dominated by IgM antibody in absence of natural priming. Toddlers had high levels of natural 
serum IgM, equivalent to that of young adults and levels were highest to serotypes shown by 
other investigators to be more commonly carried (79). The frequency of B1 and MZB cells 
decreases with age, thus despite life long exposure to pneumococci the pre-existing IgG memory 
(using SCP stimulation) detected in elderly adults was lower than in young adults. Both toddlers 
and elderly adults responded to TD-antigens equally as well as young adults suggesting the FO B 
cell response was intact in all ages.
In Figure 7.11 have summarised the picture which has been clarified by these studies showing the 
development of the B cell response and how this relates to the data discussed in this thesis. 
Following immunisation of young adults with either a single of booster dose of pneumococcal 
conjugate vaccine antigen specific B cells undergo rapid, extrafollicular proliferation and 
differentiation into short lived plasma cells (fig 7.1, panel A). The extrafollicular response is T 
cell independent and results mainly in IgM secretion unless priming has occurred via previous 
exposure to pneumococci or immunisation. The response is rapid and may be mediated by B la 
cells, Bib cells, MZB and FO B cells with the resulting, short lived plasma cells appearing in the 
peripheral blood by day 4 after immunisation.
Panel B of figure 7.1 shows how the ex vivo plasma cell data (solid green line) from the young 
adult studies in this thesis fits with the known extrafollicular kinetics of the B cell response 
shown in panel A. The magnitude of this extrafollicular IgG response (ex vivo plasma cells) was 
much lower in toddlers than in young adults, probably as a result of fewer priming events prior to
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primary immunisation and low frequencies of MZB that are in an immature state. Administration 
of a second toddler dose of Pnc7 2 months after the first dose did not enhance this IgG plasma 
cell response, even though serum IgG concentrations and IgG memory B cells increased in 
frequency. This may be confirmation that the cells involved in the extrafollicular response in 
toddlers are too few in numbers and are too immature to mount IgG responses to TI-2 antigens 
with out T cell help. Thus the IgG memory response is likely to result from FO B cell responses 
following germinal centre development.
Panel A, in figure 7.1 also shows the concurrent development of the germinal centre response 
with recruitment of TFH cells brought into close contact with B cells by antigen expressing FDC. 
The germinal centre B cells undergo further rounds of proliferation (purple cells) at which point 
class switching and somatic hypermutation of antibody variable genes occurs, increasing antibody 
avidity to specific antigen.
The cells which exit the germinal centre include plasmablasts that reside in the peripheral 
lymphoid tissues secreting antibody for prolonged periods, long-lived plasma cells homing to the 
bone marrow and memory B cells that re-circulate throughout the peripheral blood and lymph. 
Stimulation of PBMCs with SI enabled detection of IgG-AFC for up to 1 month after 
immunisation of young adults (red dotted line in panel B, fig 7.1). Prior to immunisation there 
was limited detection of IgG-AFC via this system in young and elderly adults and none in 
toddlers. In vivo exposure of B cells to specific antigen is required for continued proliferation and 
differentiation of these B cells during in vitro stimulation with SI. IgG-AFC derived from B cells 
in this culture system were only detected at significant levels during the first two weeks after 
immunisation.
The germinal centre response begins to involute by day 22, disappearing by day 28 (panel A, fig 
7.1). The SI induced IgG-AFC frequency waned with similar timing to the germinal centre 
reaction, suggesting that these cells were products of IgG secreting germinal centre B cells.
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Future work will be undertaken to measure the avidity of IgG secreted in vitro at each time point 
to confirm whether the B cells were high avidity antibody secreting germinal centre plasma cells 
or extrafollicular B cells.
IgG-AFC detected following SCP stimulation of B cells in vitro peaked at day 15 (blue dotted 
line in panel B). This time point coincides with the peak in germinal centre activity with cells in 
various states of differentiation exiting in to the peripheral blood. SCP provides the signals for 
activation of B cells in all states of activation. B cells exiting the germinal centre include cells 
that have not recently encountered specific antigen which may explain the difference in IgG-AFC 
frequency between the SCP and SI system (panel B).
Following immunisation the magnitude of the IgG memory B cell response in the young and 
elderly adults was equivalent, but in toddlers it was much lower. Serum antibody responses to 
primary immunisation in toddlers were dominated by IgM and the rate of generation of IgG 
memory was serotype dependent with serotype 4 switching to IgG more rapidly in toddlers while 
in adults serotype 23F switched more rapidly (a scheme of antibody responses to immunisation of 
young adults is shown in fig.7.1, panel C). This difference in IgG memory generation was most 
likely a result of less priming via nasopharyngeal carriage and in support of this a second dose of 
Pnc7 in toddlers produced IgG memory responses similar to those in adults after a single dose. 
Further work is planned on depletion of B cell subsets to identify the cells at each time point that 
are involved in the IgG and IgM production in response to SAC+IL-2 or SAC+CpG+PWM. 
Stimulation of B cells with specific polysaccharide along with co-stimulation by CpG and/or 
PWM may also help to identify the time point at which antigen activated B cells appear and 
disappear from the periphery. This has been studied with plain polysaccharide vaccines (109), 
but not conjugated polysaccharides vaccines. It might be expected that antigen specific memory 
cells would be present in peripheral blood for longer if germinal centre formation had been 
induced by the conjugated rather than the plain polysaccharide vaccine. Identification of antigen
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specific B cells using intracellular labelling of antigen of antigen specific plasma cells with 
fluorescent tagged polysaccharides will also be utilised to investigate this question.
In conclusion, when determining the B cell or serum antibody response to glycoconjugate 
vaccines it is important to measure the IgG and IgM response, particularly in the very young. 
IgM is the first line of defence against blood borne pathogens and low frequencies of the cells 
responsible for secretion of IgM coincides with the age at which invasive disease peaks. 
Enhancing IgM memory may be important for protection and can be replaced by generation of a 
high avidity IgG response to enhance protection in the very young and elderly through 
immunisation.
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vaccine.
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